TEM ELLS A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Stem Cells: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-84224-8 1. Stem Cells-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on stem cells. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON STEM CELLS .............................................................................................. 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Stem Cells ..................................................................................... 5 E-Journals: PubMed Central ....................................................................................................... 61 The National Library of Medicine: PubMed ................................................................................ 69 CHAPTER 2. NUTRITION AND STEM CELLS................................................................................... 115 Overview.................................................................................................................................... 115 Finding Nutrition Studies on Stem Cells .................................................................................. 115 Federal Resources on Nutrition ................................................................................................. 118 Additional Web Resources ......................................................................................................... 119 CHAPTER 3. ALTERNATIVE MEDICINE AND STEM CELLS ............................................................ 121 Overview.................................................................................................................................... 121 National Center for Complementary and Alternative Medicine................................................ 121 Additional Web Resources ......................................................................................................... 131 General References ..................................................................................................................... 132 CHAPTER 4. DISSERTATIONS ON STEM CELLS .............................................................................. 135 Overview.................................................................................................................................... 135 Dissertations on Stem Cells ....................................................................................................... 135 Keeping Current ........................................................................................................................ 137 CHAPTER 5. CLINICAL TRIALS AND STEM CELLS ......................................................................... 139 Overview.................................................................................................................................... 139 Recent Trials on Stem Cells ....................................................................................................... 139 Keeping Current on Clinical Trials ........................................................................................... 163 CHAPTER 6. PATENTS ON STEM CELLS ......................................................................................... 165 Overview.................................................................................................................................... 165 Patents on Stem Cells ................................................................................................................ 165 Patent Applications on Stem Cells............................................................................................. 204 Keeping Current ........................................................................................................................ 244 CHAPTER 7. BOOKS ON STEM CELLS ............................................................................................. 245 Overview.................................................................................................................................... 245 Book Summaries: Federal Agencies............................................................................................ 245 Book Summaries: Online Booksellers......................................................................................... 246 Chapters on Stem Cells .............................................................................................................. 255 CHAPTER 8. PERIODICALS AND NEWS ON STEM CELLS ............................................................... 257 Overview.................................................................................................................................... 257 News Services and Press Releases.............................................................................................. 257 Newsletter Articles .................................................................................................................... 262 Academic Periodicals covering Stem Cells................................................................................. 262 CHAPTER 9. RESEARCHING MEDICATIONS .................................................................................. 265 Overview.................................................................................................................................... 265 U.S. Pharmacopeia..................................................................................................................... 265 Commercial Databases ............................................................................................................... 266 Researching Orphan Drugs ....................................................................................................... 266 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 271 Overview.................................................................................................................................... 271 NIH Guidelines.......................................................................................................................... 271 NIH Databases........................................................................................................................... 273 Other Commercial Databases..................................................................................................... 275 The Genome Project and Stem Cells .......................................................................................... 275
viii Contents
APPENDIX B. PATIENT RESOURCES ............................................................................................... 279 Overview.................................................................................................................................... 279 Patient Guideline Sources.......................................................................................................... 279 Finding Associations.................................................................................................................. 285 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 287 Overview.................................................................................................................................... 287 Preparation................................................................................................................................. 287 Finding a Local Medical Library................................................................................................ 287 Medical Libraries in the U.S. and Canada ................................................................................. 287 ONLINE GLOSSARIES................................................................................................................ 293 Online Dictionary Directories ................................................................................................... 293 STEM CELLS DICTIONARY ...................................................................................................... 295 INDEX .............................................................................................................................................. 377
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with stem cells is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about stem cells, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to stem cells, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on stem cells. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to stem cells, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on stem cells. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON STEM CELLS Overview In this chapter, we will show you how to locate peer-reviewed references and studies on stem cells.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and stem cells, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “stem cells” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Neuronal Stem Cells: Their Characterization and Utilization Source: Neurobiology of Aging. 15(Supplement 2): S191. 1994. Summary: Many cells of the developing brain can be induced to proliferate and differentiate into neurons in vitro. The fate and longevity of those cells is not well known, nor is there terminology to describe them during various stages of proliferation, migration, and differentiation. Research is progressing to assess in vivo cellular replacement in a therapeutic context. This research relates to Alzheimer's disease by expanding the focus beyond the understanding of cell death to one of cell birth. Brain cell homeostasis is likely a balance between death and birth, and age-related degeneration may be influenced both by preventing cell death and inducing neurogenesis in the adult brain. 10 references.
4
•
Stem Cells
State of Stem Cell Research Source: Access. 16(1): 22-29. January 2002. Contact: Available from American Dental Hygienists' Association. 444 North Michigan Avenue, Chicago, IL 60611. Summary: This article familiarizes dental hygienists with stem cell research, focusing on the political decisions made to Federally fund research on only approximately 60 of the already existing stem cell lines. The author discusses the uneasy compromise that presently exists and the perspectives of each of the interested groups, including embryonic stem cell researchers, the biotech industry, patients' rights groups, and members of the pro-life movement. Other topics include the issue of using so called leftover embryos from in vitro fertilization, the location of the stem cell lines presently in existence, and other sources of stem cells (such as placenta and umbilical cords). The author also cautions that even with full support of stem cell research, the chasm between theory and useful application for therapy is still huge. 1 table.
•
Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus Source: Rheumatic Disease Clinics of North America. 26(2): 377-387. May 2000. Summary: This journal article provides health professionals with information on the use of hematopoietic stem cell transplantation (HSCT) to treat systemic lupus erythematosus (SLE). Most allogenic HSCTs are from a human leukocyte antigen matched sibling donor. Bone marrow from the donor is infused into the patient following completion of a myeloablative preparative regimen. Autologous HSCT involves removal, cryopreservation, and reinfusion of hematopoietic stem cells following myeloablative therapy. The source of autologous stem cells can be either the bone marrow or peripheral blood progenitors. Many institutions throughout the world are conducting clinical studies using immunoablative therapy followed by HSCT for the treatment of SLE. Interpretation of these studies will be complicated by the differences in patient selection, conditioning regimens, and methods of stem cell collection. A major concern with this approach is that autoreactive effector cells will be reinfused with the autologous graft. The recent demonstration that immunoablative therapy can be safely delivered without the need for stem cell rescue offers a possible way to circumvent this problem. Early results using immunoablative therapy, with or without stem cell rescue, are encouraging; however, longer followup and additional patients are needed to validate this approach. 51 references. (AA-M).
•
Tissue Engineering, Stem Cells, and Cloning: Applications in Urology (Part 1) Source: Contemporary Urology. 14(10): 40, 42, 44, 46-47,50-52,55-57. October 2002. Contact: Available from Medical Economics Publishing Inc. Montvale, NJ 07645. (800) 432-4570. Summary: Using the principles of cell transplantation, materials science, and engineering, researchers are replacing damaged urologic structures with biologic substitutes that can restore and maintain normal function. This article reviews applications of tissue engineering, stem cells, and cloning in the field of urology. Tissue engineering is used to develop biologic substitutes that will restore and maintain normal function. Tissue engineering may involve matrices alone (where the body's natural ability to regenerate is used to orient or direct new tissue growth) or the use of matrices with cells. The authors review how tissue engineering has been used to generate tissues for a variety of urologic structures, including the urethra, bladder, penis, and kidney.
Studies
5
Other topics include fetal tissue engineering, injectable therapies, and testicular hormone replacement. 4 figures. 58 references.
Federally Funded Research on Stem Cells The U.S. Government supports a variety of research studies relating to stem cells. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to stem cells. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore stem cells. The following is typical of the type of information found when searching the CRISP database for stem cells: •
Project Title: A CELL-BASED THERAPY FOR CATARACTS Principal Investigator & Institution: Lang, Richard A.; Associate Professor; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2006 Summary: (provided by applicant): Our long term objective is to develop a cell-based therapy for cataracts. In the case of the cataractous lens in adults, this approach offers the advantage, when compared with plastic prosthetic lenses, that the regenerated lens would be entirely natural in function and would accommodate normally. The regenerated organ would also be young in cellular terms and would therefore have extended function even in an environment, such as the diabetic patient, that favored the formation of cataracts. A cell-based therapy would also offer a unique advantage for the treatment of cataracts in newborns where conventional intraocular lens implantation is complicated by the rapid growth of the immature eye (a newborn's eye is 17 mm in length but grows to 22 mm by the end of the second year). The experimental strategy is to develop the techniques for production, identification and isolation of lens progenitor cells from mouse embryonic stem cells, and then to determine whether lens progenitors will form a lens in situ after implantation in the empty lens capsule of an experimental animal. Three Aims are designed to lead us towards this long-term goal. Aim 1 - to derive ES cell lines that give lens progenitor-GFP expression in chimeric mice. To prepare for the derivation on lens progenitor cells in culture, we will generate ES celt lines that give the normal Pax6 ectoderm enhancer expression pattern in chimeric mice. Aim 2 - To determine whether lens progenitor cells can be identified and isolated from embryonic stem cells. We will ask whether mouse embryonic stem cells are a source of lens progenitor cells using a variety of differentiation conditions in culture. Aim 3 - To determine whether lens progenitors will form a lens in situ. We will determine if lens
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
6
Stem Cells
progenitors isolated according to Aim 2 can generate a lens when placed in the empty lens capsule in nude (immune deficient) rats. If we are able to observe lens development from implanted progenitors, we will have established the basis of a cell-based therapy. Once established in animal models, the techniques described would be used with human ES cells and additional steps taken toward a practical therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACTIVATION & PROLIFERATION OF HEMATOPOIETIC STEM CELLS Principal Investigator & Institution: Lansdorp, Peter M.; Associate Professor; British Columbia Cancer Research Centre 601 W 10Th Ave Vancouver, Timing: Fiscal Year 2002; Project Start 01-AUG-1990; Project End 31-MAY-2007 Summary: (provided by applicant): Hematopoietic stern cells (HSC), unlike e.g. embryonic stem cells, have a finite potential to divide. Limitations in the replication potential of HSC appear to be important in hematological disorders such as aplastic anemia and chronic myeloid leukemia. Such limitations could furthermore hamper the development of novel therapeutic strategies, including ex vivo stem cell expansion and gene therapy. Based on these considerations, studies that may help define and extend the replicative potential of HSC are important and a general interest. Previous studies with purified human "candidate" HSC funded by this grant have shown that the functional properties of HSC change dramatically during ontogeny and that the loss in HSC proliferative potential with age correlates with measurable shortening of telomeres. Here we propose to further examine the role of telomerase and telomeres in hematopoiesis. Specifically, we want to test the hypothesis that the replication history of HSC can be traced by studies of their telomere length. In order to test this hypothesis, we will examine the telomere length in subsets of purified HSC and their cultured progeny relative to defined populations of more mature cells using refined flow cytometry techniques developed in our laboratory. These techniques will also be used to further study the age related decline in telomere length in nucleated blood cells from normal individuals, patients with various hematological disorders and pedigrees of genotyped normal baboons. We will furthermore attempt to manipulate the telomere length in HSC using gene transfer and protein transduction strategies and study the functional properties of cells with extended telomeres in vitro and in vivo. The specific aims are:1) To study the telomere length in purified HSC and nucleated blood cells from normal individuals and patients with various hematological disorders before and after therapy.2) To study the telomere length in nucleated blood cells from baboons in relation to their age and genotype.3) To study the effect of artificial telomere elongation and telomerase inhibition on the proliferation, differentiation and replicative potential of purified "candidate" HSC in vitro and in vivo.Taken together, these studies will provide crucial baseline information on the role of telomeres in the biology of HSC. Such information is relevant for a basic understanding of hematopoiesis as well as applications of stem cells in and outside hematology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ADULT STEM CELL THERAPY IN PARKINSON'S DISEASE Principal Investigator & Institution: Li, Jia-Yi; University of Lund Box 1703 Lund, Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2005 Summary: (provided by applicant): Objective: The aim of this project is to develop a novel source of adult stem cells as an alternative to embryonic-derived stem cells/tissue
Studies
7
for neural grafting in Parkinson's disease (PD). Bone marrow-derived hematopoietic stem cells and brain-derived adult ependymal stem cells will be investigated with respect to their potential to differentiate into dopaminergic (DA-ergic) neurons in vitro: In a final phase, the cells will be grafted into PD animal models. The work program includes (phase 1) isolation and purification of both cell types by using specific markers and magnetic sorting or FACS. In phase 2, cells will be propagated in vitro and characterized; respective mitogenes screened and protocols optimized. Phase 3 involves the identification of factors promoting neuronal/DA-ergic differentiation for the respective cell types and optimization of differentiation protocols in vitro. Cells will be characterized morphologically by immunocytochemistry and functionally by measuring K+-stimulated DA release in vitro. Subsequently, to verify a possible clinical application of the investigated cell types for neural grafting, undifferentiated as well as differentiated cells will be transplanted intracerebrally in rat/mouse models of PD in phase 4. Grafted cells will be assessed morphologically by immunohistochemistry, their ability to form synaptic contacts with the host brain by staining for synaptic vesicle proteins (such as synaptophysin) in combination with confocal and electron microscopy. Functionality of grafted cells will be tested by rotational behavior pre- and post transplantation. The project is aimed at further understanding of neural stem cell biology and more importantly, to use a highly goal-derived approach to develop a translation protocol for adult-derived stem cells that can be readily applied in future clinical trials in PD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AGE-RELATED RESPONSES OF EPIDERMAL STEM CELLS TO ENVIRON Principal Investigator & Institution: Bickenbach, Jackie R.; Associate Professor; Anatomy and Cell Biology; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: Homeostasis of continuously renewing tissues, such as the epidermis, is maintained by somatic stem cells. These are undifferentiated, self-renewing cells, which also produce daughter transient amplifying (TA) cells that make up the majority of the proliferative population. TA cells undergo a finite number of cell divisions before leaving the proliferative compartment and moving toward terminal differentiation, whereas it has been assumed that the stem cells persist throughout the lifetime of the organism. Through a series of labeling experiments with tritiated thymidine, we previously showed that stem cells from adult mouse skin did not divide as often as the other basal cells, but they did divide at a steady rate in vivo. We also showed that they continued to proliferate in vivo throughout life, and that they have a high proliferative potential in vitro. Thus, it may be that epidermal stem cells do not follow the Hayflick theory and possibly "live forever." Last year, we developed a sorting method that yields a viable population of stem cells from the epidermis. We showed that these stem cells have the capacity to regenerate the epidermis and to continuously express a recombinant gene in the regenerated tissue. Thus, they are the stem cells for the epidermis. Very recently, we determined that these epidermal stem cells also have the remarkable ability to participate in the formation of the other tissues, a plasticity similar to that of embryonic stem cells and a few other somatic stem cells. Our preliminary data show that the epidermal stem cells isolated from neonatal mouse skin incorporate into a variety of tissues and alter their phenotype after injection into blastocysts. Thus, the fate determination of these stem cells appears to be in direct response to their environment. We also determined that the cell cycle profile of these cells appears to be
8
Stem Cells
an intrinsic property of the stem cell and not related to the age of the cell. These data have led us to ask what happens to epidermal stem cells as the organism ages? In this application, we propose to test whether the age of the stem cells has an effect on its response to the environment or extrinsic factors in determining its fate pathway. We propose the following specific aims: 1) to compare old vs. young murine epidermal stem cells by determining their number, altered phenotype and longevity after injection into blastocysts, and to determine whether there is a difference in the life span of mice derived from blastocysts injected with old vs. young stem cells; and 2) to compare old vs. young adult human epidermal stem cells by determining if there is a difference in their in vitro growth potential and if they respond differently to extrinsic environmental signals in vitro and after injection into blastocysts. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOACTIVE FACTORS IN SKELETAL REPAIR (STEM CELLS) Principal Investigator & Institution: Caplan, Arnold I.; Professor; Biology; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2002; Project Start 01-APR-1985; Project End 31-MAY-2004 Summary: (Adapted from the Applicant's Abstract): The initially supported studies associated with this grant focused on the isolation and characterization of bioactive molecules which caused ectopic bone and cartilage formation when implanted into in vivo sites. This work emphasized the presence of progenitor mesenchymal cells which responded to these bioactive factors. The focus of the first subsequent renewal application was to characterize a preparation of progenitors (referred to collectively as "Mesenchymal Stem Cells"). It is suggested (by the applicant) that substantial progress has been made on the two Specific Aims of that proposal and this second competitive renewal application now focuses on one of these Aims, in which efforts were previously proposed to optimize cell-mediated repair of large femoral defects in rodents. The investigators now propose a multi-institutional collaboration to study the factors involved in engineering fracture repair. A 2 mm femoral gap in rodents will be analyzed for repair by inserting a uniform plug of cultured-expanded and marked marrowderived "mesenchymal stem cells". It is suggested that this model allows a detailed analysis of this "pseudo repair blastema" and focuses on the cellular and molecular contributions of these cells to the repair tissue. Three Specific Aims are complimented by three separate experimental projects. In the first Aim, the applicants propose to determine the contribution of these stem cells to the repair process and to the repair tissue. In the second Aim, they propose to insert plugs which contain relatively homogenous populations of cells that are at three different stages of osteogenic lineage and to determine their contribution to the fracture repair tissue. The last Aim will focus on the contribution of mechanical load to this repair process and its effects on stem cells and the population of cells from the three distinct stages of osteogenic lineage. The goal of the proposed research is to test several predictions related to the control of engineered fracture repair at one well-defined site. The molecular, cellular and mechanical determinants involved in such an engineered fracture repair have considerable clinical complications and the proposed studies are designed to highlight the key and controlling features of these events. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BIOLOGY OF STEM CELLS FROM THE ADULT BRAIN Principal Investigator & Institution: Leonard, Jack L.; Professor; Nuclear Medicine; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, Ma 01655
Studies
9
Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: The recent discovery of multipotent progenitor cells in the adult central nervous system (CNS) offers the potential that these cells can be used to re-wire damaged neural circuits. These progenitor cells are propagated by relatively simple culture conditions, and implants of in vitro propagated neural stem cells can reverse and even cure neurological problems in animals. Cell-based strategies to CNS repair using both totipotent embryonic stem (ES) cells, and in vitro amplified spinal cord progenitor cells (SCPC) has restored a significant level of function to spinal cord injured rats, and overcome genetic defects in cerebellar function. In this proposal we will compare the expressed gene profiles of the totipotent ES cell, with those of the in vitro propagated neural progenitor cells isolated from the adult cerebral cortex and the spinal cord, from the cerebrospinal fluid, from fat and from the neonatal cerebellum. We will identify progenitor cell specific genes by DNA microarray analysis and characterize the developmental expression pattern of cerebellar external granule layer (EGL) progenitor cells during their differentiation into granule neurons. The Specific Aims of the proposal will address the following questions: 1) Do the transcript profiles of in vitro amplified progenitor cells isolated from adult cerebral cortex, spinal cord, the cerebrospinal fluid, the neonatal cerebellum and fat differ from the totipotent ES cell? 2) How does the expressed gene profile change when neural progenitor cells differentiate into neurons in vitro? The proposed body of work will provide the basic information required to establish the similarity/differences between the ES cell and the adult progenitor cells at the genomic level. The results of the proposed studies will provide the basic information required to generate sufficient numbers of undifferentiated progenitor cell for therapeutic use and establish the consequences of in vitro amplification on the fate of the progenitor cell. In addition, this work will lead to studies aimed at predetermining program of an important in situ pool of neuronal precursors that can be used to repair the lost circuitry typically found in the aging CNS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BONE MARROW-DERIVED STEM CELL TRANSPLANTATION TO RETINA Principal Investigator & Institution: Mcloon, Steven C.; Professor; Neuroscience; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2006 Summary: (provided by applicant): Degeneration of retinal photoreceptor neurons, such as that seen in age-related macular degeneration (AMD), is the most common cause of blindness in the United States. There are compelling reasons to believe that subretinal cell transplantation could be used to replace missing photoreceptor neurons. No effective and practical source of cells for transplantation is currently available. The goal of this project is to develop cells to be used for transplantation to replace photoreceptor neurons in AMD and related diseases. Bone marrow-derived stem cells offer numerous advantages over other cell types as a possible source of donor cells. These cells can differentiate into neurons. They are readily available, and if used for autologous transplantation to the retina, they would not have the same immunological consequences inherent in the use of other cell types. To our knowledge, no other laboratories are investigating bone marrow-derived stem cells for transplantation to the retina. At this time, there is no evidence that bone marrow-derived stem cells can differentiate into retinal neurons. The specific aim of this preliminary investigation is to determine conditions that would allow these cells to differentiate as photoreceptor neurons or other retinal cell types. The study has three sequential steps. First, treat GFP-
10
Stem Cells
labeled, bone marrow-derived stem cells in ways likely to induce the photoreceptor phenotype. This includes culturing cells in factors such as FGF-2, EGF, retinoic acid, sonic hedgehog and taurine, and/or transfecting the cells with a gene for the photoreceptor cell specific transcription factor, Crx. Second, co-culture treated bone marrow-derived stem cells with embryonic retina or transplant the cells to the subretinal space in animals depleted of photoreceptor cells. Third, assess histologically the differentiation of bone marrow-derived stem cells in the retinal co-cultures or after transplantation to the retina by determining their laminar distribution in the host retina and by immunohistochemistry with antibodies specific to retinal cell types. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELL CYCLE RELATED TRANSDIFFERENTIATION INTO LUNG CELLS Principal Investigator & Institution: Quesenberry, Peter J.; Chair, Department of Research; Roger Williams Hospital 825 Chalkstone Ave Providence, Ri 02908 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JUL-2007 Summary: (provided by applicant): Recent studies have indicated the phenotype of the hematopoietic stem cell may show dramatic cell cycle related plasticity as relates to long-term engraftment, progenitor numbers, and probably differentiation profile. These data have led to the concept that at the primitive marrow hematopoietic stem cell level, there is a continuum rather than a hierarchy with a continuously shifting phenotype. Other data have shown that marrow cells and purified marrow stem cells when infused into mice under varying conditions may give rise to nonhematopoietic cells in liver, skin, lung, brain, heart, and GI tract. In several instances, both quantitatively and functionally, significant transdifferentiation has been attained and shown to impact on specific disease manifestations, i.e., in the liver and heart. These data form the basis for the current proposal in which we will be exploring whether or not the transdifferentiation of marrow to lung cells is a phenotype which also shifts with phase of cell cycle. We will study whole marrow cells or purified marrow stem cells stimulated to transit cell cycle by IL-3, IL-6, IL-11, and Steel factor and at different points in cell cycle we will evaluated their ability to form lung cells. Host animals will be subjected to different lung injuries including intertracheal bleomycin and irradiation. Marrow cells will be infused at varying times after injuries. We will utilize B6129SF1/J, Rosa26, and C57BL/6 mice for these studies and track donor cells determining lacZ expression. In separate experiments, we will establish Rosa 26 donor marrow chimerism in lethally irradiated mice, allow for a period of stability, and then evaluate the ability of those chimeric cells subjected to varying stem cell mobilizations to produce lung cells in damaged lung. We plan to evaluate clonality as a measure of the heritogeneity of potential marrow to lung cells and an evaluation of the surface phenotype of stem cells at particular lung differentiation hot spots. We will evaluate adhesion proteins, cytokine receptors, and other epitopes of interest. These studies utilize MoFIo high-speed cell sorting, standard engraftment techniques, phage display biopanning, and immunohistochemical staining. We will also evaluate specific lungs from mice with specific injuries for possible homing peptides using phage display. This proposal hopes to define populations of cells either with cytokine stimulation at particular points in cell cycle or selected from whole marrow populations which will have a phenotype of producing lung cells and which might provide an approach to get quantitatively and functionally significant lung cell production, such that a pre-clinical model might be established. This could then lead to therapies of various lung disorders such as acute respiratory distress syndrome.
Studies
11
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHARACTERIZATION OF HUMAN LEUKEMIC STEM CELLS Principal Investigator & Institution: Bonnet, Dominique A.; Assistant Professor/Chief; Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 01-JUN-2000; Project End 31-MAY-2004 Summary: Understanding the processes that regulate the developmental program of normal stem cells and how aberrations in this program initiate leukemic proliferation remain a major challenge in biology. Progress to address these major questions in the human hematopoietic system has been hampered, until recently, by the lack of in vivo assays for normal and leukemic stem cells. The only way to conclusively assay stem cells is to follow their repopulating capacity. The recent development of methods to transplant human hematopoietic cells into immune-deficient mice provides an important approach to characterize stem cells and to develop animal models for hematopoietic diseases including leukemia. The development of an in vivo model that replicates many aspects of human AML and allows the identification of a novel leukemic stem cell (termed the SCID-Leukemia Initiating Cell, SL-IC) based on the ability of that cell to initiate AML in NOD/SCID mice provides the foundation of an assay to define the biological and molecular properties of such new leukemic stem cells. The major long-term objectives of my research program are to further characterize human leukemic stem cells. The research project proposed here will focus on three objectives: 1) determine the existence of an heterogeneity at the leukemic stem cell level (both Lin-CD34+ and Lin-CD341o/- subfractions have leukemic stem cell properties); 2) evaluate the biological properties of the leukemic stem cell pool (i.e., self-renewal, proliferation and differentiation capacities, response to cytokines and/or stromal cell environment); 3) to study the gene expression pattern of six regulatory molecules (AML1, PU.1, GATA- 1, Hox A5, Hox B4 and SCL/tal-1), known to be involved in the early stage of hematopoietic development and/or in the physiopathology of leukemia, before and after induction of differentiation of the leukemic stem cell fraction. The information obtained from these studies will gave us a more complete understanding of the nature of the leukemic stem cells, their biological properties, and the early molecular factors involved in the maintenance and/or differentiation of such leukemic stem cells. Furthermore, the knowledge gained about leukemic stem cells will allow us to devise new therapeutic strategies such as cell purging strategy, gene suicide therapy, antisense therapy and others, targeted specifically to the leukemic stem cell pool. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHARACTERIZATION OF NEURAL STEM CELLS IN THE ADULT BRAIN Principal Investigator & Institution: Alvarez-Buylla, Arturo; Professor; Neurological Surgery; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2002; Project Start 01-SEP-1994; Project End 31-JUL-2005 Summary: Adapted from applicant's abstract): New neurons continue to be born in the adult mammalian brain subventricular zone (SVZ) of the lateral ventricles and the subgranular layer (SGL) of the hippocampal dentate gyrus. Neural stem cells, cells that self-renew and generate neurons and glia, have been isolated from the SVZ and SGL with growth factors in vitro. The presence of neurogenic stem cells in the adult brain and the potential to manipulate these cells offers unprecedented opportunities for the
12
Stem Cells
replacement of brain cells lost in injury or disease. Recent work has identified the SVZ stem cell as Type B cell. Type B cells have the structure of astrocytes and express glial fibrillary acidic protein (GFAP). To understand the molecular regulation of adult neurogenesis, it is necessary to catalog the cell types and cell-cell interactions in these germinal zones, and describe the gene expression of the specific cell types. We thus propose the following Specific Aims: (1) To identify the cell types and architecture of the developing SVZ. Preliminary data suggests that cells containing a single specialized cilium in the ventricle walls of the juvenile animal are equivalent to the Type B cell in the adult. We present experiments to test this hypothesis. (2) To purify different SVZ cell types and construct representative cDNA libraries for each cell type. The libraries will be used to generate probes for GeneChip arrays to profile the gene expression of the major cell types of the adult SVZ. This experiment will be performed in collaboration with Affymetrix. Gene profiling data will be made available to the scientific community via the Internet. This data will reveal the molecular regulatory signals present in the SVZ cells as well as provide markers differentiating Type B cells from other brain astrocytes. (3) To investigate the cell types and architecture of the hippocampal SGL. The SGL stem cell will be identified using techniques similar to those used to identify the SVZ stem cell. Preliminary results suggest that SGL stem cells have properties in common with SVZ Type B cells. The combined knowledge of stem cell biology in the two major germinal regions of the adult brain will advance the ability to utilize adultderived neural stem cells for brain repair. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHEMOKINES/CYTOKINES AND RECEPTORS IN STEM CELL HOMING Principal Investigator & Institution: Broxmeyer, Hal E.; Professor; Microbiology and Immunology; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2002; Project Start 01-SEP-1997; Project End 31-MAR-2006 Summary: (provided by applicant): Little is known regarding homing/engraftment and mobilization of hematopoietic stem and progenitor cells. We hypothesized that the CXC chemokine Stromal cell derived factor-1 (SDF-l/CXCL12) and its receptor CXCR4 are involved in these important and clinically relevant processes. Towards our long-term goals to modulate homing and mobilization for clinical benefit, we propose the following two Specific Aims: 1. Evaluate roles of SDF-1 (CXCL12) and its receptor, CXCR4, in the processes of stem and progenitor cell homing, engraftment and growth factor-induced or spontaneous mobilization in mice by modulating expression and activities of SDF-1 and/or CXCR4 in stem/progenitor cells and/or the microenvironment. To these goals, use the SDF-1 antagonist AMD 3100 as well as RSVSDF-1 and LCK-SDF-1 transgenic mice to evaluate homing and engraftment, and AMO 3100 and G-CSF to evaluate mobilization in mice of differing genetic backgrounds as well as in RSV-SDF-1 and LCK-SDF-1 transgenic mice, and CCR1 -/- mice. 2. Evaluate mechanisms involved in SDF-1/CXCR4 effects on chemotaxis and mobilization of hematopoietic stem and progenitor cells in mice by determining intracellular signaling molecules and pathways involved in these effects in normal primary stem and progenitor cells, and by use of mice with functional deletions in selected intracellular signaling molecule. To the goals of aim 2, evaluate signaling in phenotypically defined populations of primary stem and progenitor cells using multivariate intracellular and cell surface flow cytometry, and use cells from mice functionally deleted in specific intracellular molecules or normal cells transduced with genes expressing dominant
Studies
13
negative or activated forms of intracellular molecules. Also use intracellular gene deleted mice to assess their response to in viva mobilization with AMD 3100 and/or GCSF. These studies should clarity the relevance of SDF-1 and CXCR4 for homing/engraftment and mobilization of primary stem/progenitor cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONNEXINS: STEM CELLS AND EPIDERMAL DIFFERENTIATION Principal Investigator & Institution: Matic, Maja; Oral Biology and Pathology; State University New York Stony Brook Stony Brook, Ny 11794 Timing: Fiscal Year 2002; Project Start 18-APR-2000; Project End 31-MAR-2005 Summary: (Taken from the applicant's abstract): The long-term objective is to identify markers whose modulation results in epithelial differentiation. This objective has a direct impact on the application of epithelial grafts as therapy for full thickness skin injury and as a delivery system for specific gene products. Connexin-negative cells are found in the basal cell layers that harbor stem cells. Connexin expression or lack thereof will be correlated with markers thought to be indicative of stem cells. For correlation with label retaining cells, which are putative stem cells, thymidine-labeled mouse skin will be used. For correlation with K19 expressing follicular cells, also purported to be stem cells, human skin will be utilized. To accomplish this aim, FACS analysis and immunohistochemistry combined with fluorescent and confocal microscopy will be employed. The functionality of gap junctions within both mouse skin and human hair follicles will also be evaluated. Cell populations able to carry out dye transfer will be compared to those populations containing label retaining cells in mouse skin, and K19 expressing cells in human hair follicles. These experiments will further indicate whether stem cells lack gap junction-mediated cell-to-cell communication. The connexinnegative cells of the epidermis will be isolated and compared in culture with other cells of the basal layer. For these experiments, antibodies against the extracellular domain of connexin molecule will be used as a negative selection factor in isolating cells by FACS. Individual cell populations will be assayed for culture life-span, and colony forming efficiency at each passage. Finally, retroviral vectors will be used to introduce both Cx43 gene and antisense oligonucleotides into keratinocytes. The effects will be assessed in submerged cultures, organotypic cultures and on organotypic cultures grafted onto athymic mice. The proposed research plan, as well as the activities described in the application, are aimed at achieving the career goals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CONTROL SPERMATOGENESIS
OF
STEM
CELL
FATE
IN
DROSOPHILA
Principal Investigator & Institution: Matunis, Erika L.; Staff Associate; Carnegie Institution of Washington, Dc 1530 P St Nw Washington, Dc 20005 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: (Scanned from the applicant's abstract) Spermatogenesis relies on the establishment and maintenance of a stem cell population within the testis. Although spermatogonial stem cells are essential for reproduction, little is known about their regulation. Environmental cues from nearby cells are thought to be crucial for stem cell maintenance, but identifying them is extremely challenging in mammalian systems. Drosophila spermatogenesis provides an excellent model system for studying stem cell regulation, since spermatogonial stem cells can be identified, and genetics can be used to systematically identify regulatory molecules. In this proposal the role of the highly
14
Stem Cells
conserved Jak-STAT signal transduction pathway in stem cell maintenance is examined. The Jak kinase homologue Hopscotch (Hop) is required for stem cell maintenance, and overactivation of the Jak-Stat signaling pathway leads to ectopic cells with stem cell character. Also, the ligand activating Jak-STAT is present in a small group of somatic cells, called the hub, to which the stem cells are anchored. This leads to the hypothesis that the hub comprises a stem cell niche, or specialized local environment, that instructs nearby cells to retain a stem cell fate by activating the Jak-STAT pathway within these cells. To test this hypothesis, the precise role of Jak-STAT signaling in the niche will be examined. In Aim 1, marked loss-of-function clones will be generated to determine if stem cells directly require Jak-STAT signaling. In Aim 2, both loss-of-function and ectopic expression of Jak-Stat signaling molecules will test whether Jak-STAT signaling instructs stem cell fate or, alternatively, is required to permit stem cell viability. In Aim 3, the role of Jak-STAT signaling in limiting stem cell numbers in the niche will be studied. Finally, since it is likely that other factors act either in concert with Jak-STAT, or subsequent to it in maintaining the stem cell niche, we employ genetic approaches to systematically identify these factors in Aim 4. Since Drosophila and mammalian spermatogenesis are conserved, the regulatory mechanisms uncovered in this proposal will likely add to the understanding of the regulation of stem cells residing in more complex and less defined environments, such as mammalian spermatogonial stem cells, which are essential for human fertility. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORNEA BIOENGINEERING
EPITHELIAL
STEM
CELL
ISOLATION
FOR
Principal Investigator & Institution: Li, De-Quan; Assistant Professor; Ophthalmology; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2006 Summary: (provided by applicant): Corneal epithelial stem cell disease or dysfunction, known as limbal stem cell deficiency, is among the most common blinding eye conditions worldwide. There was no effective therapy for these conditions until the potential of limbal transplantation for surface reconstruction of eyes with this condition was realized in the past decade. The success of limbal transplantation has been attributed to the healing potential of the corneal epithelial stem cells that are only a small subpopulation contained within the mixture of cells transplanted in these grafts. The ability to isolate a pure population of corneal epithelial stem cells from small limbal biopsies, expand them in culture and use them for regenerating a corneal surface of normal phenotype and regenerative capacity would represent a major advance in this field. But to date, no specific markers for corneal epithelial stem cells have been identified. Isolation of corneal epithelial stem cells has not been achieved. Our preliminary studies have provided encouraging results in support of our hypothesis that the novel isolation methods and proposed markers for stem cells and basal cells in non-ocular tissues can be utilized to isolate a pure population of corneal epithelial stem cells. Two proposed Specific Aims will realize the long-term objectives. Aim 1 will create novel approaches to isolate corneal epithelial stem cells based on their unique properties and molecular markers for use in corneal tissue engineering. Three isolating strategies in combination will be used: 1) Size sorting based on the correlation between cell differentiation and enlarged size; 2) Enrichment by their rapid adherence to extracellular matrix based on their higher-expression of beta1integrin; 3) Purification of stem cells as a side population by flow cytometry using a vital DNA binding dye, Hoechst 33342. Aim 2 will search for new specific markers for corneal epithelial stem
Studies
15
cells by characterizing gene expression patterns in the purified populations of stem cells using advanced gene array/microarray techniques. With the proposed Aims accomplished, pure populations of corneal epithelial stem cells will be available for the first time, which will make the corneal epithelial stem cell concept become reality and bring stem cell research and clinical application into a new age. This work will have important scientific significance and high impact on the adult stem cell concept, not only for cornea and ocular surface, but also for other tissues. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DERIVATION OF SMOOTH MUSCLE LINEAGES FROM STEM CELLS Principal Investigator & Institution: Owens, Gary K.; Professor and Associate Dean; Mol Physiol/Biological Physics; University of Virginia Charlottesville Box 400195 Charlottesville, Va 22904 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2005 Summary: (provided by applicant): A large number of major human diseases including coronary artery disease, hypertension, and asthma are associated with abnormal function of the smooth muscle cell (SMC). The long term goal of the studies in this proposal is to develop methods for producing SMC or SMC "progenitor" cells from various human multi-potential stem cell populations with the intent of potentially using these cells for a variety of clinical applications including: a) in vitro production of SMC tissues or cells for surgical repair or augmentation; and b) production of SM tissues or cells that are genetically engineered to express a desired therapeutic gene or agent. Of particular relevance to this grant application, we have developed unique experimental methods, employing SMC specific/selective promoter-enhancers initially characterized in our laboratory, that permit high efficiency induction, identification, and purification of SMC and SMC "progenitor" cells from multi-potential murine P19 stem cell populations. The studies outlined in this proposal will: 1) use representative difference analyses (RDA), and gene array analyses of unique P19 derived mouse SMC "progenitor" cell lines previously developed in our lab to identify markers of SMC progenitor cells, and/or genes that control early commitment/determination events in SMC (Aim 1); 2) test the applicability of our unique SM a-actin/SM MHC promoterenhancer based screening methods for identifying and purifying SMC or SMC "progenitor" cells from various murine and human stem cell populations (Aim 2-3); and 3) characterize the properties of stem cell derived SMC and SMC "progenitors" upon surgical re-implantation in vivo (Aim 4). Taken together studies will provide novel insights of mechanisms that control specification of SMC during embryonic development, and lead to development of unique methods for producing SMC from stem cell sources for potential therapeutic applications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DEVELOPMENTAL LYMPHOPOIESIS
STAGE-RELATED
CHANGES
IN
Principal Investigator & Institution: Kincade, Paul W.; Head; Oklahoma Medical Research Foundation Oklahoma City, Ok 73104 Timing: Fiscal Year 2004; Project Start 01-JAN-2004; Project End 31-DEC-2008 Summary: (provided by applicant): The immune system is initially formed and replenished by differentiation of hematopoietic stem cells into various types of lymphocytes. Recently developed knock-in mice now make it possible to study early
16
Stem Cells
specification of stem cells into lymphoid fates, correlating changes in gene expression, function and surface markers with activation of the RAG-1 locus. As information accumulates about the sequence of events in adult bone marrow, it has become increasingly clear that it differs substantially from the fetal/neonatal process. Stem cells emerge in at least two sites in embryonic life, but developmental relationships between those populations and their counterparts in adult marrow remain poorly understood. Unique features and limitations to the newborn immune system could result from differentiation mechanisms that are only used for fetal lymphocyte production. We will chart emergence of the earliest lymphoid progenitors in murine embryos, comparing and contrasting their characteristics with ones in adults. Transplantation and culture experiments may attribute many differences to residence in fetal versus adult environments, exposure to unique differentiation cues and/or the recent proliferation of stem cells. Other properties of lymphoid progenitors in embryos may be intrinsic and related to their origin from fetal, rather than adult, stem cells. We will use new transgenic animal models to test the hypothesis that early emerging hematopoietic stem cells are replaced by ones that arise later. The resulting information may suggest new ways to augment neonatal immunity, treat immunodeficiency and restore lymphocytes following transplantation. It will also be useful within a broader context of developmental changes in stem cells, highlighting limitations and opportunities in regenerative medicine. For example, desirable properties of fetal stem cells may be used to advantage or artificially conferred on their adult counterparts. Furthermore, basic investigation of this type could provide explanations for the sensitivity of neonates to lymphocytic leukemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EMBRYONIC STEM CELLS AND SQUAMOUS EPITHELIA Principal Investigator & Institution: Green, Howard; Cell Biology; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2005 Summary: (provided by applicant): Human embryonic stem (ES) cells are now available for the study of the generation of somatic cell types. For this purpose, human ES cells have important advantages over the murine ES cells available earlier. We propose to study the generation of keratinocytes of stratified squamous epithelium from the human ES cells (WA01). ES cells are known to have the capacity to generate such epithelium outside the developing embryo, since the epithelium develops when the ES cells are injected into scid mice. But our main intention is to find conditions promoting differentiation of the ES cells in culture and then to isolate strains of keratinocytes resulting from that differentiation, using 3T3 support. We will examine the factors that influence the development of keratinocytes, using as criterion a quantitative measure of the number obtained, and in this way arrive at the conditions producing maximal yield of keratinocytes. We will identify, when possible, the specific squamous epithelium to which isolated keratinocytes belong. We will attempt to find somatic stem cell precursors of the mature keratinocytes using stem cell markers for their identification. Depending on the nature of the keratinocytes or keratinocyte precursors isolated, practical applications can be readily envisioned. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
17
Project Title: ENGINEERING BONE FROM HUMAN ADIPOSE DERIVED STEM CELLS Principal Investigator & Institution: Hedrick, Marc H.; Associate Professor; Dental Research Institute; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2006 Summary: Bone engineering with osteoprogenitor cells has enormous clinical potential for the treatment of aging-related bone loss (osteoporosis) or traumatic bone defects. Osteoprogenitor cells such as mesenchymal stem cells (MSCs) from bone marrow are a source of such cells. When combined with polymeric scaffolds and/or osteogenic growth factors these cells may provide new therapies for bone replacement. Our longrange objective is the development of new treatments for human bone loss through tissue engineering. Our central hypothesis is that human adipose tissue contains stem cells or adipose-derived stem cells (ADSCs) which offer advantages over MSCs and other osteoprogenitor cell types. The specific aims of this application are: (1) to clone and characterize human ADSCs, (2) to investigate their ability to form bone both in vitro and in vivo and (3) to determine their ability to repair non-healing bone defects. An understanding of ADSC function and ultimately their regulation, has important implications. First, tissue engineering strategies will benefit by an autologous stem cell source (adipose tissue) that is easily obtainable in 'liter' quantities through a minor surgical procedure (liposuction) that is well tolerated by patients. Second, a detailed understanding of the regulation of stem cell differentiation in adipose tissue could significantly impact the treatment of diseases that are characterized by dysregulated mesodermal cell growth and differentiation such as osteoporosis, heterotopic calcification and obesity. Finally, fundamental issues of mesodermal cell differentiation, mesodermal phylogeny and ontogeny, may be better understood by study of these cells. At the completion of this grant, our expectation is that human adipose tissue will be shown to be a reservoir of stem cells. We will also begin to have a basic understanding of the phenotypic changes occurring in differentiating ADSCs after commitment to the osteogenic lineage. Finally, we will assess the clinical utility of ADSCs to repair criticalsized bone defects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ENGINEERING INSULIN PRODUCTION BY K-CELLS TO TREAT T1DM Principal Investigator & Institution: Wice, Burton M.; Internal Medicine; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2005 Summary: (provided by applicant): Preliminary and published results provide strong evidence that engineering short-lived Gut K-Cells to express the insulin gene is a potential therapy to treat type 1 diabetes mellitus (T1DM). Transgenic technologies are not amenable for human gene therapy, and a mechanism to stably introduce transgenes into small intestinal [epithelial] stem cells of adults is required. All published studies have demonstrated inefficient transduction of this stem cell population in vivo. Organoids containing functional intestinal epithelial stem cells can be isolated from rat small intestine and then grafted back onto denuded colonic muscle. The neomucosa exhibits a small intestinal, rather than colonic, phenotype. Grafts generated within the PI's laboratory contained Gut K-Cells, a cell normally present in the proximal small intestine and absent from colon. Thus, transplanted stem cells are hardwired to express
18
Stem Cells
genes from their original position along the duodenal to colonic axis. This suggests that organoids isolated from the proximal small intestine could be genetically modified before grafting back into the host and if so, could be engineered so Gut K-Cells derived from these stem cells could express the human insulin gene. Initial studies to test the feasibility of this strategy will determine whether the intestinal epithelial stem cells within the organoids can be genetically modified ex vivo by retroviral vectors (encoding beta-galactosidase) and then transplanted onto denuded colonic muscle. Grafts will also be assessed to determine whether beta-galactosidase expression is maintained for extended periods of time (9 months). Since retroviral vectors only infect proliferating cells, agents known to enhance crypt cell proliferation and/or inhibit apoptosis will be used in conjunction with viral infection in an attempt to increase the efficiency of stem cell transduction. Organoids can be grafted onto synthetic biodegradable polymers instead of colonic muscle and then anastomosed into the jejunum where the grafts remain intact for >9 months. If grafts containing genetically engineered Gut K-Cells were anastomosed back into the jejunum, they would be positioned to respond to normal metabolic and secretory signals. Thus, engineered Gut K-Cells would secrete insulin at the proper time to treat T1DM. Studies will be conducted to bring this alternative technique to the laboratory. Results from these pilot studies should provide a sound basis for devising a strategy to isolate, genetically modify and then transplant adult human intestinal epithelial stem cells as a potential treatment for T1DM. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EPITHELIAL DIFFERENTIATION OF BONE MARROW STEM CELLS Principal Investigator & Institution: Krause, Diane S.; Associate Professor; Laboratory Medicine; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-JUL-2005 Summary: (provided by applicant): My laboratory has recently demonstrated engraftment from bone marrow cells of fully differentiated pneumocytes in mice and hepatocytes in mice and humans. This remarkable discovery and those of others showing a previously unexpected level of differential plasticity of stem cell, open up many new avenues of research. In order to efficiently address the critical questions in this new broad field of stem cell plasticity, I have brought together a group of experienced researchers, each of whom has clinical or scientific expertise in a different organ system. The focus for this proposal is to determine the cellular and biological mechanisms that induce the bone marrow cells to differentiate into epithelial cell, and to use stem cell plasticity as a therapeutic moiety by autologous transplantation of gene modified cells. In order to dissect the mechanisms of this phenomenon in vivo, I will first determine whether epithelial engraftment as liver, lung, and skin cells can be directed in vivo in mice and in humans by induction of tissue repair mechanisms in response to injury or disease. Identification of the cellular and biological mechanisms by which bone marrow cells differentiate into hepatocytes will require the development of in vitro systems in which bone marrow derived cells become liver cells. I will use three dimensional collagen system and organ culture to achieve this differentiation in vitro. Finally, using viral vectors to infect bone marrow stem cells, I will use an autologous/syngeneic transplantation model to obtain liver specific gene expression in vivo. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
19
Project Title: EXPANSION OF STEM CELLS BY FIBROBLAST GROWTH FACTOR1 Principal Investigator & Institution: De Haan, Gerald; State University at Groningen 5 Broerstraat Groningen, Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JUL-2007 Summary: (provided by applicant): Hematopoietic stem cell transplantations are increasingly employed to restore normal blood cell production after high-dose cytotoxic therapy in cancer patients. In addition, recent studies suggest that bone marrow-derived stem cells may have the potential to contribute to non-hematopoietic tissue regeneration after transplant, which potentially increases the clinical applications of these cells vastly. A significant problem in the field of stem cell therapy remains the inability to expand the number of multilineage long-term repopulating stem cells in vitro. In a large body of preliminary data we show that in the mouse long-term repopulating stem cells reside in the lineage-depleted, fibroblast growth factor receptor-positive cell fraction. Most importantly, fibroblast growth factor-1 (FGF1) has the unique ability to stimulate the generation of long-term repopulating stem cells in vitro in serum-free cultures. Thus, our data show for the first time that large-scale expansion of stem cells in vitro is feasible, and we provide a simple method to generate rapidly engrafting stem cells in vitro. However, we show that this expansion potential is highly mouse-strain specific, as C57BL/6 stem cells are easily expanded but DBA/2 stem cells are refractory to FGF1. Preliminary genetic linkage studies reveal that a locus on chromosome 11 is associated with the variation. It is the overall aim of the present proposal to investigate how incubation of bone marrow cells with FGF1 results in massive amplification of transplantable stem cells. To this end we defined 4 specific aims: 1. Identification of the target cell on which FGF1 exerts its activity, 2. Assessment of the clonal composition of hematopoiesis in recipients reconstituted with FGF1-expanded stem cells, 3. Determine whether the defect of DBA/2 stem cells is a cell-intrinsic trait, and 4. Investigate the genetic constrains that specify FGF1-induced stem cell expansion? In order to address these 4 issues we will use an extensive set of stem cell purification strategies to search for the FGF1-responsive cell. We will perform stem cell marking studies in which cells are retrovirally transduced prior to expansion and transplantation in lethally irradiated recipients. Using co-cultures of C57BL/6 and DBA/2 bone marrow cells we will evaluate whether DBA/2 stem cells are intrinsically impaired in their response to FGF1. Finally, using a genetical genomics approach we will search for an association between gene expression profiles and stem cell expansion potential in a set of 30 recombinant inbred BXD strains of mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FUNCTION OF STEM CELL-DERIVED NEURONS IN THE AGING BRAIN Principal Investigator & Institution: Gage, Fred H.; Salk Institute for Biological Studies 10010 N Torrey Pines Rd La Jolla, Ca 920371099 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: Cells proliferate in the inner granular zone of the dentate gyrus of the adult hippocampus of all mammals. It is hypothesized that some of the dividing cells are stem cells because they can give rise to neurons and glia in the dentate gyrus. Additionally, we have demonstrated that cells from the adult hippocampus can be isolated in vitro and induced to proliferate indefinitely. Under specific conditions the cells can be transplanted back into the adult brain where they can differentiate into neurons and
20
Stem Cells
glia. We demonstrated previously that there is a progressive decrease in the number of proliferative cells in the dentate gyrus of adult rodents with aging. This decrease in neurogenesis in the aged dentate gyrus can be partially reversed by environmental stimulation. We do not know whether newly born cells in the aged brain can become neurons that are anatomically and functionally similar to the new neurons in the young adult brain. Further, we do not know if environmental stimulation like voluntary exercise will affect only the proliferation rate and survival of the newly born neurons, or whether it will also affect the anatomical or physiological properties of the differentiated cells. To determine the answer to these questions in vivo we developed new methods that allow us to measure anatomical and physiological properties of individual, newly born cells in acute brain slices. Further, we developed methods to isolate adult stem cells in vitro and measure their functional and electrophysiological properties in vitro. Finally, using transplantation methods established in this lab we can directly compare the effects of the age of the host hippocampus on survival and function of grafted aged versus young adult stem cell populations propagated in vitro. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTIONAL ISOLATION OF HUMAN HEMATOPOIETIC STEM CELLS Principal Investigator & Institution: Scadden, David T.; Professor; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2002; Project Start 01-AUG-1995; Project End 31-MAR-2005 Summary: (Applicant's Description Verbatim): Hematopoietic stem cells undergo a development stage-specific translocation during ontogeny and ultimately reside in the adult bone marrow. Maintenance of this highly regenerative cell pool through adult life is dependent upon their relative quiescence. We generated a cDNA library from quiescent human hematopoietic stem-like cells derived from bone marrow and identified by subtractive cloning a seven transmembrane molecule with a signature motif of the chemokine receptor family. Antiserum raised against this gene product identified cells from human fetal bone marrow, but not other fetal hematopoietic organs and very rare cells from adult bone marrow. These cells were enriched for quiescent cells with the ability to sustain mature blood cell generation for prolonged periods on stromal feeder layers. Calcium flux was induced upon exposure of transfected cells to bone marrow stroma conditioned medium, but not medium from other hematopoietic tissue stromal sources or from a panel of recombinant chemokines. Transduction of the receptor into hematopoietic cell lines resulted in enhanced transmigration toward bone marrow stroma in vitro and to bone marrow in irradiated mice. Transduced primary CD34+ progenitors had reduced proliferative potential, but sustained LTC-IC capability. Stem cell-G protein-coupled receptor-i (SC-GPR1) is a chemokine receptor that identifies bone marrow-derived hematopoietic stem cells and mediates growth regulatory and cell localization signals. This proposal builds upon these observations to address the following specific aims: 1. Define the functional role of SC-GPR1 in development using a mouse engineered to be deficient in the gene and its role in adult hematopoiesis using transplantation of cells identified by a monoclonal antibody specific for SC-GPR1. 2. Purify and clone the ligand for SC-GPR1. 3. Determine the mechanism by which ectopic expression of SC-GPR1 induces or maintains a primitive phenotype. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: GENOMIC HEMATOPOIESIS
APPROACH
TO
INVESTIGATING
EX
21
VIVO
Principal Investigator & Institution: Papoutsakis, Eleftherios T.; Walter P. Murphy Professor; Chemical Engineering; Northwestern University 633 Clark Street Evanston, Il 60208 Timing: Fiscal Year 2003; Project Start 01-APR-1993; Project End 31-MAR-2008 Summary: (provided by applicant): High-dose chemotherapy with autologous or allogeneic stem-cell rescue results in prolonged pancytopenia that is accompanied by infectious and bleeding complications requiring antibiotic and transfusion therapy and, at times, prolonged hospitalization. Infusion of large numbers of ex vivo expanded hematopoietic cells -as a supplement to the conventional auto- or allograft - has the potential to close the window of neutropenia and/or thrombocytopenia. Furthermore, the recently discovered plasticity of hematopoietic stem cells suggests that these readily available stem cells may be used for generating autologous or allogeneic cells and tissues for non-hematopoietic cell and gene therapies. Success of such therapies depends on the ability to generate large numbers of cells with the desired, therapy-dependent state of cell differentiation. This remains an elusive task despite the great progress in basic and applied biology. Culture conditions, such as cytokine combinations and presentation, oxygen tension (pC2) and pH, alter stem- and progenitor-cell differentiation and proliferation with substantial patient-to-patient variability. Little is known about the underlying molecular biology of these effects, and specifically, about the large-scale transcriptional program during differentiation. Such knowledge has large predictive and diagnostic potential for both ex vivo and in vivo outcomes. Thus, a comprehensive examination of the transcriptional program of ex vivo expanded human primary myeloid cells - initiated with CD34+ cells - will be examined using 8,300-gene DNA microarrays, and key findings further explored using standard molecular-biology tools. Studies include examination of the temporal and differential transcriptional program of G and Mk cells cultured either under high or low pC2 and/or pH, and with different cytokine combinations. Specific issues to be examined include the extent to which apoptosis is linked to Mk differentiation; if Mk apoptosis employs a machinery similar to that of general apoptosis; and why, in contrast to Mk cultures, there is such a low level of apoptosis in G cultures. Furthermore, gone-clustering and regulatorynetwork techniques applied to DNA-microarray data may lead to the discovery of unknown Mk- and G-differentiation genes. These experiments will provide the basis for future studies in which clinical specimens could be examined in the context of clinical stem cell transplantation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEMATOPOIETIC STEM CELL--BIOLOGY, PRECURSORS, AND PROGEN Principal Investigator & Institution: Weissman, Irving L.; Professor; Pathology; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 01-JUN-2000; Project End 31-MAY-2005 Summary: Hematopoietic stem cells are defined as clonogenic cells that can give rise to all blood cell lineages, as well as self-renew, at least for a significant period of time. There are 3 subsets of stem cells (HSC) and multipotent progenitors, and only the longterm (LT-HSC) self-renew for the life of the host, while ST-HSC renew for up to 8 weeks, and MPP for much less. Downstream of HSC/MPP are 2 classes of oligopotent progenitors - the common lymphoid progenitor (CLP) and the common myeloid
22
Stem Cells
progenitor (CMP). Each of these progenitors have been purified and can be prospectively identified by phenotype and isolated. In the first section of the grant, dividing LT-HSC, ST-HSC, and MPP will be tested for self-renewal or differentiation to one or the other downstream fates at the bulk level and at the single cell level to determine whether the cell fate decisions these multipotent cells make are largely symmetrical or asymmetrical. HSC cannot be expanded in vitro by any known protocol, but it is relatively simple to demonstrate their ability to expand by several orders of magnitude in various in vivo settings. To determine what intrinsic or extrinsic programs might regulate LT-HSC self-renewal, enforced expression of cell survival genes such as bcl-2, telomere extending genes such as TERT and TPC3, and genes downstream of particular signal transduction pathways such as beta catenin will be tested in HSC and other multipotent progenitors, and their progeny analyzed in an in vivo setting. Within the past year a large number of stem cells ranging from totipotent stem cells to organ specific stem cells (such as for the central nervous system) have been identified or claimed, with very surprising putative transdifferentiation possibilities between them and stem cells of the hematopoietic system. In this grant an effort will be made to establish unequivocal clonogenic assays for totipotent stem cells, and the relationship between various tissue specific stem cells, totipotent stem cells, and HSC will be examined. The study of HSC biology could be enhanced if HSC could be observed in situ by means of their expression of stem cell related genes. A long-term project that is part of this proposal is to begin to identify proteins that are useful fluorochromes among a plethora of recent discovered proteins such as the green fluorescent protein, and from amongst those that appear to be useful, to "knockin" different color genes as fusion proteins for these stem cell related genes already known (ckit, Sca1, Thy- 1.1, Flk2/Flt3, SCL) as well as others recently identified as being stem cell specific in their expression (e.g., a new serpin gene cloned in this laboratory). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEMATOPOIETIC STEM CELLS FROM TOTIPOTENT STEM CELL TYPES Principal Investigator & Institution: Daley, George Q.; Whitehead Fellow; Whitehead Institute for Biomedical Res Biomedical Research Cambridge, Ma 02142 Timing: Fiscal Year 2002; Project Start 01-AUG-2001; Project End 31-JUL-2005 Summary: (provided by applicant): This proposal explores the hematopoietic potential of mouse embryonic stem (ES) cells, with the ultimate goal of discovering principles that govern the differentiation of ES cells into hematopoietic stem cells (HSCs) that can be used to model transplantation in murine systems. To date, there has been no definitive demonstration that a pluripotent stem cell capable of engrafting irradiated adults arises in vitro during ES cell differentiation into embryoid bodies (EBs). Following differentiation of ES cells genetically modified to express BCR/ABL, HoxB4, or STAT5, we have succeeded in demonstrating hematopoietic engraftment of irradiated adult mice with a common lymphoid-myeloid progenitor from EBs. We are thus well positioned to investigate the nature of the common lymphoid-myeloid progenitor in EBs, and the mechanisms governing the potential for such cells to engraft in embryonic and adult hematopoietic microenvironments. We have proposed methods for isolating enriched populations of EB-derived progenitors using selectable markers driven off of hematopoietic specific promoters, and will endeavor to more carefully define the surface antigen phenotype and in vivo properties of this cell. We will determine whether the native cells have a distinct developmental potential (i.e., capacity for engraftment of fetal or newborn sites but not adult). We will test the hypotheses that engraftment is
Studies
23
facilitated by homing, enhanced cell survival, or cell proliferation, and probe the molecular basis for these observations. Our results will enable methods for enhanced hematopoietic development from ES cells and reconstitution of the adult hematopoietic system as a model for hematopoietic research and cellular therapies. Future efforts will explore the similarities and differences in the hematopoietic potential of murine and human ES cells, making use of repopulation studies of human cells in NOD/Scid mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIGH PERFORMANCE MAGNETIC CELL SORTING Principal Investigator & Institution: Chalmers, Jeffrey J.; Professor; Chemical Engineering; Ohio State University 1960 Kenny Road Columbus, Oh 43210 Timing: Fiscal Year 2003; Project Start 21-JUL-2003; Project End 31-MAR-2007 Summary: (provided by the applicant): An area of increasing interest, and potentially significant clinical use, is performing mismatched stem cell transplants for high-risk and refractory hematological malignancies using related donors. Such patients currently undergo transplants using HLA matched sibling or unrelated donor stem cells. Using haplotype-mismatched donors from siblings, parents or children would permit the availability of suitable donors for more than 90-95% of candidate patients. However, the main limitation is graft-versus-host disease (GVHD). GVHD can be almost eliminated by extensive T-cell depletion (>5 logs). While T cell depletion increases the risk of graft rejection, this can be overcome by the use of very large doses of stem cells. Therefore, it is desirable to have a system where very large numbers of stem cells can be efficiently processed to deplete T-cells, and with minimal loss of these stem cells. A second area of increasing interest, and potentially significant clinical use, is the isolation of Natural Killer (NK) Cells for Immunotherapy. NK cells are important cells of the innate immune system that are not involved in specific antigen recognition. These cells are important in the defense against infections, but also have potent anti-tumor effects. Currently, there is growing interest in the use of both autologous and allogeneic activated NK cells for cancer immunotherapy. In particular, the use of allogeneic NK cells mismatched for HLA-C alleles of the recipient can exert very potent anti-leukemic effect in vitro. Infusion of NK cells may also assist engraftment of stem cells in the bone marrow transplant setting. This project will focus on the development/application of a high throughput, flow through immunomagnetic cell separation system currently under development for clinical scale T-cell depletion and NK isolation. While several systems have been developed, none are currently approved for these indications, and their performance is generally suboptimal. With respect to the recovery of stem cells during T-cell depletion, a significant increase in stem cell recovery is needed, from reported mean values of 41 to over 80%, to facilitate 'mega-dose' CD34 cell therapy in mismatched transplants. Less research has been carried out for clinical scale NK cell separation technology, with current methods performing sub-optimally due to loss of over 50% of the NK cells. Specifically, therefore, our objectives are: 1.To demonstrate significantly superior performance for T-cell depletion with the aim of achieving 5 log10 depletion of T cells, with >90% recovery of CD34+ cells in greater than or equal too 80% of clinical apheresis samples obtained from normal donors. 2. To demonstrate significantly superior performance of NK cell isolation with the aim of isolating CD56+ CD3- NK cells with > 90% recovery and with <1 x 10/5 CD3+ cell contamination in greater than or equal to 90% of peripheral blood apheresis products processed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
24
•
Stem Cells
Project Title: HTLV INFECTION ON HEMATOPOIESIS Principal Investigator & Institution: Feuer, Gerold; Microbiology and Immunology; Upstate Medical University Research Administration Syracuse, Ny 13210 Timing: Fiscal Year 2002; Project Start 16-APR-1998; Project End 31-MAR-2003 Summary: The development of adult T cell leukemia (ATL) correlates with HTLV-1 infection at the perinatal or postnatal stage in humans and the thymus may be a critical target organ in the establishment and maintenance of infection. HTLV can productively infect human hematopoietic progenitor (CD34+) cells and these stem cells transmit viral infection when implanted into the human thymus engrafted in SCID-hu mice. The goal of this proposal is to characterize the events involved in HTLV infection in the thymus and to establish an in vivo model of viral leukemogenesis. Additionally, the HTLV tax1 or tax2 oncogenes will be transduced into hematopoietic stem cells, using retroviral expression vectors, to evaluate the effect of Tax on the differentiation of hematopoietic stem cells in vitro and in vivo. It is hypothesized that the establishment of persistent HTLV-1 or -2 infection and/or tax gene expression in CD34+ cells and prothymocytes results in the perturbation of lymphopoiesis and that this is a predisposing factor for leukemogenesis. The Specific Aims of this proposal are: 1. Establish HTLV-1 and -2 infection in human hematopoietic progenitor (CD34+) cells and characterize the effects on hematopoiesis. HTLV infection of CD34+ cells will be analyzed to quantify the effect on the differentiation of stem cells in vitro and to determine if viral gene expression is maintained in differentiated progeny cells. 2. Study the effect of HTLV infection on TIymphopoiesis in vivo. Reconstitution of SCID-hu mice with infected CD34+ cells will determine if establishment of high levels of HTLV can perturb the development of T cells in the thymus and whether these mice develop leukemia. 3. Determine the role of tax expression on the differentiation of hematopoietic progenitor cells in vitro and on transformation of human thymocytes in vivo. High-efficiency transduction of the tax genes into CD34+ cells will be accomplished by pseudotyping retroviral expression vectors with VSV-G envelope and selecting transduced stem cells to test whether Tax can transform human thymocytes in vivo. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HUMAN NEURAL STEM CELLS TARGET GENE THERAPY-BRAIN TUMORS Principal Investigator & Institution: Mcgrogan, Michael P.; Vice President; Layton Bioscience, Inc. 709 E Evelyn Ave Sunnyvale, Ca 94086 Timing: Fiscal Year 2002; Project Start 26-JUN-2000; Project End 31-JUL-2004 Summary: Neural stem cells (NSCs) show a remarkable ability to migrate throughout the CNS, intermingle with host cells, and express foreign transgenes following transplantation. Intriguingly, this inherent migratory property of NSCs emulates the migratory pattern of some brain tumors, such as gliomas, characterized by invasive single cell migration. Potentially, the migratory properties of NSCs can be harnessed to disseminate therapeutic genes products to invading brain tumor cells. As the first step toward this goal, results from phase I studies demonstrated that human NSCs displayed significant tumor targeting migratory behavior toward gliomas while stable expressing a reporter gene. Phase II entails genetically modifying NSCs to express an array of therapeutic genes, and then assessing their potential to target tumor cells and elicit an anti-tumor response. It is anticipated that genetically modified NSCs will infiltrate the tumor mass, track individual tumor cells, and stably express oncolytic proteins that can destroy the cancerous cells in rodent models. These studies will advance the
Studies
25
development of a potentially revolutionary treatment strategy using human NSCs as a novel, efficient delivery vehicle to target therapeutic genes to refractory brain tumors. PROPOSED COMMERCIAL APPLICATIONS: Neural stem cells represent a compelling new technology platform for the treatment of neurological diseases. Their natural migratory capacity provides a powerful vehicle to target therapeutic agents directly to refractory brain tumors. This project will evaluate an array of therapeutic genes to expedite the development of a potentially revolutionary cancer therapy strategy to treat deadly brain tumors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNODEFICIENT MOUSE MODEL OF STEM CELL PLASTICITY Principal Investigator & Institution: Nolta, Jan A.; Associate Professor; Medicine; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-JUL-2005 Summary: (provided by applicant): Recent intriguing observations indicate that stem cell plasticity may exist. Rodent bone marrow cells have been shown to contribute to liver, skeletal and cardiac muscle. These extremely exciting findings could impact health care in a dramatic way in the future, if applicable to the human system. Marrow stem cells could theoretically be harvested from a patient and used to repair his or her damaged heart, muscle tissue, or liver. In order to realize this potential, the scientific community must determine the phenotype(s) of the human counterparts to the murine cells that have displayed plasticity, must determine whether a single totipotent stem cell from human marrow is capable of differentiation into tissue and blood, and must optimize isolation and transplantation of the totipotent cells. We hypothesize that there are true totipotent cells that reside in the adult human and mouse bone marrow and in neonatal umbilical cord blood. We hypothesize that common stem cells exist for blood and liver, and that in the human, their phenotype will be plastic non-adherent CD34/lin-, and in the mouse their phenotype will be plastic non- adherent SP or c-kit+Thy1.1(lo)Lin-sca-1+. We predict that human and murine cells that can repair muscle are actually plastic adherent mesenchymal stem cells (MSC) and will not generate blood cells. We will use our novel immunodeficient nude/NOD/SCID mouse strain, which has a lifespan of two years, as the recipient for marked stem cells of defined phenotype, isolated from murine bone marrow, human marrow, and human umbilical cord blood. Retroviral and lentiviral vector marked MSC and HSC fractions from each source will be assessed in vivo for their capacity to form blood cells and muscle, following muscle injury, or blood cells and liver, following liver injury to the recipient. Clonal integration analysis at the single cell level, with sequencing, will determine whether the progeny were derived from the same precursor, or from discrete stem cells. We will also determine whether it is possible to modulate the survival, differentiation, and recruitment of candidate murine and human totipotent stem cells to specific tissues by expression of supraphysiological levels of Hepatocyte Growth Factor/Scatter Factor (HGF/SF). HGF is a chemoattractant and viability factor that is elevated in injured liver, cardiac, and skeletal muscle. HGF affects the motility and maintains the viability of myoblasts, hepatic oval cells, and hematopoietic stem cells. We hypothesize that HGF, secreted locally in response to tissue injury, is a major factor in recruiting totipotent stem cells from the circulation into the site of muscle or liver injury. We hypothesize that HGF may maintain the viability of recruited, totipotent stem cells, while they are directed by other inductive, tissue-specific factors in the local microenvironment to differentiate, to regenerate the damage tissue. The impact of HGF on the recruitment, survival and differentiation of human and murine totipotent stem cell candidates will
26
Stem Cells
be tested in vitro and in vivo. Our studies will provide definitive proof that stem cell plasticity exists, will identify the phenotypes of the murine and human cells that can generate liver or muscle tissue in addition to blood cells, and will determine methods to enhance the recruitment of those cells to damaged tissue. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IN UTERO STEM CELL TRANSFER IN MPS VII Principal Investigator & Institution: Barker, Jane E.; Senior Staff Scientist; Jackson Laboratory 600 Main St Bar Harbor, Me 04609 Timing: Fiscal Year 2003; Project Start 30-SEP-1994; Project End 31-JUL-2007 Summary: (provided by applicant): Progressive childhood diseases should be treated before pathological sequelae are evident. A technically promising but underdeveloped approach experimentally and clinically is in utero transplantation. Two major causes for unsuccessful human in utero therapy were identified by animal studies. They are microrather than macro-chimerism following congenic and allogeneic transfers and allogeneic donor cell rejection initiated by unexpected and inexplicable immune complications. It is critical that we understand the mechanisms behind these failures and develop alternative approaches to correct them. This is the goal of our current proposal. We investigate stem cell biology and curative interventions in Mucopolysaccharidosis type VII (MPS VII) mice, a model that mimics human lysosomal storage diseases. MPS VII mice lack the enzyme beta glucuronidase (GUSB). This allows us to track and enumerate GUSB+ donor cells by histochemistry and confirm our results by flow cytometry, biochemistry, and pathogenesis. Disease symptoms are ameliorated by enzyme replacement. We compared repopulation in genetically myeloablated and non-ablated MPS VII fetal recipients of congenic fetal GUSB+ hematopoietic cells. Results indicate that the donor cells do not have a selective advantage as previously hypothesized in the rapidly growing nonablated fetuses. Surprisingly, donor cells do amplify modestly between birth and one week of age and are maintained at a low percentage long term. Donor cells undergo rapid proliferation within 24 hours in the genetically myeloablated fetus and increase thereafter until they completely repopulate the host. We predict that donor cell amplification is directly linked to levels of stem cell implantation. Following allogeneic transfers, there are reasons to believe that the dam and fetus supply immunologically competent cells to one another and that allogeneic donor cell expansion after birth occurs in a hostile environment. We hypothesize that significant allogeneic donor cell implantation and expansion can be effected in utero without serious immune consequences. Our aims are to: Determine if donor stem cell implantation levels in utero affect subsequent stem and differentiated cell amplification; Identify procedures that increase corrective donor cells in the fetus; Define the role of dam and fetal immune response in allogeneic in utero transplantation; and Block immune responses to allogeneic cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INDUCTION AND MAINTENANCE OF PLURIPOTENT-PLASTIC STATE Principal Investigator & Institution: Asch, Adam S.; Associate Professor of Medicine; Medicine; Weill Medical College of Cornell Univ New York, Ny 10021 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-JUL-2005 Summary: (provided by applicant): Recently, the traditional view that somatic stem cells remain faithful to their tissue of origin has been challenged. The capability of
Studies
27
muscle-derived, and neural-derived cultures to produce cells capable of hematopoietic reconstitution following transplant, as well as the ability of hematopoietic cultures to give rise to muscle cells raises profound questions about the plasticity of somatic cells. The possibility that such plasticity might be exploited for therapeutic potential is compelling and makes a better understanding of its nature and the ways in which might be regulated of great interest. Plasticity, or the ability of cells that we think of as being lineage committed, to generate an alternative tissue or cell type must require the cells to reprogram and take an alternative developmental path. This must be true even of the stem cell populations within a tissue. An understanding of the basic mechanisms that define the pluripotent and plastic state somatic stem cells is the focus of this proposal. Our hypothesis is that the plasticity of stem cells a function of the translational repression of critical transcription factors present in the pluripotent stem cell. Plasticity, we also hypothesize, involves inhibition of expression of lineage defining transcripts already present within a cell resetting the developmental program along an alternative developmental pathway. To date, a proteomic approach to defining gene expression has not been undertaken. We have explored a novel and robust method for defining the change in translation upon the differentiation of stem cells. Using this approach we will be able to identify and study transcripts that are translationally repressed in the plastic/pluripotent state and gain an understanding of the basic mechanisms that underly plasticity and pluripotency. Specifically we will 1) identify critical translationally regulated mRNA transcripts and define an accurate picture of overall gene expression in the pluripotent cell by quantitating polysome-associated transcripts and their translational state using a rapid throughout screening assay in an in vitro model of stem cell plasticity; 2) define the mechanisms of translational regulation in transcripts critical to plasticity and pluripotency; and 3) define the role of translational regulation in modulating and maintaining pluripotency. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INITIAL CHARACTERIZATION OF PIG HEMANGIOBLASTS Principal Investigator & Institution: Quertermous, Thomas; Professor; Medicine; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 15-JUN-2001; Project End 31-MAY-2004 Summary: (Verbatim from the application): Multipotent stem cells exist in a variety of embryonic and post-embryonic tissues, and include neural and hematopoietic stem cells. These cells, which have the ability to both self-renew and differentiate in response to biological stimuli, hold great potential for replacing damaged or diseased tissues. The greatest utility for such cells will be in their application to the treatment of cardiovascular disease. Specifically, hemangioblastic stem cells will provide for cellular angiogenic therapy, and allow modulation of the immune system for cardiac xenotransplantation. There is mounting evidence that human and mouse hemangioblasts exist in embryonic life and may persist into adulthood. Understanding the conditions which control their expansion and differentiation would facilitate direct investigation of these cells in treating pathologic conditions. The full therapeutic potential of stem cells can only be realized if they are characterized and isolated to near homogeneity in animal models relevant to human disease. We propose to isolate and characterize hemangioblasts from pigs by cloning and developing antibodies to highly conserved stem cell markers. The pig has distinct advantages in applied animal research because of its size, hemodynamic similarity to humans, and breeding characteristics. Pigs are used extensively to test percutaneous vascular interventions, and they are also the most likely animal source for organ xenotransplantation. The specific aims of this
28
Stem Cells
proposal are: 1) To isolate pig blood and bone marrow cells which lack features of terminal differentiation, and which express hemagioblast-associated surface antigens using newly generated pig-specific antibodies. Isolated cell populations will be adapted to culture. 2) To characterize the vascular and hematopoietic potential of the above isolated cell populations in vitro, and assess their self-renewing potential. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ISOLATION OF INTESTINAL EPITHELIAL STEM CELLS Principal Investigator & Institution: Henning, Susan J.; Professor; Pediatrics; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 02-AUG-2002; Project End 31-JUL-2004 Summary: (provided by applicant): Currently there is considerable interest in adult stem cells from a variety of tissues because of their potential to contribute to our basic understanding of differentiation and development as well as their long-term therapeutic potential. Of all adult tissues, the small intestinal epithelium has by far the most stem cells and the highest rate of turnover. The intestinal stem cells are located deep in the crypts of Leiberkuhn and have been demonstrated to be multipotent precursors of the 4 principal lineages within the epithelium. Although the in vivo behavior (e.g. kinetics) of intestinal stem cells has been studied for many years, our understanding of the properties of these cells has been greatly hampered by lack of methods to isolate, identify and characterize them. Likewise, there is currently a lack of suitable cell transplantation models in which to study proliferation and differentiation of putative intestinal epithelial stem cells. Finally, in light of recent findings in both mice and humans, the possibility that stem cells from other tissues make a quantitatively significant contribution to the intestinal epithelium appears worthy of investigation. Thus, the Specific Aims of this exploratory R21 proposal are: 1) To develop flow cytometry methods for isolation of viable stem cells from the epithelium of mouse small intestine. Specifically, to subject intestinal epithelial cells to novel sorting procedures that have been successfully used with bone marrow cells to identify a fraction which is highly enriched in stem cells; 2) To develop a mouse model with local, limited sterilization of intestinal crypts to create an ideal region for subsequent transplantation of putative epithelial stem cells; 3) To transplant putative intestinal epithelial stem cells into damaged regions of mouse small intestine and subsequently assess the morphology as well as the expression of lineage-specific markers in epithelium derived from the transplanted cells; and 4) To repeat the studies of Specific Aim 3 using bone marrow hematopoietic stem cells. These studies should set the stage for a variety of future investigations regarding both the basic biology and the therapeutic potential of intestinal epithelial stem cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ISOLATION OF LIMBAL EPITHELIAL STEM CELLS Principal Investigator & Institution: Lavker, Robert M.; Professor; Dermatology; Northwestern University Office of Sponsored Research Chicago, Il 60611 Timing: Fiscal Year 2002; Project Start 01-AUG-2001; Project End 31-JUL-2004 Summary: (Applicant's Abstract) Epithelial stem cells are responsible for the homeostasis of self-renewing epithelia. Moreover they play a central role in wound repair and are the target cell for tumor initiation. My work during the past decade has contributed to the identification of stem cells within the corneal epithelium. Isolation of limbal epithelial stem cells will greatly facilitate their characterization. Furthermore,
Studies
29
isolation of pure populations of limbal stem cells will provide the ultimate starting material for epithelial cells needed for transplantation in corneal reconstruction. The lack of specific markers for epithelial stem cells has become a major impediment in their isolation and subsequent biochemical characterization. The goal of this project is to identify specific markers for limbal epithelial stem cells. Towards this end we will: 1) use single cell technology in combination with molecular biology to obtain mRNA from limbal epithelial stem cells and corneal epithelial transit amplifying (TA) cells; 2) use suppressive subtractive hybridization (SSH) and cDNA microarrays to identify genes that are differentially expressed in limbal epithelial stem cells versus corneal epithelial TA cells; and 3) characterize the limbal epithelial stem cell-specific genes and investigate their potential function(s), focusing on those genes that are associated with the cell surface. Data obtained from these studies should lead to the isolation of pure populations of limbal epithelial stem cells. This will facilitate the biochemical characterization of these cells, and will provide a better understanding of the mechanisms involved in the self-renewal of stem cells, and in the mechanisms of limbal and corneal epithelial growth and differentiation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ISOLATION OF MURINE PANCREATIC LIVER STEM CELLS Principal Investigator & Institution: Grompe, Markus C.; Professor; Molecular and Medical Genetics; Oregon Health & Science University Portland, or 972393098 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2005 Summary: (provided by applicant): Many organs depend on highly regenerative stem cells for tissue renewal after injury or during normal turnover. During embryonic development a common endodermal pre-cursor/stem cell gives rise to both the hepatic and pancreatic parenchyma, including the ductular, exocrine and endocrine components of the pancreas. The isolation and purification of this hepato-pancreatic stem cell would greatly advance the understanding of the biology of the pancreas and possibly generate a therapeutic agent for the treatment of diabetes. The hematopoietic stem cell was identified by a biological assay, the ability to reconstitute the blood and immune system of a host after lethal irradiation. Unfortunately, a transplantation based in vivo repopulation assay for pancreatic stem cells has not been developed. However, several independent lines of evidence suggest that adult mouse pancreas continues to contain cells which can give rise to hepatocytes under certain experimental conditions. The fumarylacetoacetate hydrolase knockout mouse represents a robust liver repopulation assay in which permits the identification of cells that have the capacity to regenerate the liver. Preliminary data have shown that adult murine pancreas contains cells, which have high liver repopulating capacity (pancreatic liver stem cells). We hypothesize that the repopulating activity is a primitive endodermal precursor capable of giving rise to multiple cell types including hepatocytes, bile ducts, pancreatic ducts, acinar cells and endocrine cells. This application pertains to the use of liver repopulation as a surrogate assay for primitive murine pancreatic stem cells. The assay will be used to develop methods for their optimal isolation. Monoclonal antibodies useful for FACS sorting of pancreatic cells will be generated. We will apply cell-sorting methods to enrich pancreatic liver stem cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
30
•
Stem Cells
Project Title: MARKING PROGENITOR CELL LINEAGES IN THE VASCULAR SYSTEM Principal Investigator & Institution: Stuhlmann, Heidi; Associate Professor; Scripps Research Institute Tpc7 La Jolla, Ca 92037 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2005 Summary: (provided by applicant): Stem cells are self-renewing, pluripotent cells that can give rise to multiple cell lineages and/or cell types of the body. The development of human and mouse embryonic stem cells and the isolation of adult stem cells have received much attention. The possibility of using stem/progenitor cells to replace damaged or diseased human tissue has been widely publicized. One application of this technology would be to repair damaged cardiac and vascular tissue; however, this will first require identification and characterization of vascular stem/progenitor cells. The goal of this project is to identify and characterize vascular stem/progenitor cells and to explore their developmental potential in vitro and in vivo. We will mark early vascular progenitor cells with an autofluorescent reporter suitable for flow cytometry, such as enhanced green fluorescent protein (EGFP). We will "knock-in" the auto fluorescent tag into the endogenous locus of early endothelial genes in mouse embryonic stem (ES) cells. Second, we will isolate and characterize marked progenitor populations from differentiating ES cells and embryonic yolk sac membranes. Third, we will examine the lineage differentiation potential of these progenitor cells in vitro and in vivo. We anticipate that this project will provide important insights into the nature of stem cells at the beginning of the vascular system, and possibly common to the hematopoietic and endothelial lineages. Ultimately, these studies will address basic questions of using stem cells for damaged or diseased blood vessels. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: METHODS DEVELOPMENT
FOR
MODULATING
HEMATO-VASCULAR
Principal Investigator & Institution: Baron, Margaret H.; Associate Professor; Medicine; Mount Sinai School of Medicine of Nyu of New York University New York, Ny 10029 Timing: Fiscal Year 2003; Project Start 20-SEP-2003; Project End 31-JUL-2008 Summary: (provided by applicant): The first organ system to form in the developing mouse embryo is the cardiovascular system. Defects within the heart and vasculature are largely responsible for embryonic lethality in utero. Within the developing vascular network of the yolk sac as well as in certain intra embryonic regions, endothelial and hematopoietic cells arise in close spatial and temporal association and are thought to derive from a common mesodermal progenitor, the "hemangioblast." Recent work has indicated that hemangioblasts may also have smooth muscle cell potential. Regulation of hemangioblast and embryonic hematopoietic stem cell formation and cell fate specification are still not well understood. This proposal focuses on the characterization and functional analysis of specific subsets of mesodermal cells that give rise to hematopoietic, vascular endothelial, and smooth muscle cells during development. First, we will evaluate the hematopoietic potential and functional activity in vitro and in vivo of prospectively identified mesodermal stem/progenitorcell populations from differentiating embryonic stem cells (embryoid bodies) and from early mouse embryos. Cells will be isolated by flow cytometry on the basis of their expression of primitive cell surface markers and, using a GFP reporter transgene, on the basis of their expression of mMix, a homeodomain transcriptionfactor expressed in embryoid body subsets thought to contain hemangioblasts. The sorted cells will be analyzed using several different
Studies
31
assays for stem/progenitor cells in culture and transplantation models in the mouse. Second, in analogous studies, we will evaluate the endothelial and smooth muscle potential and functional activity in vitro and in vivo of prospectively identified mesodermal stem/progenitor cell populations. Third, we will evaluate the role of the Mix homeodomain protein on the developmental potential and functional activity in vitro and in vivo of embryoid body derived mesodermal stem/progenitor cell populations. The origin of embryonic hematopoietic / vascular stem cells and their relationship to stem cells of the adult are unknown. With the increasing focus on regenerative medicine and interest in potential therapeutic applications of human embryonic and adult stem cells, the characterization of mesodermal stem/progenitor cell populations takes on high significance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODEL AGAMMAGLOBULINEMIA
FOR
GENE
THERAPY
IN
X
LINKED
Principal Investigator & Institution: Rawlings, David J.; Associate Professor; Pediatrics; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 01-JUN-1999; Project End 31-MAR-2004 Summary: (Adapted from applicant's abstract). Human X-linked agammaglobulinemia (XLA) results from deficient function of Bruton's tyrosine kinase (Btk). In affected males, the production of B lineage cells is profoundly reduced resulting in life threatening humoral immunodeficiency. Definitive genetic therapy utilizing expression of wild type Btk in stem cells or B lineage progenitors would represent a significant advantage over the current supportive management of XLA. The Investigator proposes to establish preclinical cellular models for the genetic treatment of XLA through three aims. Aim 1. Development of a multistage human B cell culture system that can be used to evaluate reconstitution of B cell function in vitro. The Investigator will improve the derivation of B cells representing multiple stages of the B lineage from long-term human B progenitor cell cultures. This will be done by exploiting a range of culture modifications and signals that lead to activation, maturation, and production of secreted immunoglobulin by immature B cells. Soluble factors and cell surface ligands on stromal cells will be evaluated. The Investigator will also utilize in vivo transfer studies in SCID/NOD mice. Aim 2: Development and testing of the capacity of retroviral vectors capable of high level, sustained expression in hematopoietic stem cells, and of novel hybrid adenoviral/EBV episome vectors for Btk gene transfer and rescue of Btk signaling in vitro. Alternative gene transfer systems will be evaluated using a new signaling competent human B cell model developed by the Investigator's laboratory. This will allow the Investigator to rapidly test the transduction efficiency, and the levels and duration of protein expression of alternative vectors. In addition, the Investigator will directly evaluate the capacity of these vectors to rescue Btk dependent signaling events and determine the dosage of Btk required for functional reconstitution in human B cells. Aim 3. Evaluation of the capacity of those gene transfer vectors that successfully restore Btk signaling in vitro to reconstitute Btk dependent immune function in vivo in Btk-/mice, and ultimately, in vitro in long term cultured XLA B cells. The Investigator will evaluate gene transfer using hematopoietic stem cells and growth factor expanded B progenitors from Btk-/-mice as target cell populations. Reconstitution of B lineage development and function will be evaluated using multiple measures of Btk dependent immune function. Those vectors demonstrating optimal restoration of Btk function in vivo will be utilized for gene transfer into stem cells or B progenitors in pre-clinical studies of patients with XLA.
32
Stem Cells
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR & CELLULAR BIOLOGY OF HAIR FOLLICLE STEM CELLS Principal Investigator & Institution: Lyle, Stephen R.; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2007 Summary: (provided by applicant): The overall goal of this project is to characterize the expression of genes within hair follicle stem cells and to study the role of specific genes in maintaining the stem cell phenotype. The hair follicle is a model for studying epithelial stem cells and understanding the mechanisms which maintain the homeostasis of hair follicle stem cells and may lead to advances in the areas of tumorigenesis, wound healing and hair disorders. Similar to other self renewing tissues, such as bone marrow, gastrointestinal tract and epidermis, the hair follicle contains slowly cycling stem cells with a high proliferative capacity and the ability to produce differentiated cells to regenerate the tissue. Unlike other tissues, however, hair follicle growth (anagen) is interrupted by periods of regression (catagen) and rest (telogen), with subsequent regeneration. Since the lower follicle degenerates in the catagen phase, leaving only the telogen club structure, this residual epithelial cap surrounding the club hair represents an enriched source of stem cells which are responsible for regenerating a new lower follicle in anagen. They have extracted RNA from the stem cell rich area of telogen follicles as well as from the bulb area of anagen follicles dissected from human scalp. Through cDNA expression arrays, a number of genes appear to be expressed in the stem cell area that are not expressed in matrix keratinocytes of the anagen bulb. Several of the genes have been shown to mediate proliferative behavior and differentiation pathways in other experimental systems. The hypothesis that will be tested in this proposal is that specific genes expressed in the stem cells of the hair follicle are important in maintaining stem cell properties. The specific aims are: 1. To characterize the expression of specific genes identified by the expression array through in situ hybridization, immunohistochemistry and immunofluorescence with confocal microscopy. Three genes which likely have roles in maintaining stem cell properties will be examined. 2. To test the significance of these three genes in maintaining in vitro properties of hair follicle stem cells through retroviral transfection of human hair follicle stem cells with wild type and mutant gene constructs. Clonogenicity assays and other in vitro experiments of native and transfected stem cells will be used to study the role of these genes in clonality and other stem cell attributes. 3. To test the function of the specific genes during hair follicle development and cycling through in vitro and in vivo methods. Hair reconstitution assays performed with native and genetically altered stem cells will be used to analyze potential functions in folliculogenesis and cycling. In addition to the established mouse hair reconstitution system, they will attempt to develop a human hair follicle reconstitution system from hair follicle stem cells and microdissected dermal papillae using acellular dermal analogues with transplantation onto athymic mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR CONTROL OF PANCREATIC ISLET DEVELOPMENT Principal Investigator & Institution: German, Michael S.; Associate Professor of Medicine; Hormone Research Institute; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-JUL-2005
Studies
33
Summary: The objective of this Program Project is to bring together four research groups and to apply their complementary expertise to the problem of how undifferentiated cells develop into insulin-secreting beta-cells in organizing islets of Langerhans. Deriving data from zebrafish, chicks, mice, and humans, each project focuses on different but overlapping steps in the progression from embryonic stem cells to organized islets. Ultimately this information will be applied to the development of strategies for the production of new islets for patients with diabetes. Project 1 (Bell) will focus on the identification, characterization and purification of pancreatic stem/progenitor cells. Using progenitor-specific promoters developed by German, cells at discrete stages of differentiation will be fluorescently tagged in transgenic mice. These mouse models will be used to isolate and characterize presumptive pancreatic stem/progenitor cells. In addition, genes involved in islet development identified by German, Hebrok and Stainier will be screened for mutations in human populations. Project 2 (German) will focus on the progression of pancreatic progenitor cells to differentiated beta-cells utilizing the fluorescent transgenics derived by Cell, transcription factor knockout mice previously developed in this lab, and the microarray core. These studies will generate a picture of the gene expression changes that occur during beta-cell genesis, and provide candidate genes will be tested for their ability to affect the beta- cell fate decision in collaboration with Bell, Hebrok, and Stainer. Project 3 (Hebrok) will study endocrine cell migration and islet formation. Using mouse genetic models, he will test the role of migration guidance molecules and extracellular matrix modulators in islet morphogenesis and function. He will test the hypothesis that proper islet formation is critical for optimal islet function and homeostasis both in mice (with German) and humans (with Bell). Project 4 (Stainer) will examine the role of endoderm specification from zebrafish in activating the endodermal program in embryonic stem cells, the first step in the pathway to differentiated beta-cells. The zebrafish model will also be used in two collaborations with German: first to characterize the function of progenitor-specific promoters and second to test the role of candidate beta-cell determination genes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EXPRESSION
MOLECULAR
MECHANISMS
THAT
REGULATE
CD11D
Principal Investigator & Institution: Noti, John D.; Associate Professor; Guthrie Foundation for Education and Res Education and Research Sayre, Pa 18840 Timing: Fiscal Year 2002; Project Start 15-AUG-2001; Project End 31-JUL-2005 Summary: The development of the myeloid lineage from totipotent stem cells is the result of the expression of transcription factors that are either constitutively expressed or differentially induced at specific times during differentiation. A number of key transcription factors have been found that direct myeloid development. A number of specific genes affected by these transcription factors have been revealed and their expression contributes to the overall phenotype of myeloid cells. Understanding the process of normal myeloid development will require the identification of transcription factors and their co- factors that activate or silence lineage-specific genes. The restricted pattern of expression of the leukocyte integrin CD11d serves as an excellent model to identify some of these factors. CD11d is expressed on stem cells, myelomonocytic cells, and strongly on macrophage foam cells, and splenic red pulp and alveolar macrophages. Its expression pattern clearly differs from myeloid-specific leukocyte integrins CD11b and CD11c. We determined that CD11d is regulated during myeloid differentiation of stem cells, and during differentiation of monocytes to macrophages and foam cells. We propose that myeloid-specific transcription factors can be identified
34
Stem Cells
with a study of the CD11d promoter. Further, identification of cis elements and the interacting transcription factors that control CD11d expression could provide a means to direct expression of specific genes to myeloid cells in gene therapy approaches. The goals of this project are to identify myeloid-specific transcription factors that control CD11d expression and test their role in myeloid differentiation. We present evidence for 3 sites within a region in CD11d that confer myeloid-specificity, and that transcription factors that bind this region affect myeloid differentiation. One-hybrid analysis of this region led to the isolation of two myeloid-specific cDNAs. We also present evidence that CD11d expression and foam cell development may utilize shared transcription factors. Two silencers, one being cell-specific, are also in the CD11d locus. We propose to further characterize these and possibly other essential cis elements by site-directed mutagenesis, transfection analysis, DNase I hypersensitivity, mobility shift and DNase I footprint analyses. Yeast one-hybrid technology will be used to isolate novel myeloid-specific transcription factors. Model systems in which to study the CD11d promoter and myeloid-specific factors will include embryonic stem cells, peripheral blood monocytes, and myeloid cell lines. Identified factors will be up- or downregulated through forced overexpression or antisense approaches to determine their effect on myeloid differentiation. Transgenic analysis of the CD11d cis elements will be done to complement these studies. These studies will expand our understanding of normal myeloid development and leukemogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOUSE MODELS OF EARLY INTESTINAL NEOPLASIA Principal Investigator & Institution: Shibata, Darryl K.; Professor; Pathology; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2003; Project Start 01-JAN-1999; Project End 31-MAR-2008 Summary: (provided by applicant): Human cancers contain multiple mutations and it is uncertain which mutations are necessary and sufficient, which are passive passenger mutations, and whether there are other yet undiscovered mutations crucial for transformation. One prospective approach to better understand the roles of specific mutations is to engineer these mutations in normal cells. We propose to engineer tumors in mice by sporadically and somatically creating "mutant" stem cells with defined genotypes. Unlike most mice models, our approach will better mimic sporadic tumorigenesis because Cre-mediated inactivation of floxed tumor suppressor genes (TSGs) will stochastically occur in isolated, widely scattered single cells. A nonfunctional out-of-frame (An+l) germline Cre-allele will become activated (An+l to An) in a DNA mismatch repair deficient background and subsequently recombine floxed genes to create well-defined mutant genotypes. A current An+l transgenic Cre allele will be targeted to the ubiquitously expressed ROSA26 locus to better control its activation. Similar to sporadic tumorigenesis, stochastic and somatic mutations will occur in single cells surrounded by normal cells. Our studies will examine sporadic Apc, Pten, or Trp53 inactivation in the intestines. Because it is uncertain how many mutations are required for transformation, a floxed B-galactosidase allele will be included so that "mutant" cells may be identified regardless of resultant phenotype. Certain TSGs may modulate stem cell survival, and even though loss of a single TSG may not confer a neoplastic phenotype, stem cell survival may be increased, resulting in greater numbers of blue staining "mutant" cells in otherwise normal appearing intestines. Multistep tumor progression implies that cancers arise after a series of mutations. These studies will prospectively recreate this process and define the fates of single stem cells in normal mammalian tissues that acquire one or more concomitant gene alterations. The
Studies
35
success or failure of certain mutations to confer neoplastic phenotypes will challenge or confirm canonical tumor progression models. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MPTP-INDUCED HOMING OF BONE MARROW STEM CELLS TO THE BR* Principal Investigator & Institution: Cunningham, Lee A.; Associate Professor; Neurosciences; University of New Mexico Albuquerque Controller's Office Albuquerque, Nm 87131 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-JAN-2004 Summary: Bone marrow-derived stem cells incorporate into multiple tissue types in adult mammals, where they give rise to cells of multiple lineages that cross classic embryological trilaminar boundaries [9,11,17,21,31,40,41]. This recent discovery has opened the possibility that bone marrow transplantation could be clinically useful to treat a broad spectrum of pathologies. Recently, marrow-derived progenitor cells have been shown to migrate and incorporate into the brain to give rise to cells of neuroectodermal lineage, (astrocytes and neurons), in addition to microglia [4,7,25]. Importantly, marrow-derived progenitors appear to display preferential homing to regions of CNS gliosis and degeneration [8], consistent with studies in peripheral tissues demonstrating enhanced engraftment of multi-potential marrow-derived stem cells into sites of injury [21,31] [Jackson, 2001 #360]. The focus of the current proposal is to explore the migration and differentiation of marrow-derived stem cells into the brain in a rodent model of Parkinson's disease, the MPTP-treated mouse. Questions to be addressed in this proposal include: Do marrow-derived progenitors display selective homing to the damaged nigra and striatum in response to MPTP-induced degeneration? If so, do they give rise to cells of neuroectodermal lineage? What is their contribution to the gliosis that accompanies nigrostriatal degeneration? To track marrow-derived progenitors within the CNS, we will utilize bone marrow from transgenic mice that express an enhanced green fluorescent protein (GFP) under the beta-actin promoter. The migration and differentiation of marrow-derived progenitors will be studied in chimeric mice whose endogenous hematopoietic systems have been completely reconstituted with GFP-expressing cells prior to MPTP- treatment, and in mice that receive acute intravascular injections of GFP+ expressing cells prior to MPTP-treatment, and in mice that receive acute intravascular injections of GFP+ expressing marrow following the onset of MPTP-induced degeneration. The immediate goal of the proposed studies is to delineate the relationship between marrow-derived progenitors and the brain in a rodent model of Parkinson's disease. If successful, these studies may provide the basis for future work to development new non-invasive gene therapies for Parkinson's disease, using accessible, renewable and autologous bone marrow stem cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MSC AS FACILITATORS OF TRANSPLANTION TOLERANCE Principal Investigator & Institution: Bartholomew, Amelia M.; Surgery; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2002; Project Start 20-AUG-2001; Project End 31-JUL-2004 Summary: (provided by applicant): Transplantation tolerance, or the permanent acceptance of an allograft without the need for chronic immunosuppression, has remained clinically elusive. Strategies to induce tolerance through the production of lymphohematopoietic chimerism, though successful in small and large animal models,
36
Stem Cells
have been hampered by the toxicities involved in conditioning the recipient. Host conditioning regimens have traditionally required elements to eliminate or inactivate host-alloreactive T cells and cytoreductive treatment to liberate niches within the bone marrow microenvironment for allogeneic engraftment. Recent advances in stem cell biology have provided data indicating the requirement for cytotoxic therapy can be overcome by using very large doses of HSCs. Possible explanations of this observation have included improved competition of donor stem cells for marrow niches and diminished frequencies of cytotoxic T lymphocyte precursors by the direct interaction with hematopoietic stem cells. A component of the bone marrow that has largely been ignored and is poorly understood, is the MSC. These stromal elements, occurring in very low frequency, are multipotential cells that can be induced to differentiate into bone, muscle, adipocytes, myocytes, and brain and share many functional and phenotypical characteristics of thymic stromal cells. Further, they can provide regulatory signals that inhibit or promote lympho- and myelopoiesis, differentiation, and proliferation and secrete potent molecules, such as TGF-beta, SDF-1, IL-7, and FGF that affect T and B cell migration. Interestingly, the transplantation of bone fragments for stromal microenvironment in conjunction with HSCs has led to increased hematopoietic engraftment and transplantation tolerance. We have shown that transplantation of the bone marrow microenvironment without HSCs can also lead to the permanent acceptance of murine cardiac allografts. The separate contributions of bone and MSCs in these observations are unknown. Our preliminary studies suggest that MSCs can inhibit T cell proliferation in the mixed lymphocyte reaction, prolong skin graft survival in baboons, and home to the baboon bone marrow compartment, thereby potentially influencing the host microenvironment. These observations have led us to hypothesize that MSCs have immunomodulatory properties and play a major role in the induction of transplantation tolerance. The first specific aim will test the ability of mouse MSCs to engraft in the bone marrow and thymic microenvironments and to alter host T cell repertoire. The mechanism of effect on the host immune system will be explored to determine whether MSCs directly affect host T cells or whether MSCs induce a CD8 autoregulatory subset in the host. Specific aim 2 will test whether MSCs can function as facilitators of HSC engraftment in lethally irradiated mice. We will also test whether MSCs can eliminate the need for high dose HSC in minimally conditioned mice. Insights gained on the role donor MSCs play in allograft acceptance may then be applied to our pre-clinical baboon model for development of novel pre-clinical cellular therapies in transplantation tolerance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MUSCLE-DERIVED HEMATOPOIETIC STEM CELLS Principal Investigator & Institution: Goodell, Margaret; Assistant Professor; Pediatrics; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 31-JUL-2005 Summary: (Investigator's abstract) Primitive stem cells are found in many adult tissues and, throughout life, replenish mature cells lost through attrition or injury. Although thought to be committed to differentiate into cells of their native tissues, some stem cells now appear capable of generating several different cell types, an indication that they have retained considerable plasticity in their genetic programs. The biologic and therapeutic implications of "transdifferentiation" potential are far reaching but will remain speculative until the concept is better substantiated and the mechanisms that might drive this process are known. Evidence from the applicant's laboratory indicates that adult murine skeletal muscle contains stem cells capable of complete hematopoietic
Studies
37
regeneration. Thus, the central hypothesis to be tested is that these stem cells are a subset of myogenic stem cells known to participate in muscle regeneration, they share certain characteristics of bone marrow stem cells, have myogenic activity, are transducible with retroviral vectors, and can be found in human muscle. The major objectives of this proposal are to characterize the biologic properties and markers of muscle-derived hematopoietic stem cells by cell sorting and bone marrow transplantation experiments (Aim 1) so that the cells can be readily identified and purified, and their salient features an be compared with those of marrow-derived stem cells. It will also be important to assess the in vitro and in vivo myogenic potential of purified and clonal populations of muscle-derived hematopoietic stem cells (Aim 2). The results will establish whether or not the stem cells are bipotential precursors of both muscle and blood and therefore an extremely primitive stem cell with a flexible program of differentiation. If the muscle stem cells can be readily transduced with retroviral vectors and the modified cells shown to engraft and stably express a marker gene in transplant recipients (Aim 3), they may afford a novel means of delivering therapeutic genes of interest. Finally, results obtained in mice will need to be verified, both in vivo and in vitro, with stem cells derived from human muscle (Aim 4). Answers from these studies will be crucial in determining if human muscle could provide a source of hematopoietic stem cells for therapeutic exploitation. Successful completion of these aims will not only provide an estimate of the hematopoietic potential of adult muscle-derived stem cells, but also a foundation for future studies into the mechanisms of stem cell transdifferentiation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROECTODERM DIFFERENTIATION FROM MESENCHYMAL STEM CELL Principal Investigator & Institution: Verfaillie, Catherine M.; Professor; Medicine; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-JUL-2005 Summary: (provided by applicant): We identified a population of primitive cells that is co-selected when MSC are purified from human or rodent marrow that have, at the single cell level, multilineage differentiation and extensive proliferation potential, which we named Multipotent Adult Progenitor Cell or MAPC. MAPC differentiate in vitro into most mesodermal cell types as well as cells with neuroectodermal and endodermal features. Using retroviral marking we have preliminary evidence that multi-lineage differentiation is derived from single cells. We have also initial evidence that MAPC engraft in vivo, persist for 2+ months, and may be able to differentiate into tissue specific cells in response to local "cues", even though single cell origin of the engrafted cells that differentiate in multiple tissue specific cells has not yet been proven. Our finding that MAPC differentiate into cells with not only mesodermal but also endodermal and neuroectodermal characteristics in vitro and engraft in multiple tissues when transplanted, is consistent with recent publications showing that marrow derived cells can acquire markers of muscle, endothelium, liver and neuroectoderm in vivo. If proven further, such previously unrecognized plasticity of post-natal stem cells opens the exciting possibility that post-natal stem cells from easily accessible sources such as marrow could be used to treat a number of degenerative or inherited disorders. However, many questions remain, including 1) What is the nature of the stem cell with plasticity? 2) Is plasticity due to co-existence of multiple tissue specific stem cells in the marrow, or can a single cell differentiate into most tissue cells? 3) What is the mechanism underlying the commitment and differentiation of presumed multipotent
38
Stem Cells
marrow derived mesenchymal stem cells to non-mesenchymal lineages? 4) Can presumed multipotent mesenchymal stem cells repopulate organs other than marrow? 5) Will high level engraftment and differentiation in vivo require that these multipotent mesenchymal stem cells are induced to commit to the host organ tissue prior to transplantation? 6) Can multipotent mesenchymal stem cells be used in stead of organ specific stem cells to repopulate an organ in vivo? We propose the following specific aims: SA1: To demonstrate that multipotent cells exist in post-natal marrow that, at the single cell level, can differentiate into cells of mesodermal and neuroectodermal lineage. Specifically, we will demonstrate using in vitro clonal assays that single cells from murine marrow can proliferate without senescence and can at the single cell level differentiate into cells of mesodermal and neuroectodermal lineage. We also plan to assess the frequency of cells with these characteristics in MSC and develop methods to purify such cells. SA2: Can MAPC differentiate into functioning neurons in vitro and what are the intermediary cell types that are generated? We plan to use neuroectodermal differentiation from MAPC to evaluate the plasticity of somatic stem cells. We will examine the degree of differentiation that can be obtained, and also examine the mechanism of commitment and differentiation of MAPC by comparing the nature and potential of intermediary progenitors and precursors that are generated from MAPC with that of brain derived neuroprogenitors. SA3: Can MAPC differentiate into functioning neurons in vivo? We will evaluate whether multipotent marrow derived stem cells or their neuroectodermal committed progeny repopulate the host brain in vivo and acquire region specific differentiation characteristics in response to local cues. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OSTEOGENIC POTENTIAL OF HUMAN BONE MARROW CELLS Principal Investigator & Institution: Long, Michael W.; Professor; Pediatrics & Communicable Dis; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2007 Summary: (provided by applicant): This proposal seeks to understand the nature and degree to which human stem cells can form cells of the osteogenic lineage. The central hypothesis is that expression of osteogenic potential resides within a single population of multipotent stem cells that phenotypically differs depending upon its locale. We will test this hypothesis by examining three populations of cells reported to have osteogenic potential: bone marrow hematopoietic cells (focusing on CD34-negative cells), mesenchymal stem cells, and a recently described population of human bone precursor cells. The first goal of this proposal is to determine whether these populations of Osteopoietic Stem Cells (OSC) are related. This is accomplished by viral based marking studies and in vitro evaluation of the osteogenic potential of these cells. We have developed isolation and purification protocols that allow us to examine the function of osteoprogenitor cells, preosteoblasts, and osteoblast. The viral marking studies will utilize both lenti- and retroviral mediated gene transfer of GFP, taking care to deplete the three populations of more mature cells via lineage-depletion. Using our clonal osteoprogenitor cell assay, we take an alternative approach in which GFP-positive OPC from each population of virally marked cells are analyzed for integration by inversePCR. As well, a Power-Analysis of large numbers of marked OPC will be use to overcome problems of OSC frequency, integration efficiency, and signal-dilution. The second aim is to examine if the osteogenic fate of OSC populations can be enhanced. Such fate decisions are hypothesized to be modulated via manipulation of cell-intrinsic and/or cell-extrinsic mechanisms. Intrinsic mechanisms are investigated by modulation
Studies
39
of bone related transcription factors (e.g., Fral, delta-fos B and others) and evaluation of their affect on osteogenic commitment and ex vivo bone formation. Extrinsic control of osteogenic fate determine focuses on the role of an accessory cell population, recently identified in this laboratory, as well as enforced expression of bone-active cytokines by CHO cells that function as "artificial Stromal cells." The final set of experiments focuses on the fate of OSC populations in vivo. These studies will determine the degree to which OSC can "home" to the osteogenic microenvironment in immuno-compromised Nude/NOD/SCID mice. As well, we will explore the capacity of these cells to commit to the osteogenic lineage and restore bone formation in osteoporotic NOD/SCID mice, as well as mice with skeletal defects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PANCREATIC STEM CELL INDUCTION BY SMALL MOLECULES Principal Investigator & Institution: Crews, Craig M.; Associate Professor; Molecular and Cellular Physio; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2004 Summary: (provided by applicant): Recent research in stem cell biology has been driven in large part by the immense potential of stem cells in the treatment of various human diseases. Given the absence of insulin production in Type 1 diabetes, the regeneration of pancreatic beta islet cells from stem cells could have direct clinical application for diabetic patients. However, neither the isolation nor production of pancreatic stem cells is currently a viable option for pancreatic regeneration. In order to overcome these obstacles, we propose to identify small molecules capable of inducing embryonic stem (ES) cells to differentiate into pancreatic stem cells. This will involve the screening of a 15,000 compound library for compounds that induce the expression of the homeobox protein PDX-1, an early marker of pancreatic stem cells. Subsequent assays will analyze for additional pancreatic markers, (i.e., neurogenin3 and insulin). Compounds meeting these criteria will be assayed for the ability to induce pancreatic tissue in eve in the chick embryonic assay. Small molecule-generated ES-derived "islet-like" cells will then implanted in NOD mice to determine if they are functional insulin-producing cells in vivo. We anticipate that the identification of a palette of pancreatic stem cell inducers will greatly stimulate basic research in this field (e.g., identification of additional pancreatic stem cell marker proteins via differential gene analysis). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: POTENTIAL OF BLOOD PROGENITORS TO FORM NONBLOOD TISSUE Principal Investigator & Institution: Eisenberg, Carol A.; Associate Professor; Cell Biology and Anatomy; Medical University of South Carolina 171 Ashley Ave Charleston, Sc 29425 Timing: Fiscal Year 2002; Project Start 20-AUG-2001; Project End 31-JUL-2004 Summary: (provided by applicant): A dynamic area in biotechnology today is stem cell research. Stem cells are the precursor cells of every tissue in the body and thus, have the potential to provide replacement tissue for diseased and damaged organs. Our studies on stem cell differentiation suggest that adult and embryonic stem cells share a similar tissue potential. Specifically, we believe that stem cells from adult mammalian bone marrow have the capacity to give rise to all mesoderm derived tissue-although this potential is never realized in the normal adult environment. Initial studies have shown,
40
Stem Cells
for example, that hematopoietic stem cells (HSCs) from adult bone marrow-which normally give rise to the cellular components of the blood-can develop into cardiac myocytes under conditions developed for nondifferentiated embryonic tissue to undergo cardiac differentiation. As a first demonstration of our hypothesis on the broad potential of adult stem cells, we propose to extensively study the formation of cardiac tissue from adult mouse bone marrow stem cells. The experiments outlined in this project are designed to: (I) definitively identify this cardiac competent cell population of the bone marrow, (II) examine the capacity of this bone marrow cellular subpopulation to maintain their cardiac competence following their expansion in culture, (Ill) investigate their capabilities as cardiac cells, and (IV) examine their ability to integrate into adult cardiac tissue as functional cardiomyocytes. The development of methods to manipulate stem cell potential will have significant future medical impact, as it will provide the means to convert stem cells to pure populations of individual cell types for replacement tissue. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROGRAM PROJECT,RESTORATION OF ENDOCRINE PANCREAS FUNCT* Principal Investigator & Institution: Habener, Joel F.; Professor; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-JUL-2004 Summary: The overall objectives of the studies proposed in this Program Project Application (PPA) are to explore the potential efficacies of using stem/progenitor cells and modified pancreatic islets as cellular therapies to restore endocrine pancreas function and to thereby cure diabetes mellitus. The motivation for this PPA is the fortuitous occurrence of several events: (1) the independent discoveries of pancreatic stem cells by three Harvard investigators, Dr. Susan Bonner-Weir (Joslin), Dr. Joel Habener (Massachusetts General Hospital), and Dr. Richard Mulligan (Childrens' Hospital); (2) the availability from Dr. Douglas Helton (Harvard University) of normalized pancreas cDNA arrays that contain all of the genes express in the pancreas; (3) the development by Dr. Dennis Sgroi (Massachusetts General Hospital) of a means to prepare gene expression profiling probes by Dr. Bennis Sgroi (Massachusetts General Hospital) of a means to prepare gene expression profiling probes from minuscule amounts of tissue obtained by laser capture microdissection; (4) the discovery by Dr. Melissa Thomas (Massachusetts General Hospital) of active hedgehog signaling in the islets of the adult pancreas and (5) the availability from Dr. Gordon Weir (Joslin) of high quality human islets from a preexisting islet transplantation core laboratory. The application proposes three scientific projects and two scientific cores that will work synergistically together to achieve the objectives. Project 1: Pancreas-derived stem/progenitor cells for the regeneration of beta cells (PI: Dr. Bonnor-Weir) has three aims: (1) analysis of distinct populations of duct-derived stem/progenitor cells; (2) gene expression profiling comparisons of human duct-derived versus islet derived stem/progenitor cells during their differentiation; (3) regeneration of beta-cells via transplantation of stem/progenitor cells in animal models of diabetes (rat partial pancreatectomy). Project 2: Modulation of pancreatic islets for transplantation (PI: Dr. Weir) has three aims: (1) evaluation of human islets by expression profiling; (2) determination of the fate of human islets after transplantation; (3) differentiation of transplanted stem/progenitor cells (NIPs, ductal progenitors, SP cells, and others. Project 3: Morphogen signaling during pancreatic islet development (PI: Dr. Thomas) has three aims: (1) mechanisms by which hedgehog signaling regulates expression of
Studies
41
homeodomain protein IDX-1; (2) role of hedgehog signaling in the differentiation of pancreas-derived stem/progenitor cells into beta-cells; (3) hedgehog signaling in betacell development in vivo. The two scientific cores are: Core B: Islet isolation and transplantation (CD: Dr. Weir) and Core C: Laser capture microdissection and gene expression profiling (Co-CDs: Drs. Sgroi and Melton). All three projects will be heavy users of the two cores. In fact. The cores are the heart of the project, without which the objectives of the project could not be accomplished The two scientific cores are already established and running as components of the Harvard JDRF Islet Transplantation Center. In addition, all participants in this PPA application are members of one of the two NIDDK-funded Diabetes Endocrinology Research Centers (Joslin and MGH-based). An important aspect of this PPA is that the participants will be amongst the first to profile gene expression on cDNA arrays that incorporate all of the genes expressed in the pancreas and allow for determinations of the differences in genes expressed in healthy versus diseased islets and the genes expressed during the differentiation of stem/progenitor5 cells into beta-cells. This PPA proposes the initial studies on the way to providing a cure for diabetes via the approaches for regenerative medicine. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF EMBRYONIC STEM CELLS Principal Investigator & Institution: Pera, Martin F.; Monash University Faculty of Medicine, Nursing & Health Sciences Melbourne, Vic, 3181 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2006 Summary: (provided by applicant): The derivation of human embryonic stem (ES) cell lines has opened up exciting new prospects for basic biomedical research and therapeutics in the new field of regenerative medicine. In order for human ES cells to fulfill their potential, it will be necessary to understand a good deal more about the control of their growth and differentiation. The broad goal of this project is to identify the extrinsic factors that control the growth and differentiation of human ES cells and committed progenitor cells, in order to improve in our ability to grow ES cells and produce specific types of specialized cells from them in significant quantities. Focusing on the role of cell interactions in vitro, particularly between the pluripotent stem cells and cells resembling extraembryonic endoderm, a tissue now recognized to play a key regulatory role in determining cell fate in the early mammalian embryo, the first aim is to identify growth and differentiation factors, which modulate these cell interactions. The major focus here will be members of the transforming growth factor beta superfamily and their antagonists, which play important roles in early embryo development. The second aim of the project is to study the action of these candidate factors on ES cells and cells at early stages of commitment to various differentiation lineages. The third aim of this proposal is to identify isolate and characterize committed progenitor cell populations from ES cell cultures. These cell populations will be isolated either from spontaneously differentiating ES cetl cultures or from ES cultures undergoing directed differentiation, using specific culture conditions and immunoisolation methodology developed in preliminary studies or during the course of this project. The work undertaken in this project will result in the ability to obtain and amplify committed populations of progenitor cells from human ES cultures, in particular precursors of neural and endodermal lineages, and to use these progenitors to produce specific types of differentiated cells. The ability to generate committed stem cell populations from ES cells and in turn derive highly enriched populations of end cells from these precursors will greatly enhance the utility of human ES cells in basic research (the study of human gene function in health and disease and the development of new
42
Stem Cells
drugs) and in transplantation medicine. This project will use stem cell lines ES 01 02 03 04 05 06 on the NIH Embryonic Stem Cell Registry. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF HEMATOPOIESIS BY NOTCH RECEPTORS Principal Investigator & Institution: Griffin, James D.; Professor; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 01-MAR-1984; Project End 31-DEC-2007 Summary: (provided by applicant): The events that regulate the development and proliferation of hematopoietic cells are precise, complicated, flexible, and subject to many levels of controls. The control mechanisms involve both humoral and cellassociated factors from the microenvironement as well as pre-programmed patterns of gene expression intrinsic to different progenitor and stem cells. There have been two basic goals of this project over the last 18 years. The first goal has been to understand the external signals that influence patterns of differentiation, control traffic of mature and immature cells, and influence functions of mature hematopoietic cells. The second goal has been to understand how leukemia oncogenes disrupt, conscript, or deregulate the normal mechanisms that control hematopoiesis. Over the initial five years of this grant (1984-88), our aims were to identify the major cytokines affecting myelopoiesis and determine their major biological properties first in vitro, and then in vivo in human subjects. Over the next five years of the grant (1989-93), our aims were to identify the receptors for the major myeloid growth factors, begin to understand how these cytokines interact physically with their receptors, and identify the initial elements of receptor signaling. Studies during this period also led to the discovery of the significant degree of overlap between the actions of activated tyrosine kinase oncogenes, such as BCR/ABL or TEL/ABL, with the actions of ligand-activated cytokine receptors. The similarities, and differences, between BCR/ABL and IL-3 receptor function, for example, explain many of the clinical phenotypes of CML. Over the last grant period (1994-2002) the goals were to investigate in detail how signals travel from cytokine receptors to the nucleus, how positive and negative signals are integrated in hematopoietic cells, and how these different signals are similar, or distinct, from those initiated by leukemia oncogenes such as BCR/ABL. Overall, the factors, receptors, and signals that regulate proliferation and viability of many lineages of hematopoietic cells are now fairly well understood. The signals of leukemia and myeloproliferative syndrome oncogenes that induce proliferation and viability are also becoming much more clear. The external signals that regulate differentiation and lineage commitment of immature hematopoietic cells, however, are still poorly defined. There is increasing evidence that receptors of the Notch family participate in some differentiation "decisions" of stem cells, such as commitment to the lymphoid vs. myeloid lineages at an early time point. In many tissues, and in animals from flies to humans, Notch receptors determine certain types of lineage commitment, typically forcing a stem cell to commit to one lineage at the expense of another lineage. It is proposed here to determine how the signals from Notch receptors mediate these effects, using hematopoietic cells as the model system. The goals of the proposed studies will be to determine how Notch signaling influences differentiation and lineage commitment in hematopoietic cells, better define the functions of Notch in hematopoiesis, and understand the mechanism of transformation of stem cells by the human ALL oncogene, TAN-1 (a mutant allele of the Notch 1 receptor). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
43
Project Title: REGULATION OF INNATE IMMUNITY AND HEMATOPOIESIS BY MEF Principal Investigator & Institution: Lacorazza, Hugo D.; Sloan-Kettering Institute for Cancer Res New York, Ny 10021 Timing: Fiscal Year 2003; Project Start 25-AUG-2003; Project End 31-JUL-2008 Summary: (provided by applicant): Hematopoiesis consists of a series of regulated steps involving expansions (cell proliferation) and developmental choices (lineage commitment) that lead to the generation of mature blood cell lineages, including the cellular components of both acquired and innate immunity. Some immune cells complete their development in the bone marrow (e.g., NK cells) whereas others develop in secondary lymphoid tissues such as the thymus (e.g., T and NK-T cells). The goal of this proposal is to further study the role of MEF, a member of the ETS family of transcription factors, in innate immunity and hematopoiesis, based on our findings in MEF-deficient mice that we have generated in our laboratory. These mice exhibit greater numbers of hematopoietic stem cells (HSC), impairment in the development and function of natural killer cells (NK and NK-T cells) and lack of perforin expression. This phenotype resembles the human disease Familial Hemophagocytic Lymphohistiocytosis (NK cell dysfunction and immune deregulation). Insights into how the innate immune system and hematopoietic stem cell maintenance are regulated at a transcriptional level will provide a basis for optimizing therapeutic interventions in hematologic disorders and recovery after stem cell transplantation. Our findings raise important biological questions: What is the role of MEF in the function of natural killer cells and how does this affect the innate immune system? What is the precise role of MEF in stem cell quiescence? What MEF-target genes are involved in such processes? Can overexpression of MEF induce stem cell exhaustion or skew lineage commitment to the lymphoid compartment? Aiming to answer these questions we propose to further define the role of MEF in the innate immune system by studying the functional properties of MEFdeficient mice (Aim 1). We will characterize the role of MEF in stem cell quiescence, cell cycle and self-renewal by studying HSCs from MEF-deficient mice in vitro and in vivo (Aim 2). We will further study how MEF regulates the expression of a key target gene (perforin), define the molecular circuitry of NK cells and hematopoietic stem cells using DNA microarray technology, and evaluate the effect of ectopic expression of MEF on tumorigenesis and hematopoiesis (Aim 3). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REGULATION OF NEURONAL STEM CELL DEATH Principal Investigator & Institution: Bieberich, Erhard; Assistant Professor; Medicine; Medical College of Georgia 1120 15Th St Augusta, Ga 30912 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2007 Summary: (provided by applicant): Between gestational day E12 and 18, about half of the mitotic neuronal cells die in embryonal mouse forebrain due to apoptosis. Studies with caspase knockout mice have demonstrated that apoptosis is necessary to prevent hyperproliferation of neuronal stem cells and subsequent, severe brain malformation. It is not known, however, which factors selectively induce or prevent apoptosis in individual, differentiating neuronal stem cells. We have shown for the first time, that the peak time of apoptosis in embryonal mouse brain (E14.5) is concurrent with elevation of endogenous ceramide and activation of caspase 3. We have also shown that the concentration of ceramide is high enough to kill neuronal progenitor cells grown in culture. From these observations, we propose that elevation of ceramide may be critical
44
Stem Cells
for induction of apoptosis in differentiating neuronal stem cells. Recently, several studies have reported that the ceramide-mediated formation of an inhibitory complex between PAR-4 and atypical PKC ,induces apoptosis. Our own studies with in vitro differentiated embryonic stem (ES) cells have shown that induction of apoptosis by ceramide is concurrent with up-regulation of PAR-4. We propose that PAR-4 is one of probably several pro-apoptotic proteins that induce apoptosis when their expression and that of ceramide is elevated. Our main hypothesis is that simultaneous upregulation of endogenous ceramide and ceramide-associated proteins (CAPs) results in formation of a pro-apoptotic protein complex (PAC) that triggers apoptosis in mitotic neuronal stem cells by suppression of anti-apoptotic, cell survival signaling. We will test this hypothesis in three Specific Aims using murine ES cells as model system. In Specific Aim 1, we will test the hypothesis that up-regulation of ceramide induces apoptosis specifically in mitotic neuronal stem cells. In Specific Aim 2, we will test the hypothesis that ceramide/CAP-induced PAC formation results in activation of caspases. In Specific Aim 3, we will test the hypothesis that elevation of ceramide and down-regulation of cell survival signaling is synchronized by the cell cycle and growth factors. In conclusion, this study will identify mechanisms for regulation of apoptosis by ceramide that are critical for normal brain development and/or the etiology of subsequent, pathological disorders in adulthood. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATON OF UROTHELIAL GROWTH Principal Investigator & Institution: Sun, Tung-Tien H.; Professor; Dermatology; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JUL-2008 Summary: (provided by applicant): The luminal surface of the entire lower urinary tract including renal pelvis, ureter, bladder and proximal urethra is lined by a cell type described in standard textbooks as the transitional epithelium or urothelium, which is characterized by a highly specialized apical cell surface covered by rigid-looking urothelial plaques consisting of hexagonally packed 16 nm uroplakin particles. It has been suggested that urothelial defects can result in a loss of the permeability barrier function allowing the penetration of some urine irritants into the bladder wall thus causing pain in interstitial cystitis. In addition, it is generally assumed that urothelial cells lining the different portions of the urinary tract are the same; hence conclusions derived from studying cells of one region should be applicable to all urothelial cells. However, urothelia of renal pelvis/ureter/trigone are known to have a different embryological origin than urothelial cells of other sites, and there are indications that urothelium is biochemically heterogeneous. In this project, we will (i) determine whether the urothelia that cover renal pelvis, ureter, bladder, and proximal urethra actually consist of several distinct cell lineages by analyzing the relative contributions of intrinsic divergence vs. extrinsic modulation to urothelial phenotypes, and (ii) identify the stem cells in various urothelial compartments using cell kinetic, cell culture and stem cell transplantation techniques. These proposed studies can yield important information because if urothelium indeed can be separated into several distinct subpopulations belonging to different cell lineages, one needs to re-examine the validity of some earlier studies in which urothelial cells from different parts of the urinary tract were used interchangeably. Since stem cells are the preferred targets of carcinogens, gene therapy, and they are particularly suited for tissue engineering and tissue reconstitution, our studies can have practical implications on the source of urothelial cells for tissue engineering of various parts of the urinary tract, the cellular origin of in
Studies
45
vivo urothelial wound healing following the surgical removal of the bladder, the possible involvement of urothelial cells in interstitial cystitis and in site-specific variations in bacterium: urothelium interactions, and the cellular origin of various urothelial tumors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RETROVIRAL GENE TRANSFER TO EPIDERMAL STEM CELLS Principal Investigator & Institution: Andreadis, Stelios T.; Assistant Professor; Chemical Engineering; State University of New York at Buffalo Suite 211 Ub Commons Amherst, Ny 14228 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-JAN-2008 Summary: (provided by applicant): The current project seeks to understand retrovirusmediated gene transfer and to enhace the transduction efficiency to epidermal stem cells. Although retroviral transduction results in permanent genetic modification, differentiation and eventually loss of the transduced cells from the epidermis results in temporary transgene expression. Therefore, to achieve stable long-term gene expression, it is critical that the epidermal stem cells are transduced with high efficiency. Recent results from our laboratory show that gene transfer on fibronectin is significantly higher than on tissue culture plastic and implicate integrins in retroviral transduction of epidermal keratinocytes. Specifically, the efficiency of gene transfer correlates with the levels of alpha 5 and beta 1 integrins on the cell surface and blocking these integrins with antibodies decreases gene transfer significantly. We hypothesize that integrins may enhance gene transfer by enhancing the rate of keratinocyte migration on fibronectin and therefore the probability that itarget cells encounter the immobilized virus. We propose to develop two assays to test this hypothesis and use flow cytometry to identify other integrins that may also play a role in retroviral gene transfer. Since integr ns and attachment to extracellular matrix have been shown to characterize keratinocyte stem cell phenotype, we also propose to test the hypothesis that retroviral transduction on fibronectin increases the efficiency of gene transfer to epidermal stem cells. To this end we will use biochemical (e.g. flow cytometry) and functional assays (e.g. clonal analysis), as well as in vivo transplantation of genetically modified skin equivalents onto athymic mice. Finally we propose to engineer micropatterned surfaces and microfluidic networks to enhance deposition of retrovirus to the surface. Mathematical modeling and experiments will be employed to design the gene transfer "chips" in order to increase the efficiency of gene transfer and control the number of gene copies per target cell. Reaching these goals will have significant impact on the potential of genetically modified cells to treat short or long-term disease states. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RHESUS HEART REGENERATION WITH EMBRYONIC STEM CELLS Principal Investigator & Institution: Kamp, Timothy J.; Assistant Professor; Medicine; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2005 Summary: (provided by applicant): Many forms of heart disease are characterized by a loss of myocytes either by apoptosis or infarction. Therefore, strategies such as cardiac cell transplantation may provide remarkable advances in therapy for a range of heart diseases. A variety of donor cells have been tested in animal models of infarction with the most promising results from adult stem cells. However, embryonic stem (ES) cells may provide the greatest opportunity for myocardial regeneration. The overall goal of
46
Stem Cells
this proposal is to utilize nonhuman primate embryonic stem (ES) cells to regenerate infarcted myocardium as an aggressive step toward clinical applications of cardiac cell transplantation. A multidisciplinary approach will provide innovative approaches to address major roadblocks in bringing cell transplantation to the clinic. First, we hypothesize that, with appropriate priming, rhesus ES cells will be able to engraft into the infarcted rhesus myocardium and regenerate multiple cell types typical of myocardium. Specific Aim 1 will test engraftment of donor ES cells labeled with the fluorescent protein EGFP in a rhesus myocardial infarction-reperfusion model. Ex vivo immunohistochemistry will provide information on the cell types regenerated from the donor cells, and isolated myocyte studies will characterize the cellular function of regenerated myocytes. Specific Aim 2 will develop novel imaging applications using Magnetic Resonance Imaging (MRI) to track donor ES cells labeled with magnetodendrimers as well as provide structural and functional details of myocardial regeneration. Next, we hypothesize that the microenvironment of the infarcted myocardium has a rich collection of signaling molecules directing progenitor cell recruitment and milieu-dependent differentiation. In Specific Aim 3, we will search for these signaling molecules in the venous effluent following infarction using antibodybased assays as well as utilizing proteomics technology with mass spectrometry. To test putative signaling molecules in a controlled microenvironment, we will develop a microfluidics bioassay system using cultured ES cells in microchannels. Overall, these developmental approaches have the potential to dramatically advance the field of myocardial regeneration and bring cardiac cell transplantation much closer to clinical reality. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE LEUKEMOGENESIS
OF
AML1/ETO
IN
HEMATOPOIESIS
AND
Principal Investigator & Institution: Mulloy, James C.; Sloan-Kettering Institute for Cancer Res New York, Ny 10021 Timing: Fiscal Year 2002; Project Start 16-MAY-2001; Project End 31-JAN-2003 Summary: The AML 1/ETO fusion protein is causally implicated in the pathogenesis of 40% of acute myeloid leukemias of the M2 subtype, and accounts for 12% of human AMLs overall. The fusion gene is compromised of the amino-terminal portion of the AML1 (CBFA2) gene on chromosome 21 and the nearly full coding region of ETO gene on chromosome 8. Aml1/Eto interferes with the function of the transcription factor, CBF, in a dominant negative fashion, presumably by its ability to bind to the heterodimeric transcription partner CBF beta and repress transcription through CBF enhancer elements. Mice deficient in AML1 or CBF BETA lack definitive hematopoiesis, and these mice die during embryogenesis. Similarly, mice engineered to express a leukemic fusion protein that interferes with CBF function die from a similar phenotype, complicating the development of an animal model of AML. Recent advances in retroviral gene delivery systems, hematopoietic stem cell biology, and immunodeficient animal development have made it possible to overexpress genes of interest in human and murine stem cells and use these cells to reconstitute the immune system of recipient animals. The ultimate objective of this work is the development of murine model AML, specifically of AML associated with expression of AML1/ETO (Specific Aim 1). A murine retovirus optimized for expression in stem cells will be used, and the green fluorescent protein will be co-expressed from the same mRNA using an IRES element, to facilitate identification of transduced cells. Both human and murine stem cells will be used in these studies, and the appropriate animal model will be chosen to allow the
Studies
47
growth of transformed cells in vivo. In vitro studies will also be performed to determine the effects of AML1/ETO over-expression on normal hematopoiesis (Specific Aim 2). Using specific combinations of cytokines and stromal layers, the investigator will determine which hematopoietic lineage is affected by AML1/ETO expression. Mutants of AML1/ETO will also be included in the system, to decipher which signaling pathways are important in AML1/ETO-induced leukemia in vivo. mRNA from human stem cells expressing AML1/ETO will be used for differential hybridization screening of high-density microarrays to identify target genes regulated by AML1/ETO (Specific Aim 3). These target genes will be evaluated for their contribution for the phenotype elicited by expression of AML1/ETO in human stem cells, using the assays mentioned above. Taken together, these data will provide detailed information on the functional role of AML1/ETO in both hematopoeisis and leukemogenesis. The establishment of a small animal model of AML will greatly enhance our ability to develop and test treatment strategies and drugs that may be useful in the therapy of AML. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SIGNAL TRANSDUCTION DETERMINING FATE OF STEM CELLS Principal Investigator & Institution: Terada, Naohiro; Assistant Professor; American Society for Cell Biology 8120 Woodmont Ave, Ste 750 Bethesda, Md 20814 Timing: Fiscal Year 2003; Project Start 20-SEP-2003; Project End 31-JUL-2004 Summary: (provided by applicant): The Conference "Signal Transduction Determining the Fate of Stem Cells" will be held from August 9 through August 12, 2003, at the Montana State University in Bozeman, Montana. This meeting is sponsored and partially funded by the American Society for Cell Biology (ASCB). This conference is the only international meeting this year that focuses on signal transduction in stem cells and is open to a significant number of young scientists who are not established members of the field. In this application we request partial funding for the 2003 conference. Clinical application of stem cells in human disease requires an understanding of the stem cell and the long-term behavior of cells derived from stem cells. Understanding the behavior and properties of stem cells requires the integration of several disciplines in biomedical research. For example, we are just beginning to understand the role of cytokines and extracellular matrices in determining the fate of stem cells. Little is known of intracellular signaling pathways that control stem cell fate. The purpose of this conference is to bring together investigators from two disciplines, stem cell biology and signal transduction, in an attempt to initiate a collaborative effort for understanding signaling pathways that control the fate of stem cells in culture and animals. In the first three scientific sessions of the 2003 ASCB Summer Conference, we will discuss signal transduction pathways regulating self-renewal, plasticity and differentiation of stem cells. In the forth session, we will focus on analogy and difference of stem cells with cancer cells, where signal transduction has been intensively studied. In addition, the final session will introduce emerging ideas and techniques that would facilitate signal transduction studies in stem cells. These sessions will consist of a mixture of invited talks and presentations to be selected based on submitted abstracts. The latter speakers will be chosen with special attention to younger investigators and exciting recent developments. There will also be a poster session. The format of the Conference, and its small size, are designed to foster interactions among the 225 participants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
48
•
Stem Cells
Project Title: SKELETAL MUSCLE STEM CELLS FOR TISSUE REPAIR Principal Investigator & Institution: Kramer, Randall H.; Professor; Stomatology; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-MAY-2007 Summary: (provided by applicant): A major problem confronting craniofacial repair is the difficulty in restoring soft-tissue function and contour in patients with anomalies including hemifacial microsomia, unilateral clefts of lips and palate as well as defects in the TMJ. In particular, repair of skeletal muscle defects is limited by difficulty in its transplantation and survival. A logical approach is to use existing population of muscle satellite cells which are quiescent undifferentiated precursors found beneath the basement membrane of mature muscle fibers. Following injury, activated satellite cells regenerate muscle after initiating a differentiation program whereby they migrate along laminin-rich basement membrane, proliferate, differentiate, and integrate with preexisting myofibers. Recent evidence supports the notion that satellite cells are heterogeneous and have stem cell potential. We have shown that the laminin-binding alpha 7 integrin, which is important for myoblast migration, is expressed on a subset of satellite cells and is upregulated in terminally differentiated myotubes. In this application, we propose to examine the potential of using alpha 7-positive human satellite cells for direct repair of muscle defects. We will explore the hypothesis that alpha 7 expressing satellite cells are pluripotent stem cells capable of regenerating skeletal muscle and other tissue such as bone. The proposal represents three aims. In aim 1 we will characterize human muscle-derived satellite cells and correlate expression of alpha 7 integrin with their differentiation potential for skeletal muscle and other tissue lineages. Aim 2 will determine the expression and function of the alpha 7 integrin during human skeletal muscle development. Aim 3 is focused on the use of alpha 7expressing human skeletal muscle stem cells to engineer in vitro three-dimensional skeletal muscle myofibers. These studies will form the basis for strategies that target the mechanical reintegration of regenerating myotubes to repair orofacial muscle structures using adult skeletal muscle stem cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SPECIFIC GENE EXPRESSION PATTERNS IN SATELLITE STEM CELLS Principal Investigator & Institution: Csete, Marie E.; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: The long-term objective is to develop therapeutic strategies directed at satellite stem cells that will preserve muscle mass in the elderly. Satellite stem cells are the major source of adult skeletal muscle regeneration, and so, are important targets for preserving skeletal muscle mass in the elderly. Long known as muscle progenitors, cultured satellite stem cellscan also generate other daughter cell types, including adipocytes (fat cells). This pluripotentiality of satellite stem cells suggests that they may play a direct role in changing the phenotype of skeletal muscle, especially in the elderly. Satellite cell-derived adipogenesis in tissue culture is promoted by a high (20%) oxygen (O2) environment, conducive to production of reactive oxygen species (ROS), an environment that mimics the oxidative stress of old skeletal muscle. In lower (6%) O2 culture conditions satellite stem cells are much less likely to undergo adipogenesis. These phenotypic findings have important molecular correlates: Analysis of single satellite stem cells reveals that high O2/ROS induces increased expression of genes that
Studies
49
promote fat development, while low O2 conditions are associated with up-regulation of genes that promote muscle development and differentiation. High O2/ROS induces increased expression of genes that promote fat development, while low O2 conditions are associated with up-regulation of genes that promote muscle development and differentiation. High O2/ROS culture conditions also decrease satellite cell proliferation, and this defect is pronounced in satellite stem cells derived from old mice vs. those derived from young/adult mice. Thus, aging associated ROS-induced reduction in proliferation as well as adipogenesis may remove satellite stem cells from the myogenic pool and directly contribute to the characteristic pathology of muscle aging, which is a loss of muscle mass and accumulation of muscle lipid. These data suggest that the loss of muscle with aging is more than a degenerative phenomenon, and that satellite stem cells may undergo age-associated pathologic regeneration. The working hypothesis is that the imbalance between ROS accumulation and decreased antioxidant function in old muscle induces specific gene expression patterns in satellite stem cells that result in their defective proliferation, apoptosis and myogenic differentiation when compared to satellite stem cells from young/adult animals. Proliferation, apoptosis, and differentiation patterns will be quantitated and compared for satellite stem cells from old vs. young/adult mice, and from old wild type mice vs. old antioxidant-deficient mouse models. In parallel to these cellular assays, expression patterns of satellite stem cells will be compared for these different groups with the goal of identifying potential therapeutic protein products that increase survival, proliferation and myogenic differentiation of satellite stem cells in old animals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STEEL GENE PRODUCT AND STEM CELL PROLIFERATION Principal Investigator & Institution: Williams, David A.; Lampkin Chair and Professor of Pediatric; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229 Timing: Fiscal Year 2002; Project Start 01-AUG-1994; Project End 31-JUL-2003 Summary: (Adapted from investigator's abstract) Hematopoiesis occurs in a complex microenvironment made up of a variety of non-hematopoietic cells including endothelial cells, stromal cells and adipocytes. These accessory cells provide regulatory signals, in the form of positive and negative growth factors and adhesive molecules, which affect the survival, proliferation and differentiation of hematopoietic stem and progenitor cells. Although a large number of hematopoietic growth factors have been identified, no combination of these factors has been shown to maintain/expand the reconstituting capacity of stem cells over an extended period of time in vitro in the absence of adhesion to microenvironment cells. Thus, analysis of blood cell formation in the context of these microenvironment cells provides additional and important information concerning the regulation of hematopoiesis. It is also increasingly clear that multiple aspects of hematopoiesis are controlled by key transcription factors. However, less well studied is how the interaction of growth factors presented in the microenvironment with growth factor receptors and other cell-cell interactions modulate transcription factor function, and thus ultimately control blood formation under physiologic conditions or in response to commonly encountered stress situations. One essential growth factor that is expressed in the hematopoietic microenvironment (HM) is stem cell factor (SCF); the interaction of SCF with the receptor tyrosine kinase, c-kit, plays a critical role in both erythroid and mast cell production in vivo, as demonstrated by the phenotypic abnormalities seen in mouse mutants of the genes encoding SCF (Steel) and c-kit (Dominant white spotting) mice. In addition, c-kit is
50
Stem Cells
expressed on both hematopoietic stem cells and multilineage progenitor cells. SCF is expressed as both soluble and membrane bound isoforms in the HM. During the previous funding period, the PI's laboratory has shown in vitro and in vivo evidence that distinct isoforms of SCF produce different cellular responses in several c-kit+ cell populations. The overall hypothesis to be tested in the proposed research utilizing transgenic and "knock-in" mice is that the biological effects of SCF are due, in part, to the adhesion of cells within the HM and the interaction of c-kit+ with cell-associated SCF, which influences the duration of activation of c-kit and downstream signaling in these cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STEM CELL FACTOR ACTION IN NEURAL CREST DEVELOPMENT Principal Investigator & Institution: Sieber-Blum, Maya F.; Professor; Cell Biol, Neurobiol/Anatomy; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532264801 Timing: Fiscal Year 2002; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: (Adapted from applicant's abstract): The long-term goal of the proposed work is to elucidate the cellular and molecular mechanisms that control neural crest cell diversification and differentiation. The application focuses on the differentiation of neural crest stem cells into small diameter sensory neuroblasts. It is based on prior data which indicate 3 additional roles of SCF in addition to the known trophic action in pigment cell formation: (1) SCF is a survival factor for neural crest stem cells, (2) SCF is involved in the expression of the neurotrophin receptors, p75NTR and TrkC, and (3) SCF promotes differentiation of the stem cell into small diameter sensory neuroblasts. In aim 1 the role of the SCF receptor, c-kit, is investigated by knock-down and rescue of quail c-kit, and by analyzing the mouse mutants Dominant spotting (W; c-kit defect) and Steel (Sl; SCF defect) for neural crest-related deficiencies. It is hypothesized that SCF promotes expression of p75NTR with higher probability than TrkC, thus creating at least two subsets of cells (p75NTR+/TrkC+, p75NTR+/TrkC-), which possibly have restricted developmental potentials. This issue will be addressed by in vitro clonal analysis of immunoselected cells. Aim 2 is concerned with neurotrophin-mediated apoptosis, for which there is preliminary evidence, and which is suggested to function in vivo as a proof reading mechanism for the elimination of site-inappropriate precursor cells. Aim 3 deals with the mechanisms that direct p75NTR+/TrkC+ cells into the small diameter sensory neuron lineage. Initial data suggest that a subset of neural crest cells differentiates into TrkB-expressing sensory neuroblasts in a chemically defined culture medium in the presence of SCF and absence of any other added growth factors. Using antisense and mutant mouse approaches, it will be determined whether TrkB expression is mediated by SCF and/or by the other autocrine factors, NT-3 and TGF-5. Moreover, BDNF-mediated neuropeptide expression will be documented. A better knowledge of the characteristics of neural crest stem cells has implications for transplant therapy in some degenerative and familial diseases. Moreover, health relatedness pertains to human piebaldism, which is due to c-kit defects. Piebaldism is characterized by hypopigmentation and a white forelock at birth due to faulty melanogenesis. However, the newly detected additional roles of SCF in maintaining stem cells, up-regulating neurotrophin receptors and promoting sensory neurogenesis suggest additional defects in human piebaldism that remain to be elucidated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
51
Project Title: STEM CELL GENE THERAPY FOR AIDS Principal Investigator & Institution: Johnson, R. Paul.; Associate Professor of Medicine; Immunology; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 10-FEB-1997; Project End 31-MAR-2007 Summary: (Provided by the applicant): Despite the dramatic success of highly active antiretroviral therapy (HAART) in inhibiting viral replication in HIV-infected subjects, it is increasingly clear that there is a compelling need for the development of complementary therapies. Accumulating experience with HAART is documenting a significant incidence of serious side effects, an increasing prevalence of resistant viruses, and failure rates of HAART that exceed 50 percent in some cohorts. A wide range of genetic strategies are now able to achieve potent inhibition of HIV replication in vitro, and introduction of these inhibitory genes into hematopoietic stem cells offers the potential to offer long- lived immune reconstitution. However, the successful translation of these in vitro successes to clinically- applicable therapies has been limited by the disappointing rates of gene transfer to hematopoietic cells in human gene therapy clinical trials. Multiple ethical and practical considerations significantly constrain the ability to address basic questions regarding stem cell gene therapy for AIDS in human clinical trials. Experiments in nonhuman primates offer the opportunity to rigorously address these issues in an in vivo experimental model. Experiments conducted during the initial funding period of this grant have shown that significant levels of geneticallymodified cells can be obtained in nonhuman primates following autologous bone marrow transplantation with hematopoietic stem cells transduced with murine leukemia virus (MLV) vectors. Specific aims of the current proposal are: 1. To optimize MLV and lentiviral vectors for the delivery of RNA decoys into hematopoietic stem cells and evaluate their ability to inhibit SIV/HIV replication; 2. To examine levels of gene marking in uninfected macaques transplanted with hematopoietic stem cells transduced with MLV and lentiviral vectors; 3. To determine the ability of inhibitory genes to protect hematopoietic cells from SHIV infection in vivo; and 4. To examine the ability of genetically-modified hematopoietic stem cells to reconstitute immune function in SHIV-infected macaques. These studies should yield important information regarding the efficacy and safety of stem cell gene therapy for AIDS and facilitate the development of similar trials in HIV- infected people. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STEM CELL GENE THERAPY FOR LUNG DISORDERS Principal Investigator & Institution: Lutzko, Carolyn M.; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, Ca 90027 Timing: Fiscal Year 2002; Project Start 11-SEP-2002; Project End 31-JUL-2005 Summary: (provided by applicant): Gene therapy for respiratory disorders requires stable gene transfer to epithelial progenitor cells, efficient engraftment of these genetically modified progenitors in the respiratory epithelium and regulated transgene expression in differentiated progeny of these cells. Recently, cells have been identified in marrow that can contribute to tissue repair and regeneration in hematopoietic and nonhematopoietic tissues. In preliminary studies by our group, transgene expressing donor epithelial cells were detected in the lung following transplantation of retrovirally transduced bone marrow into murine recipients. At 2-5 months post-transplant, approximately 1% of cytokeratin positive epithelial cells were EGFP transgene positive donor cells. Based on these data our overall hypothesis is that cells derived from the
52
Stem Cells
bone marrow engraft in the respiratory epithelium and contribute to alveolar epithelial layer maintenance and regeneration. The hypotheses to be evaluated in this proposal are: 1) Progenitor cells in normal mouse marrow that engraft and contribute to the alveolar epithelium can be characterized and isolated based on physical properties and cell surface markers. 2) Recombinant lentiviral gone transfer vectors can be designed to efficiently transduce bone marrow derived lung epithelial progenitor cells and specifically express transgenes in respiratory epithelial cells. 3) Marrow derived multipotent stem cells can be transduced with lentiviral vectors and contribute to both respiratory epithelial and hematopoietic tissues. In the experiments proposed here we will test these hypotheses in a murine bone marrow transplant model in the following specific aims: 1) Characterize the progenitor population (s) that engraft in the lung epithelia. 2) Develop gene transfer vectors that have stable and epithelial specific transgene expression. 3) Identify and characterize the lineage potential, or plasticity, of individual, gene marked progenitor cells, that contribute to respiratory epithelia. The overall goal of these studies is to advance the development of clinical gene therapy for lung disorders by evaluating the potential of genetically modified epithelial progenitors to engraft in the lung epithelium and deliver therapeutic gene products in vivo. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STEM CELL PATCH THERAPY IN HEARTS WITH LV INFARCTION Principal Investigator & Institution: Zhang, Jianyi; Associate Professor; Medicine; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2005 Summary: (provided by applicant): Following transmural myocardial infarction left ventricular remodeling (LVR) with chamber dilation and hypertrophy occurs to compensate for loss of contracting myocardium. Although stable LV remodeling may be achieved for a period of time, progressive myocardial dysfunction can develop and ultimately lead to overt congestive heart failure (CHF). The currently available therapeutic options for heart failure due to transmural left ventricular infarct are limited. Several exciting recent studies have shown that tissue specific stem cells may have the ability to generate cells of tissues from unrelated organs. We have identified a population of primitive cells in normal human post-natal bone marrow that have multipotent differentiation and extensive proliferation potential, which we have named Multipotent Adult Progenitor Cells or MAPC. The proposed research will examine the ability of a novel fibrin patch to deliver allogenic or autologous cells into myocardial infarcts to improve LV function, and to prevent the transition to heart failure. Using a swine model of postinfarction LV remodeling, the effect of cell transplantation on LV contractile function and myocardial energy metabolism will be examined using MRI and 31P-MR spectroscopy, respectively. The following hypothesis will be tested: 1) A fibrinstem cell patch can deliver a high concentration of allogenic MAPC onto the surface of ischemic myocardium. In response to myocardial ischemic signals, the stem cells will leave the fibrin patch and home to the ischemic myocardium to repair the infarct region and to prevent the formation of LV aneurysm. 2) A fibrin-thrombin patch can be used to deliver a high concentration of autologous bone marrow stem cells within 30 minutes. The autologous bone marrow cells will gradually leave the patch and migrate to the infarct area where they continue to divide and differentiate into myocytes, smooth muscle cells and endothelial cells, and replace the myocardial infarct. 3) An artificial myocardium generated by entrapping MAPC in a bipolymer fibrin gel and allowing the cells to partially differentiate and develop contractile function in vitro before implantation onto the infarct region will reestablish LV contractile function. By
Studies
53
providing insight into the effects of the cellular patch transplantation, the results may lead to better preventive, diagnostic and therapeutic modalities for LV injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STEM CELL PLASTICITY AFTER BLASTOCYST IMPLANTATION Principal Investigator & Institution: Recht, Lawrence D.; Professor; Neurology; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, Ma 01655 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-JUL-2005 Summary: (provided by applicant): Several recent studies indicate that tissue-derived stem cells can not only differentiate into cells of the tissue from which they are obtained, but also those from other tissues. We have been interested in the range of differentiative capacity (which we term plasticity) of CNS derived stem cells and hypothesized that one way to assay this would be to implant these cells into blastocyts and assess incorporation into the resulting mice later in development. Our results indicate a robust incorporation of these cells into extraneural tissues including bone marrow, where they express lineage markers of differentiated hematopoietic cells, bone muscle and GI tract. We believe this model provides a unique insight into stem cell plasticity because of the high efficiency of implantation and production of apparently normal pups. We propose to follow-up our studies by addressing the following specific aims: 1) We will determine whether incorporation of stem cells into blastocysts varies as a function of stem cell subpopulation or type, we will create a retorviral library of neural stem cells to assess whether specific subpopulations exist as well as comparing neural stem cells with marrow stromal cells in their ability to incorporate into blastocysts; 2) We will determine whether incorporation of neural stem cells into other tissues renders them functional by performing bone marrow transplantation of cells obtained from chimeric pups into lethally irradiated mice and assessing whether neural stem cells can repair a embryonically lethal genetic defect in bone; and 3) We will assess whether neural stem cells retain their functional capacity to develop into olfactory interneurons after blastocyst transplantation and determine whether their implantation at the blastocyst stage can repair mice with an absence of myelin. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STEM CELL PROLIFERATION AND DIFFERENTIATION IN PLANARIA Principal Investigator & Institution: Newmark, Phillip A.; Cell and Structural Biology; University of Illinois Urbana-Champaign Henry Administration Bldg Champaign, Il 61820 Timing: Fiscal Year 2003; Project Start 09-JAN-2003; Project End 31-DEC-2007 Summary: (provided by applicant): The establishment of human pluripotential stem cell lines has led to a resurgence of interest in stem cell biology. This interest is largely due to the therapeutic potential of stem cells for repairing degenerative diseases and injuries. Before recent breakthroughs in studies of human stem cells can be effectively and safely applied in the clinic, many basic questions about the biology of stem cells need to be addressed. These include: how is stem cell proliferation regulated in vivo to generate the appropriate number of daughter stem cells and differentiating progeny without forming tumors? How is the developmental potential of a stem cell restricted to a particular fate? How is pluripotentiality maintained and what steps lead to loss of pluripotentiality? The work proposed here will address these fundamental questions using the freshwater planarian, Schmidt Mediterranean, as a model organism for
54
Stem Cells
studying stem cell regulation. Planarians- classic models of regeneration experiments can regenerate entire animals from small fragments of their bodies. This remarkable plasticity is based upon a stem cell population present in the adult worm. These stem cells are used both to replace cells lost during the course of cell turnover and to regenerate missing structures when the animal is transected. Recent advances permit this classic system to be re-examined in detail at both cellular and molecular levels. Thus, environmental influences on stem cell proliferation will be studied by analyzing cell cycle kinetics in intact and regenerating planarians. These experiments will determine if wounding regulates the cell cycle of planarian stem cells. If it does, these experiments will also define the phases of the cell cycle that are regulated, an important consideration for understanding the signaling pathways that lead from wounding to proliferation. The development of automated in situ hybridization techniques and the availability of over 4000 unique planarian cDNAs provide starting material for defining stem cell-specific genes and raising monoclonal antibodies to identify and study stem cells. Finally, functional analysis using double-stranded RNA-mediated genetic interference will be used to identify genes that play critical roles in stern cell regulation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STEM SPERMATOGENESIS
CELL
RENEWAL
AND
DIFFERENTIATION
IN
Principal Investigator & Institution: Dinardo, Stephen; Professor; Anatomy; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2003; Project Start 01-AUG-1999; Project End 31-JUL-2007 Summary: (provided by applicant): Cells within many tissues and organs are continually replenished throughout our lives. This is accomplished by stem cells, which balance self-renewal with more differentiated cell types. The mechanisms that control this balance are not clear. In tissues maintained by stem cells, the differentiating daughters undergo mitotic expansion before generating tissue-specific cell types. The mechanisms that control transit amplification are also not clear. Both of these phenomena are featured in Drosophila spermatogenesis, where stem cell daughters choose between self-renewal and differentiation, and where transit amplifying gonial cells switch to spermatocyte development. Gonial cells divide four times; the counting and effector mechanisms regulating this are unknown. Aim 1 tests the hypothesis that germ cells count intrinsically, and then collaborate with surrounding somatic cells to coordinate the spermatocyte transition. We discovered that a somatic cell signal promotes differentiation of stem cell daughters, while other labs discovered a signal that promotes self-renewal. Aim 2 tests the hypothesis that self-renewal and differentiation are indeed balanced by these competing signals, and then investigate how they compete. To generate and begin to test biologically based hypotheses for other candidate factors and signaling pathways that legislate between renewal and differentiation we have conducted transcript-profiling analyses of self-renewing cells or their differentiating daughters. Aim 3 proposes to complete these studies and conduct functional tests on selected candidates. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STEM CELL SELECTION & EXPANSION VIA HOX GENE ACTIVATION Principal Investigator & Institution: Emerson, Stephen G.; Professor; Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104
Studies
55
Timing: Fiscal Year 2002; Project Start 16-MAY-2001; Project End 31-MAR-2005 Summary: (Applicant's Abstract) Stem cell therapies play a major and increasing role in cancer therapies. If we were able to isolate repopulating stem cells, expand them in vitro and genetically manipulate them prior to reinfusion, we would be able to explore many avenues of protective therapies, including expansion of stem cells for multi-cycle chemotherapy, protection of stem cells with chemotherapy resistance genes, and improvement in stem cell quality with DNA repair genes. Published studies indicate that the homeobox gene HOXB4 is expressed in primitive hematopoietic cells, and that its enforced expression induces stem cell symmetric cycling. Our preliminary data indicates that we have isolated the human HOXB4 gene and its promoter, and that we have isolated at least two transcription factors that activate this promoter in both leukemic cells and normal CD34+ cells. In addition, we have found that CD34+ cells activating a HOXB4 expression construct are substantially enriched in long term culture initiating cells (LTCIC). This proposal seeks to identify and stimulate the fraction of stem cells that are capable of self-renewal, as illustrated by their ability to transcribe the homeobox gene HOXB4. In particular, we propose to: 1) Test the Ability of the Activated HOXB4 Promoter to NOD/SCID Repopulating Cells following Xenotransplantation; 2) Identify the Transcription Factors Activating the HOXB4 Promoter at the HxRE-1 (NF-1) Site; and 3) Identify Additional More Distant Genetic Elements That Enhance the Activity of the HOXB4 Promoter In Vivo. Integrated together, these aims will define a new paradigm for the molecular identification and manipulation of stem cells for hematopoietic support and genetic modification. If successful, this model should be directly translatable to clinical practice in the future. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STEM CELLS AND PERIODONTAL BIOENGINEERING Principal Investigator & Institution: Diekwisch, Thomas G.; Associate Professor and Head; Orthodontics; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-MAY-2008 Summary: (provided by applicant): Stem cells are a population of cells capable of providing replacement cells for a given differentiated cell type (Blau et al. 2001). In the current proposal, stem cell-based technologies are applied to generate novel tissueengineered, smart periodontal implants that use biomimetic strategies with the ultimate goal of achieving full regeneration of lost periodontal tissues. Mesenchymal periodontal tissues such as cementum, alveolar bone, and periodontal ligament are neural crestderived entities that emerge from the dental follicle at the onset of root formation (Diekwisch 2001, 2002). In order to mimic the differentiation of periodontal cells from undifferentiated progenitors we are planning to recapitulate and/or mimic the molecular and cellular events that occur during periodontal tissue differentiation in the developing periodontium. Dental follicle and bone marrow mesenchymal stem cells have been isolated to determine the differentiation conditions necessary for these cells to mimic periodontal cells. In order to test the applicability of periodontal stem cells, we have established a series of model systems in which we will test the feasibility of using stern cells in conjunction with biomimetic scaffolds to generate bioengineered periodontal implants for improved periodontal regeneration. Hypothesis to be tested: Mesenchymal stem cells have the potential to generate and regenerate periodontal tissues, cementum, alveolar bone, and periodontal ligament. To test this hypothesis, we propose studies with the following Specific Aims: 1. To identify and isolate stem cells for periodontal tissue-engineering. 2. To establish and characterize stem cell lines for
56
Stem Cells
periodontal tissueengineering. 3. To test the conditions necessary to differentiate stem cells into periodontal cells in vitro. 4. To ask the question whether stem cells will mimic existing periodontal tissues following tissue implantation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STEM CELLS IN AIRWAY REPAIR Principal Investigator & Institution: Stripp, Barry R.; Associate Professor; Environ & Occupational Health; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2002; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: (Applicant's abstract): Identification of pulmonary epithelial stem cells with pluripotential differentiation capacity will significantly impact development of gene therapeutic modalities, and development of new approaches for the treatment or prevention of chronic and neoplastic lung disease. Our preliminary studies have defined the neuroepithelial body (NEB) microenvironment as a critical reservoir of proliferative cells following acute airway injury and suggest that these may have stem cell-like character. Proliferation and hyperplasia of NEB-associated cells, which is common to many types of chronic lung disease in humans, is only observed among mouse models when progenitor (Clara) cells are among those injured. Goals of this application are to test the hypothesis that injury of a progenitor cell population, such as the mature Clara cell, is a stimulus for recruitment of NEB-associated stem cells for epithelial renewal. Aims will define contributions made by proliferative cells originating from the NEB towards repair from ozone or naphthalene-induced airway injury; agents preferentially targeting terminally differentiated (ciliated) or progenitor (Clara) cells, respectively. Classification of NEB-associated cells with regenerated capacity as "stem cells" will be made by fulfilling three criteria: 1) absence of certain differentiated functions, 2) pluripotential differentiation capacity and 3) relatively slow cycling time in the quiescent lung. Preliminary data demonstrate a requirement for Clara cell secretory protein (CCSP)-expressing (CE) cells in airway repair. Aim 1 will build upon these studies by further exploring variability in functional and molecular phenotype of CE cells in the quiescent and injured adult mouse lung. Aim 2 will expand upon preliminary studies demonstrating that both CE and pulmonary neuroendocrine (PNE) cells proliferate following acute naphthalene-induced airway injury. Through use of transgenic mice allowing cell type-specific conditional ablation of either CE or PNE cells, we will identify the contribution of each group to airway homeostasis and repair. Finally, studies proposed in Aim 3 will classify NEB-associated cells with proliferative potential as either progenitor cells or stem cells through analysis of cycling time and differentiation capacity. Completion of these aims will define pulmonary stem cell populations, their contributions to airway repair, and how this may be modified by injury to either progenitor or non-progenitor epithelial cell populations. These finding will significantly impact the understanding of mechanisms of normal epithelial renewal and neoplasia, and will identify critical cells to be targeted for stable maintenance of therapeutic genes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STEM CELLS IN PERIPHERAL NERVOUS SYSTEM DEVELOPMENT Principal Investigator & Institution: Morrison, Sean J.; Assistant Professor; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274
Studies
57
Timing: Fiscal Year 2002; Project Start 01-FEB-2001; Project End 31-JAN-2006 Summary: (From the Applicant's Abstract): Stem cells are self-renewing multipotent progenitors with the broadest developmental potential in a given tissue at a given time (Morrison et al. Cell 88:287). There is great interest in neural stem cells because of their importance in neural development and their therapeutic potential. Neural crest stem cells (NCSCs) migrate out of the neural tube in early to mid-gestation, and give rise to the peripheral nervous system (PNS) as well as other tissues. In order to understand PNS formation, the process by which NCSCs differentiate into the diverse cell types of the PNS must be understood. Although neural crest cells were thought to differentiate within days of migrating, we have recently discovered that NCSCs persist into late gestation by self-renewing within peripheral nerves (Morrison et al. Cell 96:737). This observation suggests that PNS development may be more dynamic than previously thought and raises several specific questions. First, why would the self-renewal of NCSCs be promoted within peripheral nerves if, as current models suggest, the neural crest only gives rise to Schwann cells in nerves? Aim #1 is to use CRE-recombinase fate mapping to test whether the neural crest actually gives rise to multiple lineages of cells within nerves. If so, nerve development would require multilineage differentiation by stem cells rather than just overt differentiation by Schwann precursors. This would fundamentally change models of nerve development. Aim #2 is to test whether postmigratory NCSCs also persist in other areas of the fetal PNS. Aim #4 is to test whether there are cell-intrinsic differences between these NCSC populations from different regions of the PNS in terms of the types of neurons they can form. If there are cell-intrinsic differences between postmigratory NCSC populations then perhaps differences between stem cell lineages interact with environmental differences to generate neural diversity. Aim #3 is to test whether rare NCSCs also persist postnatally. The discovery of NCSCs in postnatal tissues might fundamentally alter approaches to regeneration in the PNS. Answers to these questions could change the way we think about PNS development, injury, and disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STEM CELLS IN THE CNS Principal Investigator & Institution: Temple, Sally; Associate Professor; Ctr/Neuropharmacology/Neurosci; Albany Medical College of Union Univ Union University Albany, Ny 12208 Timing: Fiscal Year 2003; Project Start 15-AUG-1995; Project End 31-JUL-2007 Summary: (provided by applicant): Damage to the central nervous system (CNS) is tragically difficult to restore: the numerous types of neurons are postmitotic, and in most CNS regions their loss is permanent. The discovery that neural stem cells generate neurons in the embryo and in a few regions in the adult raises the possibility that they can be harnessed to generate new neurons for CNS repair. The long-term objective of these studies is to understand how CNS stem cells generate different neuron types, and how this can be applied clinically. Currently, we know little about the neuron types stem cells generate. In the normal adult, neurogenesis is limited to interneuron production, and it is not known whether adult stem cells can make the variety of projection neurons born during embryogenesis and early development. The neuron types that stem cells are capable of generating at different stages - their developmental potential - needs to be elucidated. In addition, the plasticity of neural stem cells - what neuron types they produce after transplantation into different stages or regions of the CNS and into the damaged CNS - needs evaluation. These issues remain unresolved largely because of the difficulty in isolating these rare cells to permit study of an
58
Stem Cells
identified, fresh stem cell population. Unfortunately, culture-expanded stem cells largely generate gila after transplantation in vivo. Recently we discovered that the carbohydrate LeX is expressed on the surface of cortical stem cells throughout life. We can now acutely isolate neural stem cells from different stages using FACS and analyze their developmental potential and plasticity. This will be done using clonal culture analysis, which provides information about the types of progeny an individual stem cell generates. In addition, we will implant these stem cells into the embryonic brain in vivo to reveal what neurons they produce in a developing system. Fresh stem cells will also be implanted into a model of ischemic damaged cerebral cortex to assess whether they can generate appropriate neuron types after CNS damage. Given LeX is expressed by all neural stem cells, we will examine its role by up and down regulating expression of the LeX-synthesizing enzymes FucT4 and FucT9 and assessing neural stem cell behavior. Because LeX is extremely abundant in embryonic regions expressing FGF-8 and Wnts, we will examine the impact of these growth factors on neural stem cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TESTING GENE THERAPY FOR EPIDERMOLYSIS BULLOSA SIMPLEX Principal Investigator & Institution: Roop, Dennis; Professor; Molecular and Cellular Biology; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2003; Project Start 07-JUL-2003; Project End 31-MAY-2008 Summary: (provided by applicant): The Dowling-Meara variant of epidermolysis bullosa simplex (EBS-DM) is a severe blistering disease inherited in an autosomaldominant fashion. Besides symptomatic care, no effective therapeutic treatment is available for EBS. Therefore, gene therapy is the only option for a permanent corrective therapy for these patients. Prior to testing gene therapy approaches for EBS in humans, it is desirable to utilize a pre-clinical animal model to determine the safety and efficacy of these approaches. We have recently generated a transgenic mouse model that mimics EBS-DM at the genetic level. This mouse model differs from the human disease in that expression of the mutant K14 allele, which contains an Arg 131 Cys mutation equivalent to the Arg 125 Cys mutation found in the majority of EBS-DM patients, can be restricted to a small area of the skin. This mouse model has provided an explanation for the lack of mosaic forms of EBS. Patients with mostly normal skin that have patches of diseased skin are referred to as mosaics. Mosaic patients have been described for several skin diseases, but not for EBS. Focal activation of the mutant K14 gene by topical application of an inducer results in blister formation. However, after a few weeks, the blister heals and never reappears. We have demonstrated that the mutant K14 gene was activated in epidermal stern cells. However, the defective EBS stem cells were replaced by normal epidermal stem cells that migrate in from the untreated area surrounding the blister. This mouse model predicts that if a mosaic patch of EBS skin formed during development of an embryo, these defective EBS epidermal stem cells would not survive, but be replaced by normal stem cells. This explains the absence of mosaic forms of EBS. This observation also has important implications for gene therapy approaches for EBS, since it suggests that if EBS stem cells were removed from a patient, genetically corrected and then returned to a blistered area, they would have a selective growth advantage over defective EBS stem cells. Of further interest was the observation that mice which express the mutant K14 allele at levels approximately 50% of wild type K14 fail to exhibit a skin phenotype. This suggests that as long as the ratio of wild type to mutant K14 is above a threshold, possibly as low as 2:1, the skin will have a normal appearance and be fully functional. Thus, successful gene therapy approaches may not
Studies
59
require correction or complete suppression of the mutant allele. This proposal will use epidermal stem cells isolated from the EBS-DM mouse model to test new gene therapy strategies that are based on these novel findings. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE BIOLOGY OF PROSTATE STEM CELLS Principal Investigator & Institution: Wilson, E Lynette.; Associate Professor; Cell Biology; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2002; Project Start 10-JUL-1997; Project End 31-MAY-2006 Summary: (provided by applicant): The objective of this proposal is to identify and characterize prostatic epithelial stem cells and to define the regulators of their growth and differentiation. The isolation of stem cells is of relevance to prostate carcinoma and benign prostatic hypertrophy, as both diseases are considered to arise from the aberrant proliferation of stem cells. We have identified a quiescent, slow-cycling population of cells with high proliferative potential in the proximal region of prostatic ducts. This region also contains cells with the greatest proliferative potential and the ability to form large, branched three dimensional glandular structures in collagen gels. In addition, we find that c-kit (receptor for stem cell factor, SCF), is expressed on 25% of basal cells while being completely absent from luminal cells. As many stem cell populations express c-kit, are quiescent and have innate high proliferative potential, we propose that a small number of prostatic stem cells are located in a 'niche' in the proximal region in the basal compartment and express c-kit on their surface. We further propose that the regulation of stem cell quiescence and proliferation is mediated by reciprocal interactions between transforming growth factor-B (TGF-B), which inhibits growth and SCF, which promotes growth. These hypotheses will be tested in three aims that exploit our ability to isolate subsets of viable basal cells expressing a6 integrin and c-kit and to test their engraftment in two in vivo models. Aim I will identify and separate subsets of basal cells most enriched for cells with stem cell properties. The proliferative potential of these subsets and their ability to generate glandular structures will be determined. In addition, culture conditions that allow their expansion while preventing their differentiation will be identified. New surface markers that will allow further selection and purification of stem cells will be sought. Aim 2 will quantitate the ability of the stem cell containing subsets to proliferate in vivo, to repopulate their organ of origin and to give rise to differentiated progeny. This will be done by implanting cells under the renal capsule and by intraprostatic inoculation in a novel transplantation model. Aim 3 will determine whether the balance between quiescence and proliferation is mediated by opposing effects of TGF-B and SCF. The sites of active TGF-J3 generation along the proximal-distal ductal axis will be identified under different hormonal conditions and the ability of TGF-13 to regulate c-kit and SCF expression studied. These experiments will define the subset of proximal cells in which prostatic stem cells reside and identify the manner in which their growth is regulated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TRANSDIFFERENTIATION POTENTIAL OF BONE MARROW STEM CELLS Principal Investigator & Institution: Ogawa, Makio; Professor; Medicine; Medical University of South Carolina 171 Ashley Ave Charleston, Sc 29425 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2007
60
Stem Cells
Summary: (provided by applicant): Recent studies demonstrated that stem cells in a number of organs/tissues have the potential to differentiate into tissues other than those specified in their origins. The most striking evidence for this "transdifferentiation" has been between bone marrow and muscular, hepatic, and CNS systems. Since all of the transplantation studies have been conducted using populations of cells, it is possible that the apparent bipotentiality of the stem cells is from engraftment by two separate populations of monopotential stem cells. Our proposal seeks definitive information on the tissue/organ engrafting capabilities of the hematopoietic and stromal stem cells by using single stem cell transplantation. We will use transgenic CD45.2 C57BL/6 (B6) mice that ubiquitously express enhanced green fluorescent protein (EGFP) as the source for donor stem cells and congenic CD45.1 B6 mice as recipients. The contribution of bone marrow EGFP-labeled donor cells to various organs/tissues of the recipient mice will be assessed using laser scanning confocal microscopy (LSCM) and conventional epifluorescence microscopy in combination with differential interference contrast (DIC) microscopy. Two Specific Aims are proposed: (1) To define the potentials of individual hematopoietic stem cells by single stem cell transplantation to lethally irradiated recipient mice. (2) To define the potentials of stromal stem cells. We have developed a highly efficient technique to create mice with clonal hematopoietic engraftment by combining FACS cell sorting and short-term suspension culture of bone marrow cells. Collaboration with the laboratory of Dr. Christopher J. Drake of Department of Cell Biology and Anatomy, who has considerable expertise in the use of LSCM and DIC and epifluorescence microscopy, has already resulted in exciting preliminary information about the potentiality of a single EGFP-labeled stem cell. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSDUCTION OF HUMAN STEM AND PROGENITOR CELLS Principal Investigator & Institution: Crooks, Gay M.; Associate Professor; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, Ca 90027 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2008 Summary: The fundamental obstacle to effective gene therapy for hematopoietic diseases continues to be the difficulty in obtaining sufficiently high levels of gene transfer into Lympho-Hematopoietic Stem Cells (LHSC). At the core of this problem is the mismatch in the biology of the chosen target cell, i.e. the non-cycling LHSC, and the use of vector systems that preferentially transduce cycling cells. We hypothesize that a combination of vector modifications, alternative cell targets and selective expansion of corrected cells will be required to achieve adequate levels of gene correction for most diseases. Our goal in this proposal is to explore the potential of all three approaches. Our Specific Aims are: 1. To determine the relative capacity of Human Foamy Virus (HFV) and Human Immune-deficiency Virus-1 (HIV-1) based vectors to transduce quiescent human hematopoietic cells; 2. To determine whether lineage-committed progenitors, i.e. Common Lymphoid (CLP), and Common Myeloid Progenitors (CMP) offer advantages over pluripotent Lympho-hematopoietic Stem Cells as targets for gene therapy; 3. To determine whether expansion of transduced human LHSC and progenitors can be accomplished by conditional expression of a "cell growth switch" linked to a binding site for a chemical inducer of dimerization. This proposal brings together various complementary experimental tools, i.e. optimal vector systems for multi-lineage expression in primitive cells, the ability to isolate primitive human hematopoietic populations with defined lineage potential and the in vitro and in vivo systems to measure the lineage potential of transduced populations, perform clonal analysis and assess engraftment and in vivo expansion of each population. The
Studies
61
biological interplay of the choice of vector, the type of target cells and the in vivo manipulation of the transduced target cells, will be analyzed in the context of the whole to understand the full therapeutic potential of these approaches. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: USE OF GENE THERAPY TO INDUCE TRANSPLANTATION TOLERANCE Principal Investigator & Institution: Kearns-Jonker, Mary K.; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, Ca 90027 Timing: Fiscal Year 2002; Project Start 15-AUG-2001; Project End 31-JUL-2004 Summary: The critical shortage of human organs available for transplantation to patients with end-stage diseases has led to an increasing amount of attention directed at developing methods to allow for the use of pigs as an alternative source of donor organs. Humans that have never been exposed to pig cells, however, have antibodies that are capable of rapidly rejecting these organs. These antibodies react predominantly with a specific sugar called the galactose tx1,3 galactose carbohydrate epitope (gal epitope) expressed on pig cells. This sugar is identified as foreign by humans or Old World primates because a mutation has occurred during evolution that prevents this carbohydrate from being expressed in humans and specific types of monkeys. Consequently, humans produce antibodies to gal when exposed to organs derived from other species (xenografts). A special strain of mice has recently been developed that serves as a good small animal model of xenograft rejection because they produce antigal antibodies similar to the antibodies that reject pig xenografts in humans. In this model, production of antibodies that reject pig cells can be prevented by introducing a single gene by bone marrow transplantation before the mouse is exposed to the pig cells. The ability to reproduce this experiment in a preclinical primate model will provide a means by which human patients may be treated prior to xenotransplantation to prevent rejection of pig organs, and will have a significant impact on the field of transplantation. This experiment has not yet been reproduced in primates because introduction of the new gene in primate stem cells of the bone marrow is more difficult compared with the mouse model using conventional methods. We have recently established a new method to introduce genes more efficiently into primate and human stem cells of the bone marrow using a new type of gene delivery vehicle (lentiviral vector). In this application, we propose to introduce the gene responsible for gal carbohydrate expression in primate stem cells and determine whether this procedure prevents anti-gal antibody production in primates. Our hypothesis is that this new vector will allow us to introduce the gene responsible for encoding the gal carbohydrate into primate stem cells at levels that are sufficient to prevent the immune response to pig cells in transplanted rhesus monkeys. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National
3
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
62
Stem Cells
Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “stem cells” (or synonyms) into the search box. This search gives you access to fulltext articles. The following is a sample of items found for stem cells in the PubMed Central database: •
8p12 Stem Cell Myeloproliferative Disorder: the FOP-Fibroblast Growth Factor Receptor 1 Fusion Protein of the t(6;8) Translocation Induces Cell Survival Mediated by Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt/mTOR Pathways. by Guasch G, Ollendorff V, Borg JP, Birnbaum D, Pebusque MJ.; 2001 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=99978
•
A molecular profile of a hematopoietic stem cell niche. by Hackney JA, Charbord P, Brunk BP, Stoeckert CJ, Lemischka IR, Moore KA.; 2002 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=130586
•
A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. by Tsai RY, McKay RD.; 2002 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=187487
•
An empty Drosophila stem cell niche reactivates the proliferation of ectopic cells. by Kai T, Spradling A.; 2003 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153607
•
An Induction Gene Trap Screen in Embryonic Stem Cells: Identification of Genes that Respond to Retinoic Acid in vitro. by Forrester LM, Nagy A, Sam M, Watt A, Stevenson L, Bernstein A, Joyner AL, Wurst W.; 1996 Feb 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=40001
•
Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. by Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP.; 2002 Sep 17; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=129446
•
Biological Characteristics of the Leukemia-Associated Transcriptional Factor AML1 Disclosed by Hematopoietic Rescue of AML1-Deficient Embryonic Stem Cells by Using a Knock-in Strategy. by Okuda T, Takeda K, Fujita Y, Nishimura M, Yagyu S, Yoshida M, Akira S, Downing JR, Abe T.; 2000 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85087
•
Characterization of the expression of MHC proteins in human embryonic stem cells. by Drukker M, Katz G, Urbach A, Schuldiner M, Markel G, Itskovitz-Eldor J, Reubinoff B, Mandelboim O, Benvenisty N.; 2002 Jul 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=125045
•
Chipping away at stem cells. by Chu VT, Gage FH.; 2001 Jul 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=35394
4
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
63
•
Cyclophosphamide /granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. by Morrison SJ, Wright DE, Weissman IL.; 1997 Mar 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20016
•
Direct isolation of human central nervous system stem cells. by Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL.; 2000 Dec 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18985
•
Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. by Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ.; 2003 Jan 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151860
•
Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. by Audet J, Miller CL, Rose-John S, Piret JM, Eaves CJ.; 2001 Feb 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=29330
•
Embryonic stem cells and mice expressing different GFP variants for multiple noninvasive reporter usage within a single animal. by Hadjantonakis AK, Macmaster S, Nagy A.; 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=116589
•
Embryonic stem cells and somatic cells differ in mutation frequency and type. by Cervantes RB, Stringer JR, Shao C, Tischfield JA, Stambrook PJ.; 2002 Mar 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122567
•
Enrichment for murine keratinocyte stem cells based on cell surface phenotype. by Tani H, Morris RJ, Kaur P.; 2000 Sep 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27131
•
Escaping the stem cell compartment: Sustained UVB exposure allows p53-mutant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutations. by Zhang W, Remenyik E, Zelterman D, Brash DE, Wikonkal NM.; 2001 Nov 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=61147
•
Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells. by Xu D, Wilson TJ, Chan D, De Luca E, Zhou J, Hertzog PJ, Kola I.; 2002 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=126157
•
Europe fragmented over embryonic stem cell research. by Birmingham K.; 2003 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=171403
•
Expression of Pax4 in embryonic stem cells promotes differentiation of nestinpositive progenitor and insulin-producing cells. by Blyszczuk P, Czyz J, Kania G, Wagner M, Roll U, St-Onge L, Wobus AM.; 2003 Feb 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=298715
•
Fbx15 Is a Novel Target of Oct3/4 but Is Dispensable for Embryonic Stem Cell SelfRenewal and Mouse Development. by Tokuzawa Y, Kaiho E, Maruyama M, Takahashi K, Mitsui K, Maeda M, Niwa H, Yamanaka S.; 2003 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=152544
64
Stem Cells
•
Flk-2 is a marker in hematopoietic stem cell differentiation: A simple method to isolate long-term stem cells. by Christensen JL, Weissman IL.; 2001 Dec 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=64718
•
Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. by Teng YD, Lavik EB, Qu X, Park KI, Ourednik J, Zurakowski D, Langer R, Snyder EY.; 2002 Mar 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122466
•
Gene Expression Profiling of Embryo-Derived Stem Cells Reveals Candidate Genes Associated With Pluripotency and Lineage Specificity. by Tanaka TS, Kunath T, Kimber WL, Jaradat SA, Stagg CA, Usuda M, Yokota T, Niwa H, Rossant J, Ko MS.; 2002 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=187571
•
Generation of neural crest-derived peripheral neurons and floor plate cells from mouse and primate embryonic stem cells. by Mizuseki K, Sakamoto T, Watanabe K, Muguruma K, Ikeya M, Nishiyama A, Arakawa A, Suemori H, Nakatsuji N, Kawasaki H, Murakami F, Sasai Y.; 2003 May 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=156286
•
Growth inhibitors promote differentiation of insulin-producing tissue from embryonic stem cells. by Hori Y, Rulifson IC, Tsai BC, Heit JJ, Cahoy JD, Kim SK.; 2002 Dec 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=138572
•
Hematopoietic colony-forming cells derived from human embryonic stem cells. by Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA.; 2001 Sep 11; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=58532
•
Hematopoietic Stem Cell Expansion and Distinct Myeloid Developmental Abnormalities in a Murine Model of the AML1-ETO Translocation. by de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H, Hiebert SW, Klug CA.; 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=133929
•
Hematopoietic stem cells and lymphoid progenitors express different Ikaros isoforms, and Ikaros is localized to heterochromatin in immature lymphocytes. by Klug CA, Morrison SJ, Masek M, Hahm K, Smale ST, Weissman IL.; 1998 Jan 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18476
•
HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34 + stem cell recruitment to the liver. by Kollet O, Shivtiel S, Chen YQ, Suriawinata J, Thung SN, Dabeva MD, Kahn J, Spiegel A, Dar A, Samira S, Goichberg P, Kalinkovich A, ArenzanaSeisdedos F, Nagler A, Hardan I, Revel M, Shafritz DA, Lapidot T.; 2003 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=164291
•
HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0 /G1 human hematopoietic stem cells. by Uchida N, Sutton RE, Friera AM, He D, Reitsma MJ, Chang WC, Veres G, Scollay R, Weissman IL.; 1998 Sep 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21744
•
Host cis-Mediated Extinction of a Retrovirus Permissive for Expression in Embryonal Stem Cells during Differentiation. by Laker C, Meyer J, Schopen A, Friel J, Heberlein C, Ostertag W, Stocking C.; 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109381
Studies
65
•
Hybrid Embryonic Stem Cell-Derived Tetraploid Mice Show Apparently Normal Morphological, Physiological, and Neurological Characteristics. by Schwenk F, Zevnik B, Bruning J, Rohl M, Willuweit A, Rode A, Hennek T, Kauselmann G, Jaenisch R, Kuhn R.; 2003 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=155215
•
Identification and isolation of candidate human keratinocyte stem cells based on cell surface phenotype. by Li A, Simmons PJ, Kaur P.; 1998 Mar 31; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=19935
•
Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. by Laywell ED, Rakic P, Kukekov VG, Holland EC, Steindler DA.; 2000 Dec 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=17670
•
Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. by Colter DC, Sekiya I, Prockop DJ.; 2001 Jul 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=35429
•
Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. by Chen CZ, Li M, de Graaf D, Monti S, Gottgens B, Sanchez MJ, Lander ES, Golub TR, Green AR, Lodish HF.; 2002 Nov 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137740
•
Identification of Novel MyoD Gene Targets in Proliferating Myogenic Stem Cells. by Wyzykowski JC, Winata TI, Mitin N, Taparowsky EJ, Konieczny SF.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=133998
•
Immortalization of a primate bipotent epithelial liver stem cell. by Allain JE, Dagher I, Mahieu-Caputo D, Loux N, Andreoletti M, Westerman K, Briand P, Franco D, Leboulch P, Weber A.; 2002 Mar 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122576
•
In vitro Differentiation of Embryonic Stem Cells into Lymphocyte Precursors Able to Generate T and B Lymphocytes in vivo. by Gutierrez-Ramos JC, Palacios R.; 1992 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50087
•
In vitro Generation of Hematopoietic Stem Cells from an Embryonic Stem Cell Line. by Palacios R, Golunski E, Samaridis J.; 1995 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41373
•
In vitro hematopoietic and endothelial potential of flk-1[minus sign] /[minus sign] embryonic stem cells and embryos. by Schuh AC, Faloon P, Hu QL, Bhimani M, Choi K.; 1999 Mar 2; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26753
•
In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. by Yang L, Li S, Hatch H, Ahrens K, Cornelius JG, Petersen BE, Peck AB.; 2002 Jun 11; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=123023
•
Integration of multiple instructive cues by neural crest stem cells reveals cell-intrinsic biases in relative growth factor responsiveness. by Shah NM, Anderson DJ.; 1997 Oct 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23470
66
Stem Cells
•
Interleukin 3 or Interleukin 1 Abrogates the Reconstituting Ability of Hematopoietic Stem Cells. by Yonemura Y, Ku H, Hirayama F, Souza LM, Ogawa M.; 1996 Apr 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39483
•
Intrinsic Human Immunodeficiency Virus Type 1 Resistance of Hematopoietic Stem Cells Despite Coreceptor Expression. by Shen H, Cheng T, Preffer FI, Dombkowski D, Tomasson MH, Golan DE, Yang O, Hofmann W, Sodroski JG, Luster AD, Scadden DT.; 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=103880
•
Long-Term Culture of Lymphohematopoietic Stem Cells. by Palacios R, Bucana C, Xie X.; 1996 May 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39230
•
Methylguanine methyltransferase --mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. by Neff T, Horn PA, Peterson LJ, Thomasson BM, Thompson J, Williams DA, Schmidt M, Georges GE, Kalle CV, Kiem HP.; 2003 Nov 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=259127
•
Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. by DeWeese TL, Shipman JM, Larrier NA, Buckley NM, Kidd LR, Groopman JD, Cutler RG, te Riele H, Nelson WG.; 1998 Sep 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21740
•
Murine hematopoietic stem cells committed to macrophage /dendritic cell formation: Stimulation by Flk2-ligand with enhancement by regulators using the gp130 receptor chain. by Metcalf D.; 1997 Oct 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23534
•
Muscle-derived hematopoietic stem cells are hematopoietic in origin. by McKinneyFreeman SL, Jackson KA, Camargo FD, Ferrari G, Mavilio F, Goodell MA.; 2002 Feb 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122192
•
Natural killer cell suppression of Friend virus-induced preleukemic hemopoietic stem cells. by Eckner RJ, Bennett M, Hettrick KL, Seidler C.; 1987 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=255714
•
Neural stem cell heterogeneity demonstrated by molecular phenotyping of clonal neurospheres. by Suslov ON, Kukekov VG, Ignatova TN, Steindler DA.; 2002 Oct 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137913
•
Neural stem cells and cholinergic neurons: Regulation by immunolesion and treatment with mitogens, retinoic acid, and nerve growth factor. by Calza L, Giuliani A, Fernandez M, Pirondi S, D'Intino G, Aloe L, Giardino L.; 2003 Jun 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=165874
•
Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. by Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY.; 2000 Nov 7; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18852
Studies
67
•
Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. by Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J.; 2002 Jul 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=123178
•
p63 identifies keratinocyte stem cells. by Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, Ponzin D, McKeon F, De Luca M.; 2001 Mar 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=30623
•
Parvovirus Infection Suppresses Long-Term Repopulating Hematopoietic Stem Cells. by Segovia JC, Guenechea G, Gallego JM, Almendral JM, Bueren JA.; 2003 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=165232
•
Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. by Gronthos S, Mankani M, Brahim J, Robey PG, Shi S.; 2000 Dec 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=17626
•
Preferential induction of apoptosis for primary human leukemic stem cells. by Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, Jordan CT.; 2002 Dec 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=138592
•
Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human [beta]-globin in engrafted mice. by Kalberer CP, Pawliuk R, Imren S, Bachelot T, Takekoshi KJ, Fabry M, Eaves CJ, London IM, Humphries RK, Leboulch P.; 2000 May 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=25842
•
Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. by Colter DC, Class R, DiGirolamo CM, Prockop DJ.; 2000 Mar 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=16218
•
Reduced Proliferative Capacity of Hematopoietic Stem Cells Deficient in Hoxb3 and Hoxb4. by Bjornsson JM, Larsson N, Brun AC, Magnusson M, Andersson E, Lundstrom P, Larsson J, Repetowska E, Ehinger M, Humphries RK, Karlsson S.; 2003 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=155209
•
Reelin function in neural stem cell biology. by Kim HM, Qu T, Kriho V, Lacor P, Smalheiser N, Pappas GD, Guidotti A, Costa E, Sugaya K.; 2002 Mar 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122641
•
Remodeling of the postnatal mouse testis is accompanied by dramatic changes in stem cell number and niche accessibility. by Shinohara T, Orwig KE, Avarbock MR, Brinster RL.; 2001 May 22; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=33443
•
Retroviral Expression in Embryonic Stem Cells and Hematopoietic Stem Cells. by Cherry SR, Biniszkiewicz D, van Parijs L, Baltimore D, Jaenisch R.; 2000 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86295
•
Serum Response Factor Is Required for Immediate-Early Gene Activation yet Is Dispensable for Proliferation of Embryonic Stem Cells. by Schratt G, Weinhold B, Lundberg AS, Schuck S, Berger J, Schwarz H, Weinberg RA, Ruther U, Nordheim A.; 2001 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86921
68
Stem Cells
•
SHED: Stem cells from human exfoliated deciduous teeth. by Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, Shi S.; 2003 May 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=156282
•
Shiga Toxin 2 Induces Macrophage-Granulocyte Colonies from Human Bone Marrow and Cord Blood Stem Cells. by Chiyoda S, Takeda T, Aoki Y.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=128287
•
Somatic mosaicism in Fanconi anemia: Evidence of genotypic reversion in lymphohematopoietic stem cells. by Gregory JJ Jr, Wagner JE, Verlander PC, Levran O, Batish SD, Eide CR, Steffenhagen A, Hirsch B, Auerbach AD.; 2001 Feb 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=30172
•
Spermatogonial stem cell enrichment by multiparameter selection of mouse testis cells. by Shinohara T, Orwig KE, Avarbock MR, Brinster RL.; 2000 Jul 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26950
•
Spermatogonial stem cells share some, but not all, phenotypic and functional characteristics with other stem cells. by Kubota H, Avarbock MR, Brinster RL.; 2003 May 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=164473
•
Synthetic small molecules that control stem cell fate. by Ding S, Wu TY, Brinker A, Peters EC, Hur W, Gray NS, Schultz PG.; 2003 Jun 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=164638
•
The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression. by Guo Y, Costa R, Ramsey H, Starnes T, Vance G, Robertson K, Kelley M, Reinbold R, Scholer H, Hromas R.; 2002 Mar 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=122580
•
The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression. by Rosu-Myles M, Gallacher L, Murdoch B, Hess DA, Keeney M, Kelvin D, Dale L, Ferguson SS, Wu D, Fellows F, Bhatia M.; 2000 Dec 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=18969
•
The kinase MSK1 is required for induction of c-fos by lysophosphatidic acid in mouse embryonic stem cells. by Schuck S, Soloaga A, Schratt G, Arthur JS, Nordheim A.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=161794
•
The Latent Transforming Growth Factor-[beta] --binding Protein-1 Promotes In Vitro Differentiation of Embryonic Stem Cells into Endothelium. by Gualandris A, Annes JP, Arese M, Noguera I, Jurukovski V, Rifkin DB.; 2000 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15073
•
The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells. by Schmitt A, Rochat A, Zeltner R, Borenstein L, Barrandon Y, Wettstein FO, Iftner T.; 1996 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190020
•
Thrombopoietin expands hematopoietic stem cells after transplantation. by Fox N, Priestley G, Papayannopoulou T, Kaushansky K.; 2002 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151089
Studies
69
•
Transduction of Human Progenitor Hematopoietic Stem Cells by Human Immunodeficiency Virus Type 1-Based Vectors Is Cell Cycle Dependent. by Sutton RE, Reitsma MJ, Uchida N, Brown PO.; 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104140
•
Transgenic mice for the preparation of hygromycin-resistant primary embryonic fibroblast feeder layers for embryonic stem cell selections. by Johnson KA, Lerner CP, Di Lacio LC, Laird PW, Sharpe AH, Simpson EM.; 1995 Apr 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=306843
•
Wheat germ agglutinin-positive cells in a stem cell-enriched fraction of mouse bone marrow have potent natural suppressor activity. by Sugiura K, Inaba M, Ogata H, Yasumizu R, Inaba K, Good RA, Ikehara S.; 1988 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=280528
•
Wnt-5A augments repopulating capacity and primitive hematopoietic development of human blood stem cells in vivo. by Murdoch B, Chadwick K, Martin M, Shojaei F, Shah KV, Gallacher L, Moon RT, Bhatia M.; 2003 Mar 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=152308
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with stem cells, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “stem cells” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for stem cells (hyperlinks lead to article summaries): •
6
A new start for stem cells. Can bone marrow seed the brain with fresh neurons? Author(s): Sohn E. Source: U.S. News & World Report. 2003 February 10; 134(4): 84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12608330&dopt=Abstract
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
70
Stem Cells
•
A new tool in restorative neurosurgery: creating niches for neuronal stem cells. Author(s): Langmoen IA, Ohlsson M, Westerlund U, Svensson M. Source: Neurosurgery. 2003 May; 52(5): 1150-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12699560&dopt=Abstract
•
Adenosine triphosphate induces proliferation of human neural stem cells: Role of calcium and p70 ribosomal protein S6 kinase. Author(s): Ryu JK, Choi HB, Hatori K, Heisel RL, Pelech SL, McLarnon JG, Kim SU. Source: Journal of Neuroscience Research. 2003 May 1; 72(3): 352-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12692902&dopt=Abstract
•
Adenoviral transduction of mouse hematopoietic stem cells. Author(s): Bradfute SB, Goodell MA. Source: Molecular Therapy : the Journal of the American Society of Gene Therapy. 2003 March; 7(3): 334-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12668129&dopt=Abstract
•
Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Author(s): Gimble J, Guilak F. Source: Cytotherapy. 2003; 5(5): 362-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14578098&dopt=Abstract
•
Adult bone marrow stem cells regenerate myocardium in ischemic heart disease. Author(s): Orlic D. Source: Annals of the New York Academy of Sciences. 2003 May; 996: 152-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12799293&dopt=Abstract
•
Adult cardiac stem cells--where do we go from here? Author(s): Edelberg JM, Xaymardan M, Rafii S, Hong MK. Source: Sci Aging Knowledge Environ. 2003 July 2; 2003(26): Pe17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12844537&dopt=Abstract
•
Adult mesenchymal stem cells and cell-based tissue engineering. Author(s): Tuan RS, Boland G, Tuli R. Source: Arthritis Research & Therapy. 2003; 5(1): 32-45. Epub 2002 December 11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12716446&dopt=Abstract
•
Adult stem cells and their importance in cell therapy. Author(s): Filip S, Mokry J, Hruska I. Source: Folia Biol (Praha). 2003; 49(1): 9-14. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12630663&dopt=Abstract
Studies
71
•
Adult stem cells for tissue repair - a new therapeutic concept? Author(s): Korbling M, Estrov Z. Source: The New England Journal of Medicine. 2003 August 7; 349(6): 570-82. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12904523&dopt=Abstract
•
Age-related changes of P-glycoprotein-mediated rhodamine 123 efflux in normal human bone marrow hematopoietic stem cells. Author(s): Calado RT, Machado CG, Carneiro JJ, Garcia AB, Falcao RP. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003 April; 17(4): 816-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12682648&dopt=Abstract
•
Akt helps stem cells heal the heart. Author(s): Koc ON, Gerson SL. Source: Nature Medicine. 2003 September; 9(9): 1109-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12949518&dopt=Abstract
•
Allogeneic stem cells, clinical transplantation and the origins of regenerative medicine. Author(s): Strom TB, Field LJ, Ruediger M. Source: Current Opinion in Immunology. 2002 October; 14(5): 601-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12183159&dopt=Abstract
•
Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Author(s): In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FH, Willemze R, Fibbe WE, Kanhai HH. Source: Blood. 2003 August 15; 102(4): 1548-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12900350&dopt=Abstract
•
An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells. Author(s): Tzukerman M, Rosenberg T, Ravel Y, Reiter I, Coleman R, Skorecki K. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 November 11; 100(23): 13507-12. Epub 2003 October 22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14573705&dopt=Abstract
•
Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenvironment. Author(s): Rafii S, Avecilla S, Shmelkov S, Shido K, Tejada R, Moore MA, Heissig B, Hattori K. Source: Annals of the New York Academy of Sciences. 2003 May; 996: 49-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12799282&dopt=Abstract
72
Stem Cells
•
Astrocytes as stem cells: nomenclature, phenotype, and translation. Author(s): Steindler DA, Laywell ED. Source: Glia. 2003 July; 43(1): 62-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12761868&dopt=Abstract
•
Australia agonises over stem cells. Author(s): Nowak R. Source: New Scientist (1971). 2002 September 21; 175(2361): 9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12731537&dopt=Abstract
•
Autologous peripheral blood stem cell transplantation of stem cells harvested in imatinib-induced complete cytogenetic remission: an example of in vivo purging in CML. Author(s): le Coutre P, Kreuzer KA, Massenkeil G, Baskaynak G, Zschieschang P, Genvresse I, Lupberger J, Mapara M, Dorken B, Arnold R. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003 December; 17(12): 2525-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14562118&dopt=Abstract
•
Autologous stem cells for functional myocardial repair. Author(s): Schwartz Y, Kornowski R. Source: Heart Failure Reviews. 2003 July; 8(3): 237-45. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12878832&dopt=Abstract
•
Berashis cells in human umbilical cord blood vs. embryonic stem cells. Author(s): Ende N. Source: J Med. 2002; 33(1-4): 167-71. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12939115&dopt=Abstract
•
Bio-engineering inslulin-secreting cells from embryonic stem cells: a review of progress. Author(s): Roche E, Sepulcre MP, Ensenat-Waser R, Maestre I, Reig JA, Soria B. Source: Medical & Biological Engineering & Computing. 2003 July; 41(4): 384-91. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12892359&dopt=Abstract
•
Biological and mechanical quality of red blood cells cultured from human umbilical cord blood stem cells. Author(s): Maggakis-Kelemen C, Bork M, Kayser P, Biselli M, Artmann GM. Source: Medical & Biological Engineering & Computing. 2003 May; 41(3): 350-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12803302&dopt=Abstract
Studies
73
•
Biology and plasticity of CD133+ hematopoietic stem cells. Author(s): Handgretinger R, Gordon PR, Leimig T, Chen X, Buhring HJ, Niethammer D, Kuci S. Source: Annals of the New York Academy of Sciences. 2003 May; 996: 141-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12799292&dopt=Abstract
•
Biology of hematopoietic stem cells and progenitors: implications for clinical application. Author(s): Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF, Shizuru JA, Weissman IL. Source: Annual Review of Immunology. 2003; 21: 759-806. Epub 2002 December 17. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12615892&dopt=Abstract
•
Biology of human bone marrow stem cells. Author(s): Bonnet D. Source: Clinical and Experimental Medicine. 2003 November; 3(3): 140-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14648228&dopt=Abstract
•
Bioterrorism, embryonic stem cells, and Frankenstein. Author(s): Guinan P. Source: Journal of Religion and Health. 2002 Summer; 41(2): 305-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12728944&dopt=Abstract
•
BM-derived stem cells for the treatment of nonhematopoietic diseases. Author(s): Krause DS. Source: Cytotherapy. 2002; 4(6): 503-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12568982&dopt=Abstract
•
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Author(s): Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, Clarke MF. Source: Nature. 2003 May 15; 423(6937): 302-5. Epub 2003 April 20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12714971&dopt=Abstract
•
Bmi1, stem cells, and senescence regulation. Author(s): Park IK, Morrison SJ, Clarke MF. Source: The Journal of Clinical Investigation. 2004 January; 113(2): 175-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14722607&dopt=Abstract
74
Stem Cells
•
BMP responsiveness in human mesenchymal stem cells. Author(s): Diefenderfer DL, Osyczka AM, Reilly GC, Leboy PS. Source: Connective Tissue Research. 2003; 44 Suppl 1: 305-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12952214&dopt=Abstract
•
Bone induction by BMP-2 transduced stem cells derived from human fat. Author(s): Dragoo JL, Choi JY, Lieberman JR, Huang J, Zuk PA, Zhang J, Hedrick MH, Benhaim P. Source: Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society. 2003 July; 21(4): 622-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12798061&dopt=Abstract
•
Bone marrow stem cells contribute to healing of the kidney. Author(s): Poulsom R, Alison MR, Cook T, Jeffery R, Ryan E, Forbes SJ, Hunt T, Wyles S, Wright NA. Source: Journal of the American Society of Nephrology : Jasn. 2003 June; 14 Suppl 1: S4854. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12761239&dopt=Abstract
•
Bone marrow stem cells do not repopulate the healthy upper respiratory tract. Author(s): Davies JC, Potter M, Bush A, Rosenthal M, Geddes DM, Alton EW. Source: Pediatric Pulmonology. 2002 October; 34(4): 251-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12205565&dopt=Abstract
•
Bone marrow stem cells regenerate infarcted myocardium. Author(s): Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Source: Pediatric Transplantation. 2003; 7 Suppl 3: 86-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12603699&dopt=Abstract
•
Bone marrow-derived stem cells and “plasticity”. Author(s): Huttmann A, Li CL, Duhrsen U. Source: Annals of Hematology. 2003 October; 82(10): 599-604. Epub 2003 July 24. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12898189&dopt=Abstract
•
Bone marrow-derived stem cells for ischemic hearts. Author(s): Kocher AA. Source: Wiener Klinische Wochenschrift. 2003 February 28; 115(3-4): 77-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12674679&dopt=Abstract
Studies
75
•
Bone-marrow stem cells as a source for cell therapy. Author(s): Chiu RC. Source: Heart Failure Reviews. 2003 July; 8(3): 247-51. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12878833&dopt=Abstract
•
Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. Author(s): Meng XL, Shen JS, Ohashi T, Maeda H, Kim SU, Eto Y. Source: Journal of Neuroscience Research. 2003 October 15; 74(2): 266-77. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14515356&dopt=Abstract
•
Breast cancer stem cells revealed. Author(s): Dick JE. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 April 1; 100(7): 3547-9. Epub 2003 March 25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12657737&dopt=Abstract
•
Cancer research. Mutant stem cells may seed cancer. Author(s): Marx J. Source: Science. 2003 September 5; 301(5638): 1308-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12958339&dopt=Abstract
•
Cancer stem cells. Author(s): Masters JR, Foley CL, Bisson I, Ahmed A. Source: Bju International. 2003 November; 92(7): 661-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14616438&dopt=Abstract
•
Cancerous stem cells can arise from pediatric brain tumors. Author(s): Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 December 9; 100(25): 15178-83. Epub 2003 November 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14645703&dopt=Abstract
•
Cardiomyocyte-mediated contact programs human mesenchymal stem cells to express cardiogenic phenotype. Author(s): Rangappa S, Entwistle JW, Wechsler AS, Kresh JY. Source: The Journal of Thoracic and Cardiovascular Surgery. 2003 July; 126(1): 124-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12878947&dopt=Abstract
76
Stem Cells
•
CDCP1 is a novel marker for hematopoietic stem cells. Author(s): Conze T, Lammers R, Kuci S, Scherl-Mostageer M, Schweifer N, Kanz L, Buhring HJ. Source: Annals of the New York Academy of Sciences. 2003 May; 996: 222-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12799299&dopt=Abstract
•
Cellular cardiomyoplasty--cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure? Author(s): Reffelmann T, Kloner RA. Source: Cardiovascular Research. 2003 May 1; 58(2): 358-68. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12757870&dopt=Abstract
•
Characterization and culture of human embryonic stem cells. Author(s): Laslett AL, Filipczyk AA, Pera MF. Source: Trends in Cardiovascular Medicine. 2003 October; 13(7): 295-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14522470&dopt=Abstract
•
Characterization and differentiation of human embryonic stem cells. Author(s): Carpenter MK, Rosler E, Rao MS. Source: Cloning and Stem Cells. 2003; 5(1): 79-88. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12713704&dopt=Abstract
•
Characterization of cord blood hematopoietic stem cells. Author(s): Mazurier F, Doedens M, Gan OI, Dick JE. Source: Annals of the New York Academy of Sciences. 2003 May; 996: 67-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12799284&dopt=Abstract
•
Chinese fusion method promises fresh route to human stem cells. Author(s): Dennis C. Source: Nature. 2003 August 14; 424(6950): 711. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12917645&dopt=Abstract
•
Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Author(s): Frank JA, Miller BR, Arbab AS, Zywicke HA, Jordan EK, Lewis BK, Bryant LH Jr, Bulte JW. Source: Radiology. 2003 August; 228(2): 480-7. Epub 2003 June 20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12819345&dopt=Abstract
Studies
77
•
Cloning and stem cells. Author(s): Wilmut I. Source: Cloning and Stem Cells. 2002; 4(2): 103-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12171702&dopt=Abstract
•
Cloning and stem cells: processes, politics, and policy. Author(s): Curtis MG. Source: Curr Womens Health Rep. 2003 December; 3(6): 492-500. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14613671&dopt=Abstract
•
Cloning and stem cells--handicapping the political and scientific debates. Author(s): Daley GQ. Source: The New England Journal of Medicine. 2003 July 17; 349(3): 211-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867604&dopt=Abstract
•
Coculture and transplant of purified CD34(+)Lin(-) and CD34(-)Lin(-) cells reveals functional interaction between repopulating hematopoietic stem cells. Author(s): Hess DA, Karanu FN, Levac K, Gallacher L, Bhatia M. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003 August; 17(8): 1613-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12886251&dopt=Abstract
•
Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Author(s): Coppo P, Dusanter-Fourt I, Millot G, Nogueira MM, Dugray A, Bonnet ML, Mitjavila-Garcia MT, Le Pesteur D, Guilhot F, Vainchenker W, Sainteny F, Turhan AG. Source: Oncogene. 2003 June 26; 22(26): 4102-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12821944&dopt=Abstract
•
Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Author(s): Angelopoulou M, Novelli E, Grove JE, Rinder HM, Civin C, Cheng L, Krause DS. Source: Experimental Hematology. 2003 May; 31(5): 413-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12763140&dopt=Abstract
•
Cyclic strain enhances matrix mineralization by adult human mesenchymal stem cells via the extracellular signal-regulated kinase (ERK1/2) signaling pathway. Author(s): Simmons CA, Matlis S, Thornton AJ, Chen S, Wang CY, Mooney DJ. Source: Journal of Biomechanics. 2003 August; 36(8): 1087-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12831733&dopt=Abstract
78
Stem Cells
•
Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Author(s): Mollee P, Pereira D, Nagy T, Song K, Saragosa R, Keating A, Crump M. Source: Bone Marrow Transplantation. 2002 September; 30(5): 273-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12209348&dopt=Abstract
•
Cystatin-B is expressed by neural stem cells and by differentiated neurons and astrocytes. Author(s): Brannvall K, Hjelm H, Korhonen L, Lahtinen U, Lehesjoki AE, Lindholm D. Source: Biochemical and Biophysical Research Communications. 2003 August 22; 308(2): 369-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12901878&dopt=Abstract
•
Derivation and potential applications of human embryonic stem cells. Author(s): Gepstein L. Source: Circulation Research. 2002 November 15; 91(10): 866-76. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12433831&dopt=Abstract
•
Development and analysis of megakaryocytes from murine embryonic stem cells. Author(s): Eto K, Leavitt AL, Nakano T, Shattil SJ. Source: Methods Enzymol. 2003; 365: 142-58. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14696343&dopt=Abstract
•
Developmental origins of hematopoietic stem cells. Author(s): Robin C, Ottersbach K, de Bruijn M, Ma X, van der Horn K, Dzierzak E. Source: Oncology Research. 2003; 13(6-10): 315-21. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12725520&dopt=Abstract
•
Developmental potentials of hematopoietic and neural stem cells following injection into pre-implantation blastocysts. Author(s): Harder F, Kirchhof N, Petrovic S, Schmittwolf C, Durr M, Muller AM. Source: Annals of Hematology. 2002; 81 Suppl 2: S20-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12611062&dopt=Abstract
•
Differences and similarities among phenotypes of mesenchymal and neural stem cells. Author(s): Magrassi L. Source: Haematologica. 2003 February; 88(2): 121. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12604398&dopt=Abstract
Studies
79
•
Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts. Author(s): Wierenga PK, Setroikromo R, Kamps G, Kampinga HH, Vellenga E. Source: Experimental Hematology. 2003 May; 31(5): 421-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12763141&dopt=Abstract
•
Differential apoptosis and Fas expression on GPI-negative and GPI-positive stem cells: a mechanism for the evolution of paroxysmal nocturnal haemoglobinuria. Author(s): Ismail MM, Tooze JA, Flynn JA, Gordon-Smith EC, Gibson FM, Rutherford TR, Elebute MO. Source: British Journal of Haematology. 2003 November; 123(3): 545-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14617023&dopt=Abstract
•
Differentiating embryonic stem cells: GAPDH, but neither HPRT nor beta-tubulin is suitable as an internal standard for measuring RNA levels. Author(s): Murphy CL, Polak JM. Source: Tissue Engineering. 2002 August; 8(4): 551-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12201995&dopt=Abstract
•
Differentiation and genetic manipulation of human embryonic stem cells and the analysis of the cardiovascular system. Author(s): Lavon N, Benvenisty N. Source: Trends in Cardiovascular Medicine. 2003 February; 13(2): 47-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12586438&dopt=Abstract
•
Differentiation of human antigen-presenting dendritic cells from CD34+ hematopoietic stem cells in vitro. Author(s): Ju XS, Zenke M. Source: Methods in Molecular Biology (Clifton, N.J.). 2003; 215: 399-407. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12512315&dopt=Abstract
•
Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. Author(s): Levenberg S, Huang NF, Lavik E, Rogers AB, Itskovitz-Eldor J, Langer R. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 October 28; 100(22): 12741-6. Epub 2003 Oct 15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14561891&dopt=Abstract
80
Stem Cells
•
Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Author(s): Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Brink S, Hassink R, van der Heyden M, Opthof T, Pera M, de la Riviere AB, Passier R, Tertoolen L. Source: Circulation. 2003 June 3; 107(21): 2733-40. Epub 2003 May 12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12742992&dopt=Abstract
•
Differentiation of human neural stem cells into retinal cells. Author(s): Dong X, Pulido JS, Qu T, Sugaya K. Source: Neuroreport. 2003 January 20; 14(1): 143-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12544846&dopt=Abstract
•
Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Author(s): Boheler KR, Czyz J, Tweedie D, Yang HT, Anisimov SV, Wobus AM. Source: Circulation Research. 2002 August 9; 91(3): 189-201. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12169644&dopt=Abstract
•
Differentiation of rhesus embryonic stem cells to neural progenitors and neurons. Author(s): Calhoun JD, Lambert NA, Mitalipova MM, Noggle SA, Lyons I, Condie BG, Stice SL. Source: Biochemical and Biophysical Research Communications. 2003 June 20; 306(1): 191-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12788087&dopt=Abstract
•
Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Author(s): Spees JL, Olson SD, Ylostalo J, Lynch PJ, Smith J, Perry A, Peister A, Wang MY, Prockop DJ. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 March 4; 100(5): 2397-402. Epub 2003 February 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12606728&dopt=Abstract
•
Direct and indirect induction of apoptosis in human mesenchymal stem cells in response to titanium particles. Author(s): Wang ML, Tuli R, Manner PA, Sharkey PF, Hall DJ, Tuan RS. Source: Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society. 2003 July; 21(4): 697-707. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12798071&dopt=Abstract
Studies
81
•
Direct selection of human bone marrow mesenchymal stem cells using an anti-CD49a antibody reveals their CD45med,low phenotype. Author(s): Deschaseaux F, Gindraux F, Saadi R, Obert L, Chalmers D, Herve P. Source: British Journal of Haematology. 2003 August; 122(3): 506-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12877680&dopt=Abstract
•
Donor-derived hematopoietic stem cells in organ transplantation: technical aspects and hurdles yet to be cleared. Author(s): Herve P. Source: Transplantation. 2003 May 15; 75(9 Suppl): 55S-57S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12819493&dopt=Abstract
•
Dramatic expansion of germinal stem cells by ectopically expressed human glial cell line-derived neurotrophic factor in mouse Sertoli cells. Author(s): Yomogida K, Yagura Y, Tadokoro Y, Nishimune Y. Source: Biology of Reproduction. 2003 October; 69(4): 1303-7. Epub 2003 June 11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12801989&dopt=Abstract
•
Effect of rat Schwann cell secretion on proliferation and differentiation of human neural stem cells. Author(s): An YH, Wan H, Zhang ZS, Wang HY, Gao ZX, Sun MZ, Wang ZC. Source: Biomed Environ Sci. 2003 March; 16(1): 90-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12747012&dopt=Abstract
•
Effects of peripheral benzodiazepine receptor ligands on proliferation and differentiation of human mesenchymal stem cells. Author(s): Lee DH, Kang SK, Lee RH, Ryu JM, Park HY, Choi HS, Bae YC, Suh KT, Kim YK, Jung JS. Source: Journal of Cellular Physiology. 2004 January; 198(1): 91-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14584048&dopt=Abstract
•
Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector. Author(s): Tsuda H, Wada T, Ito Y, Uchida H, Dehari H, Nakamura K, Sasaki K, Kobune M, Yamashita T, Hamada H. Source: Molecular Therapy : the Journal of the American Society of Gene Therapy. 2003 March; 7(3): 354-65. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12668131&dopt=Abstract
82
Stem Cells
•
Electrophysiological profiling of cardiomyocytes in embryonic bodies derived from human embryonic stem cells: therapeutic implications. Author(s): Vanderlaan RD, Oudit GY, Backx PH. Source: Circulation Research. 2003 July 11; 93(1): 1-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12855668&dopt=Abstract
•
Embryonic stem cells generated by nuclear transfer of human somatic nuclei into rabbit oocytes. Author(s): Chen Y, He ZX, Liu A, Wang K, Mao WW, Chu JX, Lu Y, Fang ZF, Shi YT, Yang QZ, Chen da Y, Wang MK, Li JS, Huang SL, Kong XY, Shi YZ, Wang ZQ, Xia JH, Long ZG, Xue ZG, Ding WX, Sheng HZ. Source: Cell Research. 2003 August; 13(4): 251-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12974615&dopt=Abstract
•
Embryonic stem cells. Stem cell programs. Author(s): Zerhouni E. Source: Science. 2003 May 9; 300(5621): 911-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12738840&dopt=Abstract
•
Engineering mesenchymal stem cells for immunotherapy. Author(s): Jorgensen C, Djouad F, Apparailly F, Noel D. Source: Gene Therapy. 2003 May; 10(10): 928-31. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12732877&dopt=Abstract
•
Engraftment of human cord blood-derived stem cells in preimmune ovine fetuses after ultrasound-guided in utero transplantation. Author(s): Young AJ, Holzgreve W, Dudler L, Schoeberlein A, Surbek DV. Source: American Journal of Obstetrics and Gynecology. 2003 September; 189(3): 698701. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14526296&dopt=Abstract
•
Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. Author(s): Tamaki S, Eckert K, He D, Sutton R, Doshe M, Jain G, Tushinski R, Reitsma M, Harris B, Tsukamoto A, Gage F, Weissman I, Uchida N. Source: Journal of Neuroscience Research. 2002 September 15; 69(6): 976-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12205691&dopt=Abstract
•
Ethics of human stem cells and cloning - a personal view. Author(s): Ludwig H, Diedrich K. Source: Archives of Gynecology and Obstetrics. 2002 August; 266(4): 185-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12192474&dopt=Abstract
Studies
83
•
EU will fund research on stem cells only from embryos created before June 2002. Author(s): Watson R. Source: Bmj (Clinical Research Ed.). 2003 July 19; 327(7407): 124. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12869446&dopt=Abstract
•
European Union. At odds again over stem cells. Author(s): Vogel G. Source: Science. 2003 July 18; 301(5631): 289. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12869730&dopt=Abstract
•
Evidence for transdifferentiation of human bone marrow-derived stem cells: recent progress and controversies. Author(s): Tao H, Ma DD. Source: Pathology. 2003 February; 35(1): 6-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12701678&dopt=Abstract
•
Ex vivo expansion of corneal limbal epithelial/stem cells for corneal surface reconstruction. Author(s): Ramaesh K, Dhillon B. Source: Eur J Ophthalmol. 2003 July; 13(6): 515-24. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12948308&dopt=Abstract
•
Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. Author(s): Amsellem S, Pflumio F, Bardinet D, Izac B, Charneau P, Romeo PH, DubartKupperschmitt A, Fichelson S. Source: Nature Medicine. 2003 November; 9(11): 1423-7. Epub 2003 October 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14578882&dopt=Abstract
•
Ex vivo expansion of limbal epithelial stem cells: amniotic membrane serving as a stem cell niche. Author(s): Grueterich M, Espana EM, Tseng SC. Source: Survey of Ophthalmology. 2003 November-December; 48(6): 631-46. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14609709&dopt=Abstract
•
Ex vivo gene therapy in autologous bone marrow stromal stem cells for tissueengineered maxillofacial bone regeneration. Author(s): Chang SC, Chuang HL, Chen YR, Chen JK, Chung HY, Lu YL, Lin HY, Tai CL, Lou J. Source: Gene Therapy. 2003 November; 10(24): 2013-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14566360&dopt=Abstract
84
Stem Cells
•
Ex vivo preservation and expansion of human limbal epithelial stem cells on amniotic membrane for treating corneal diseases with total limbal stem cell deficiency. Author(s): Tseng SC, Meller D, Anderson DF, Touhami A, Pires RT, Gruterich M, Solomon A, Espana E, Sandoval H, Ti SE, Goto E. Source: Advances in Experimental Medicine and Biology. 2002; 506(Pt B): 1323-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12614074&dopt=Abstract
•
Ex vivo targeting of p21Cip1/Waf1 permits relative expansion of human hematopoietic stem cells. Author(s): Stier S, Cheng T, Forkert R, Lutz C, Dombkowski DM, Zhang JL, Scadden DT. Source: Blood. 2003 August 15; 102(4): 1260-6. Epub 2003 April 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12702511&dopt=Abstract
•
Existence of reserve quiescent stem cells in adults, from amphibians to humans. Author(s): Young HE. Source: Curr Top Microbiol Immunol. 2004; 280: 71-109. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14594208&dopt=Abstract
•
Factors affecting purification of CD34(+) peripheral blood stem cells using the Baxter Isolex 300i. Author(s): Gryn J, Shadduck RK, Lister J, Zeigler ZR, Raymond JM. Source: Journal of Hematotherapy & Stem Cell Research. 2002 August; 11(4): 719-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12201961&dopt=Abstract
•
Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Author(s): Carral A, de la Rubia J, Martin G,